0001615774-16-006802.txt : 20160815 0001615774-16-006802.hdr.sgml : 20160815 20160815163813 ACCESSION NUMBER: 0001615774-16-006802 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160815 DATE AS OF CHANGE: 20160815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEMISPHERX BIOPHARMA INC CENTRAL INDEX KEY: 0000946644 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 520845822 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-27072 FILM NUMBER: 161833345 BUSINESS ADDRESS: STREET 1: 1617 JFK BLVD, SUITE #500 STREET 2: ONE PENN CENTER CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: 215-988-0080 MAIL ADDRESS: STREET 1: 1617 JFK BLVD, SUITE #500 STREET 2: ONE PENN CENTER CITY: PHILADELPHIA STATE: PA ZIP: 19103 10-Q 1 s103890_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

For the Quarterly Period Ended June 30, 2016

Commission File Number: 1-13441

HEMISPHERX BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware		52-0845822
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

1617 JFK Boulevard, Suite 500, Philadelphia, PA 19103

(Address of principal executive offices) (Zip Code)

(215) 988-0080

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).

x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

¨ Large accelerated filer	¨ Accelerated filer
¨ Non-accelerated filer	x Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ Yes x No

248,932,220 shares of common stock were outstanding as of August 1, 2016.

PART I - FINANCIAL INFORMATION

ITEM 1:

Financial Statements

HEMISPHERX BIOPHARMA, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(in thousands, except for share and per share amounts)

	June 30, 2016			December 31, 2015
	(Unaudited)			(Audited)
ASSETS
Current assets:
Cash and cash equivalents	$	1,538		$	2,115
Escrow account for litigation settlement		1,750			-
Marketable securities		4,974			6,795
Inventory-work in process		1,326			1,326
Assets held for sale		764			-
Prepaid expenses and other current assets		378			335
Total current assets		10,730			10,571

Property and equipment, net		10,057			11,237
Patent and trademark rights, net		899			862
Other assets		232			134
Total assets	$	21,918		$	22,804

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,391		$	1,213
Accrued expenses		3,038			1,219
Current portion of capital lease		-			1
Total current liabilities		4,429			2,433

Commitments and contingencies (Note 6)

Stockholders’ equity:
Preferred stock, par value $0.01 per share, authorized 5,000,000; issued and outstanding; none		—			—
Common stock, par value $0.001 per share, authorized 350,000,000 shares; issued and outstanding 248,829,720 and 247,559,487, respectively		249			247
Additional paid-in capital		313,619			313,220
Accumulated other comprehensive income (loss)		87			(97	)
Accumulated deficit		(296,466	)		(292,999	)

Total stockholders’ equity		17,489			20,371
Total liabilities and stockholders’ equity	$	21,918		$	22,804

See accompanying notes to consolidated financial statements.

-2-

HEMISPHERX BIOPHARMA, INC. AND SUBSIDIARIES

Consolidated Statements of Comprehensive Loss

(in thousands, except share and per share data)

(Unaudited)

	Three months ended June 30,						Six months ended June 30,
	2016			2015			2016			2015
Revenues:
Clinical treatment programs	$	15		$	47		$	54		$	83

Total revenues		15			47			54			83

Costs and expenses:
Production costs		290			507			558			879
Research and development		900			2,439			1,902			5,113
General and administrative		1,639			2,002			4,087			3,915

Total costs and expenses		2,829			4,948			6,547			9,907

Operating loss		(2,814	)		(4,901	)		(6,493	)		(9,824	)

Interest expense		—			—			—			(2	)
Interest and other income/expense		55			56			116			162
Insurance proceeds from legal settlement, net		1,436			—			1,436			—
Gain (Loss) on sales of short term marketable securities		20			—			(87	)		—
Gain from sale of income tax net operating losses		—			—			1,561			1,374

Net loss		(1,303	)		(4,845	)		(3,467	)		(8,290	)

Other comprehensive income (loss):
Reclassification adjustments for loss on sales of short term marketable securities included in net loss		—			—			87			—
Unrealized gain (loss) on marketable securities		38			(137	)		97			(26	)
Net comprehensive loss	$	(1,265	)	$	(4,982	)	$	(3,283	)	$	(8,316	)

Basic and diluted loss per share	$	(0.01	)	$	(0.02	)	$	(0.01	)	$	(0.04	)

Weighted average shares outstanding, basic and diluted		248,008,113			236,149,999			247,786,026			224,954,200

See accompanying notes to consolidated financial statements.

-3-

HEMISPHERX BIOPHARMA, INC. AND SUBSIDIARIES

Consolidated Statement of Changes in Stockholders' Equity

For the Six Months Ended June 30, 2016

(in thousands except share data)

(Unaudited)

	Common Stock Shares		Common Stock $0.001 Par Value		Additional Paid-In Capital		Accumulated Other Compre- hensive Income (Loss)			Accumulated Deficit			Total Stockholders’ Equity
Balance at December 31, 2015		247,559,487	$	247	$	313,220	$	(97	)	$	(292,999	)	$	20,371
Equity-based compensation		—		—		238		—			—			238
Shares sold at the market		1,270,233		2		161		—			—			163
Net comprehensive loss		—		—		—		184			(3,467	)		(3,283	)

Balance at June 30, 2016		248,829,720	$	249	$	313,619	$	87		$	(296,466	)	$	17,489

See accompanying notes to consolidated financial statements.

-4-

HEMISPHERX BIOPHARMA, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

For the Six Months Ended June 30, 2016 and 2015

(in thousands)

(Unaudited)

	2016			2015
Cash flows from operating activities:
Net loss	$	(3,467	)	$	(8,290	)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment		576			458
Amortization and abandonment of patent and trademark rights		70			79
Equity-based compensation		238			111
Realized loss on sale of marketable securities		87
Change in assets and liabilities:
Escrow account for litigation settlement		(1,750	)		—
Inventories		—			(1,009	)
Prepaid expenses and other current assets		(43	)		61
Accounts payable		178			189
Accrued expenses		1,819			(836	)
Net cash used in operating activities		(2,292	)		(9,237	)

Cash flows from investing activities:
Purchase of property, equipment and construction in progress		(160	)		(240	)
Additions to patent, trademark and licensing rights		(207	)		(169	)
Deposits on capital leases refunded		2			—
Sales and maturities of short-term and long-term marketable securities		1,918			54
Net cash provided by (used in) investing activities		1,553			(355	)

Cash flows from financing activities:
Payments on capital leases		(1	)		(15	)
Proceeds from sale of stock, net of issuance costs		163			9,293
Net cash provided by financing activities		162			9,278

Net decrease in cash and cash equivalents		(577	)		(314	)

Cash and cash equivalents at beginning of period		2,115			2,156

Cash and cash equivalents at end of period	$	1,538		$	1,842

Supplemental disclosures of non-cash investing and financing cash flow information:
Issuance of common stock for accounts payable	$	—		$	672
Unrealized (loss) gain on marketable securities	$	184		$	(26	)
Supplemental disclosure of cash flow information:
Cash paid for interest expense	$	-		$	(2	)
Insurance proceeds from legal settlement	$	3,536		$	-

See accompanying notes to consolidated financial statements.

-5-

HEMISPHERX BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1: Basis of Presentation

The consolidated financial statements include the financial statements of Hemispherx Biopharma, Inc. and its wholly-owned subsidiaries (“Company”). The Company has three domestic subsidiaries: BioPro Corp., BioAegean Corp. and Core Biotech Corp., all of which are incorporated in Delaware and are dormant. The Company also has a foreign subsidiary, Hemispherx Biopharma Europe N.V./S.A., which was established in Belgium in 1998. All significant intercompany balances and transactions have been eliminated in consolidation.

In the opinion of Management, all adjustments necessary for a fair presentation of such consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year.

The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto.

These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2015 and 2014, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

Note 2: Net Loss Per Share

Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 18,814,995 and 17,228,280 shares for the six months ended June 30, 2016 and 2015, respectively, are excluded from the calculation of diluted net loss per share since their effect is anti-dilutive.

Note 3: Equity-Based Compensation

The fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, expected life and forfeiture rates. There were 2,225,000 and 800,000 options or equity warrants granted in the six months ended June 30, 2016 and 2015, respectively.

-6-

Stock option for employees' activity during the six months ended June 30, 2016 is as follows:

Stock option activity for employees:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding January 1, 2016		10,725,248		$	1.58		4.02	$	—
Granted		2,225,000			.13		—		—
Forfeited		(851,650	)		.85		—		—
Outstanding June 30, 2016		12,098,598		$	1.37		4.84	$	—
Vested and expected to vest June 30, 2016		12,098,598		$	1.37		4.84	$	—
Exercisable June 30, 2016		9,898,598		$	1.39		3.56	$	—

Unvested stock option activity for employees:

	Number of Options			Weighted Average Exercise Price		Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding January 1, 2016		333,333		$	0.29		7.82	$	—
Granted		2,225,000			.13		—		—
Vested		(358,333	)		.24				—
Forfeited		—			—		—		—
Outstanding June 30, 2016		2,200,000		$	.14		9.74	$	—

Stock option activity for non-employees:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding January 1, 2016		3,303,000		$	1.29		4.31	$	—
Granted		550,000			.13		—		—
Exercised		—			—		—		—
Forfeited		(380,000	)		3.73		—		—
Outstanding June 30, 2016		3,473,000		$	.84		5.21	$	—
Vested and expected to vest June 30, 2016		3,473,000		$	.84		5.21	$	—
Exercisable June 30, 2016		2,923,000		$	.97		4.31	$	—

-7-

Unvested stock option activity for non-employees during the year:

	Number of Options		Weighted Average Exercise Price		Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding January 1, 2016		—	$	—		—	$	—
Granted		550,000		.13		—		—
Vested		—		—		—		—
Forfeited		—		—		—		—
Outstanding June 30, 2016		550,000	$	.13		10.00	$	—

The impact on the Company’s results of operations of recording equity-based compensation for the six months ended June 30, 2016 and 2015 was to increase costs and expenses by approximately $238,000 and $111,000, respectively, which had no impact on earnings per share.

As of June 30, 2016 and 2015, respectively, there was $380,000 and $269,000 of unrecognized equity-based compensation cost related to options granted under the Equity Incentive Plan.

On January 26, 2016, the Board, based on the recommendation of its Compensation Committee, established two programs - the 2016 Senior Executive Deferred Cash Performance Award Plan for Dr. William A. Carter and Thomas K. Equels, the Company’s two primary executive officers, and the 2016 Voluntary Incentive Stock Award Plan for Company employees and Board members other than Dr. Carter and Mr. Equels. Both Plans include a Base Pay Supplement provision.

Note 4: Inventories

The Company uses the lower of first-in, first-out (“FIFO”) cost or market method of accounting for inventory.

Inventories consist of the following:	(in thousands)
	June 30,		December 31,
	2016		2015
Inventory work-in-process, January 1	$	1,326	$	—
Production⁽¹⁾		—		1,443
Spoilage		—		(117	)
Inventory work-in-process, end of period	$	1,326	$	1,326

(1) Commercial sales of Alferon® will not resume until new batches of commercial filled and finished product are produced and released by the FDA. The Company is continuing the validation of Alferon® production and production of new Alferon® API inventory commenced in February 2015. While the facility is approved by the FDA under the Biological License Application (“BLA”) for Alferon®, this status will need to be reaffirmed by an FDA pre-approval inspection. The Company will also need the FDA’s approval to release commercial product once it has submitted satisfactory stability and quality release data.

-8-

Note 5: Marketable Securities

Marketable securities consist of mutual funds. For the six months ended June 30, 2016 and 2015, it was determined that none of the marketable securities had other-than-temporary impairments. At June 30, 2016 and December 31, 2015, all securities were classified as available for sale investments and were measured as Level 1 instruments of the fair value measurements standard.

Securities classified as available for sale consisted of:

June 30, 2016

(in thousands)

Securities	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		Short-Term Investments		Long Term Investments
Mutual Funds	$	4,887	$	87	$	—	$	4,974	$	4,974	$	—

Totals	$	4,887	$	87	$	—	$	4,974	$	4,974	$	—

December 31, 2015

(in thousands)

Securities	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Short-Term Investments		Long Term Investments
Mutual Funds	$	6,892	$	—	$	(97	)	$	6,795	$	6,795	$	—

Totals	$	6,892	$	—	$	(97	)	$	6,795	$	6,795	$	—

Unrealized losses on investments

Investments with continuous unrealized losses for less than 12 months and 12 months or greater and their related fair values were as follows:

June 30, 2016

As of June 30, 2016 there were no investments in a loss position.

December 31, 2015

(in thousands)

			Less Than 12 Months					12 Months or Greater					Totals
Securities	Total number in loss position		Fair Values		Unrealized Losses			Fair Values		Unrealized Losses			Total Fair Value		Total Unrealized Losses
Mutual Funds		2	$	2,834	$	(159	)	$	2,041	$	(21	)	$	4,875	$	(180	)

Totals		2	$	2,834	$	(159	)	$	2,041	$	(21	)	$	4,875	$	(180	)

-9-

Note 6: Accrued Expenses

Accrued expenses consist of the following:

	(in thousands)
	June 30, 2016		December 31, 2015
Compensation, including severance	$	558	$	229
Professional fees		2,085		619
Clinical trial expenses		107		143
Other expenses		288		228
	$	3,038	$	1,219

Note 7: Property and Equipment

	(in thousands)
	June 30, 2016			December 31, 2015
Land, buildings and improvements	$	10,530		$	11,603
Furniture, fixtures, and equipment		5,630			5,490
Leasehold improvements		—			85
Total property and equipment		16,160			17,178
Less: accumulated depreciation and amortization		(6,103	)		(5,941	)
Property and equipment, net	$	10,057		$	11,237

Property and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, ranging from three to thirty-nine years.

Note 8: Stockholders’ Equity

The Equity Incentive Plan of 2009, effective June 24, 2009, authorizes the grant of non-qualified and incentive stock options, stock appreciation rights, restricted stock and other stock awards. A maximum of 15,000,000 shares of common stock is reserved for potential issuance pursuant to awards under the Equity Incentive Plan of 2009. In September 2015, the Company's shareholders approved the following amendments to the 2009 Plan: (1) increased the number of shares authorized to be issued under the Equity Incentive Plan from 15,000,000 to 22,000,000; (2) required a gradual vesting period of options issued under the Equity Incentive Plan over a three year period; (3) revised the definition of “change in control” to make it less “liberal” by amending the provision that a change in control occurs upon stockholder approval of a merger, consolidation or sale or disposition by the Company of all or substantially all of its assets (a “Business Combination”) to state that such a change in control occurs upon the consummation of the Business Combination; and (4) clarified that the definition of change in control has a double trigger. For a Participant to get the benefit resulting from a change in control, such Participant must have been terminated other than for cause within a two year period. Unless sooner terminated, the Equity Incentive Plan of 2009 will continue in effect for a period of 10 years from its effective date. For the six months ended June 30, 2016 and 2015, there were 2,775,000 and 800,000 options granted by the Company, respectively.

On December 15, 2015, the Company entered into an Equity Distribution Agreement with Chardan Capital Markets, LLC (the “Chardan Agreement”) to create an at-the-market equity program under which it may sell shares of its common stock (the “Shares”) from time to time through Chardan Capital Markets, LLC, as sales agent (“Chardan”). Under the Chardan Agreement, Chardan will be entitled to a commission at a fixed commission rate of 3.0% of the gross sales price of Shares sold under the Chardan Agreement.

-10-

Sales of the Shares, if any, under the Chardan Agreement may be made in transactions that are deemed to be “at-the-market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers’ transactions, including on the NYSE MKT, at market prices or as otherwise agreed with Chardan. The Company has no obligation to sell any of the Shares, and may at any time suspend offers under the Chardan Agreement or terminate the Chardan Agreement.

The Company’s plans to allocate the net proceeds from the offering towards research and development, operations and general and administrative purposes related to the commercialization of Ampligen® and Alferon® related products, including, but not limited to, the following: (1) costs to maintain the Alferon N Injection® manufacturing facility and to prepare for the FDA pre-approval inspections of the Ampligen® facility, (2) manufacture of commercial product, (3) potential new preclinical and/or clinical studies in order to gain commercial approval for Ampligen® and broader approvals for Alferon® and Alferon LDO®, (4) working capital to build and maintain sufficient inventory by procuring raw materials, supplies and other items for the New Brunswick manufacturing facility, as well as to remunerate outside contractors for necessary services, such as, final filling and finishing operations in order to meet any anticipated demand from normal operations as well as through the possible pursuit of other disease areas and/or geographic regions that may present themselves, (5) pursuit of potential partnering opportunities for Ampligen®, (6) potential establishment of sales and marketing capabilities, as well as consideration towards the expansion of our manufacturing capacity, and (7) working capital for general and administrative expenses.

Note 9: Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. The Company has restricted $1,750,000 of these funds in an escrow account which is designated for litigation expenses pursuant to the terms of a litigation settlement agreement.

Note 10: Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2017, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Upon the Company realizing operating revenues from the sale of commercialized product, the Company’s adoption of this guidance may have an impact on the Company’s financial statement presentation or disclosures.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 explicitly requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist which raise substantial doubt about an entity's ability to continue as a going concern and to provide related disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and annual and interim periods thereafter, with early adoption permitted. The Company will continue to evaluate and monitor at each annual or interim reporting period whether there are conditions or events that exist pertaining to this guidance.

-11-

In January 2016, the (“FASB”) has issued Accounting Standards Update (ASU) No. 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new guidance is intended to improve the recognition and measurement of financial instruments. The new guidance is effective for public companies for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The new guidance permits early adoption of the own credit provision. The Company believes that the adoption of the guidance may have an impact on the Company’s financial statement presentation or disclosures.

In February 2016, the FASB issued ASU 2016-02 - Leases, which amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective for annual reporting periods beginning after December 15, 2018, and early adoption of is permitted as of the standard’s issuance date. “ASU 2016-02” requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company has not adopted ASU 2016-02 and believes such adoption may have an impact on the Company’s financial statement presentation or disclosures.

In 2016, the FASB also issued Accounting Standards Updates (“ASU”) 2016-03 through 2016-13. These updates did not have a significant impact on the financial statements.

Note 11: Funds Received from Sale of Income Tax Net Operating Losses

As of December 31, 2015, the Company has approximately $166,000,000 of federal net operating loss carryforwards (expiring in the years 2018 through 2035) available to offset future federal taxable income. The Company also has approximately $36,000,000 of Pennsylvania state net operating loss carryforwards (expiring in the years 2018 through 2033) and approximately $29,000,000 of New Jersey state net operating loss carryforwards (expiring in the years 2034 and 2035) available to offset future state taxable income.

In January 2016, the Company effectively sold $16,000,000 of its New Jersey state net operating loss carryforward for the year 2014 for approximately $1,320,000, and also sold New Jersey research and development credits for $241,000. The utilization of certain state net operating loss carry-forwards may be subject to annual limitations. With no tax due for the foreseeable future, the Company has determined that the accounting for interest or penalties related to the payment of tax is not necessary at this time.

Note 12: Assets held for sale

The assets held for sale consists of the net book value of an underutilized building located adjacent to the site of the Company’s New Jersey manufacturing facility. As part of the Company’s objectives to achieve its commercial goals and increase stockholder value, the Company has initiated the sale of underutilized assets. As a result, the Company is in the process of selling this building at its current market value and has reclassified it as held for sale at its net book value of $764,000.

Note 13: Subsequent Events

The Company evaluated subsequent events through the date on which these financial statements were issued and determined that no subsequent event constituted a matter that required adjustment to the financial statements for the six months ended June 30, 2016.

-12-

ITEM 2:

Management's Discussion and Analysis of Financial Condition and Results of Operations

Special Note Regarding Forward-Looking Statements

Certain statements in this Report, including statements under “Item 1. Legal Proceedings” and “Item 1A. Risk Factors” in Part II, contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and are subject to risks, uncertainties and other important factors. We discuss many of these risks, uncertainties and other important factors in greater detail under “Item 1A. Risk Factors” in Part II in this Report. Because the risk factors referred to above and in our Annual Report on Form 10-K for our most recent fiscal year filed with the Securities and Exchange Commission could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us, you should not place undue reliance on any such forward-looking statements.

Further, these forward-looking statements represent our estimates and assumptions only as of the date such forward-looking statements are made. You should carefully read this Report completely and with the understanding that our actual future results may be materially different from what we expect. We can give no assurances that any of the events anticipated by the forward-looking statements will occur or, if any of them do, what impact they will have on our business, results of operations and financial condition. Any forward-looking statement speaks only as of the date on which it is made and we undertake no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which will arise. We cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Any statements in this Report about our expectations, beliefs, plans, objectives, assumptions or future events or performance that are not historical facts are forward-looking statements. You can identify these forward-looking statements by the use of words or phrases such as “believe”, “may”, “could”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “seek”, “plan”, “expect”, “should”, or “would,” and similar expressions intended to identify forward-looking statements.

Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties inherent in our business including, without limitation: our ability to adequately fund our projects, the potential therapeutic effect of our products, the possibility of obtaining regulatory approval, our ability to find senior co-development partners with the capital and expertise needed to commercialize our products and to enter into arrangements with them on commercially reasonable terms, our ability to manufacture and sell any products, our ability to enter into arrangements with third party vendors, market acceptance of our products, our ability to earn a profit from sales or licenses of any drugs, our ability to discover new drugs in the future, changing market conditions, changes in laws and regulations affecting our industry, and issues related to the improvements and construction of our New Brunswick, New Jersey facility. We have disclosed that in February 2013, we received a Complete Response from the FDA declining to approve our Ampligen® New Drug Application (“NDA”) for Chronic Fatigue Syndrome Treatment ("CFS") stating that we should conduct at least one additional clinical trial, complete various nonclinical studies and perform a number of data analyses. Accordingly, the remaining steps to potentially gain FDA approval of the Ampligen® NDA, the final results of these and other ongoing activities could vary materially from our expectations and could adversely affect the chances for approval of the Ampligen® NDA. These activities and the ultimate outcomes are subject to a variety of risks and uncertainties, including but not limited to risks that (i) the FDA may ask for additional data, information or studies to be completed or provided; and (ii) the FDA may require additional work related to the commercial manufacturing process to be completed or may, in the course of the inspection of manufacturing facilities, identify issues to be resolved. With regard to our NDA for Ampligen® to treat CFS, we note that there are additional steps which the FDA has advised Hemispherx to take in our seeking approval. The final results of these and other ongoing activities, and of the FDA review, could vary materially from Hemispherx' expectations and could adversely affect the chances for approval of the Ampligen® NDA. Any failure to satisfy the FDA’s requirements could significantly delay, or preclude outright, approval of our drugs for commercial sale.

-13-

We completed the construction of the $8 million facility enhancement project in 2015 which, upon FDA approval, should provide for a higher capacity and more cost effective manufacturing process for the production of Alferon N Injection®. Commercial sales of Alferon and Alferon API internationally are projected to begin as soon as the necessary regulatory approvals are obtained. However, commercial sales of Alferon® in the USA will not resume until new batches of commercial filled and finished product are produced and released by the FDA. We are continuing the validation of Alferon® production and production of new Alferon® API inventory commenced in February 2015. While the facility is approved by the FDA under the Biological License Application (“BLA”) for Alferon®, this status will need to be reaffirmed by an FDA pre-approval inspection. We will also need the FDA’s approval to release commercial product once we have submitted satisfactory stability and quality release data. We had anticipated that it would take approximately until at least the 2nd half of 2015 before we would have Alferon® approved for commercial sales; however, during the final stage of the manufacturing process we encountered issues regarding a change in both the contract supplier of leukocytes and the long term supply availability related to a reagent used in the formulation of Alferon®. We have substantially resolved these issues through engaging in multiple agreements with suppliers of leukocytes as well as entering into a licensing agreement with a foreign multinational chemicals and biotechnology company that has been in business for over a century for the sourcing of the primary reagent allowing us to manufacture Alferon®. However, due to the interruption of the required flow of leukocytes, production ceased, causing parts to malfunction in the upstream process when the system was restarted for testing. We were working diligently to make the necessary repairs to be able to restart the validation process; however, in the process of obtaining time estimates for the repairs we experienced a flood within portions of our manufacturing facility. As a result, we will be constrained in our ability to manufacture product in the near future due to this flood in the upstream processing cleanroom that contains the bioreactor. The flood occurred on the afternoon of January 5, 2016, caused by a malfunctioning water supply pipe for the sprinkler system covering a large amount of the cleanroom in stagnant water and silt from the sprinkler system. Our facility insurer has been proactive in addressing and covering the loss. While repairs have required preapproval by our insurer, activity has moved forward quickly. The repairs noted below required special action because of the need to keep this critical manufacturing room within International Organization for Standardization (ISO) classifications and the need to certify that all the equipment that was exposed, or submerged, is in proper condition and operating effectively following the corrective actions. All HEPA filters affected by the flood were tested by an outside contractor and have passed all required tests. The flooring that was damaged has been repaired using a special epoxy that is used in cleanrooms. A large portion of the walls in the ISO classified area were damaged. We had a damage mitigation company come in to stop any moisture from seeping further into the ISO classified areas. Subsequently, all damaged walls and ceilings have been replaced with cleanroom grade materials and need no further work. Six pumps that were affected by the flood were sent back to the manufacturer for inspection and repair. Repairs that were required have been completed on the pumps and they were reinstalled in the Alferon manufacturing facility after the floor repair work was completed. All pumps will need to be qualified for use in the manufacturing process prior to the validation process for a Pre-Approval Inspection. All air ducts supplying the Alferon manufacturing area needed to be cleaned and insulation replaced along with ceiling tiles. The duct insulation and ceiling tile replacement will be performed after the duct cleaning work is completed. All smaller pieces of machinery and equipment that could not be salvaged have been replaced. The final repair step required to be performed will be HVAC air balancing and qualification.

Currently, the manufacturing process is on hold and there is no definitive timetable to have the facility back online. In addition, due to the repair issues mentioned above and the high cost estimates to bring the facility back online, we most likely will need additional funds to finance the revalidation process in our facility to initiate commercial manufacturing, thereby readying ourselves for an FDA Pre-Approval Inspection. If we are unable to gain the necessary FDA approvals related to the manufacturing process and/or final product of new Alferon® inventory, our operations most likely will be materially and/or adversely affected. In light of these contingencies, there can be no assurances that the approved Alferon N Injection® product will be returned to production on a timely basis, if at all, or that if and when it is again made commercially available, it will return to prior sales levels. Please see “Risks Associated with Our Business” in Part II. Item 1A. Risk Factors below - There are no long-term agreements with suppliers of required materials and services for Ampligen® and there are a limited number of raw material suppliers. If we are unable to obtain the required raw materials and/or services, we may not be able to manufacture Ampligen®.

-14-

Our overall objectives include plans to continue seeking approval for commercialization of Ampligen® in the United States and abroad as well as to widen existing commercial therapeutic indications of Alferon N Injection® presently approved in the United States and Argentina. In addition, we have formed collaborations with multiple research laboratories around the world to examine Ampligen®, an experimental therapeutic, and Alferon N, an FDA-approved commercial product (for refractory venereal warts (HPV)) as potential preventatives for, and treatments of, Ebola Virus Disease (EVD) among others. Our ability to commercialize our products, widen commercial therapeutic indications of Alferon N Injection® and/or capitalize on our collaborations with research laboratories to examine our products as potential preventatives for, and treatments of, MERS, among others, are subject to a number of significant risks and uncertainties including, but not limited to our ability to enter into more definitive agreements with some of the research laboratories and others that we are collaborating with, to fund and conduct additional testing and studies, whether or not such testing is successful or requires additional testing and meets the requirements of the FDA and comparable foreign regulatory agencies. We do not know when, if ever, our products will be generally available for commercial sale for any indication.

On March 15, 2016, we received written notice from the NYC MKT LLC (the “NYSE MKT”) that we are not in compliance with the continued listing standards set forth in Section 1003(f)(v) of the NYSE MKT Company Guide because our common stock has been selling for a low price per share for a substantial period of time. The NYSE MKT has determined that the continued listing of our common stock is predicated on us affecting a reverse stock split of our common stock or otherwise demonstrating sustained price improvement within a reasonable period of time. We have until September 15, 2016 to demonstrate compliance.

We outsource certain components of our manufacturing, quality control, marketing and distribution while maintaining control over the entire process through our quality assurance and regulatory groups. We cannot provide any guarantee that the facility or our contract manufacturer will necessarily pass an FDA pre-approval inspection for Alferon® manufacture.

We do not undertake and specifically decline any obligation to publicly release the results of any revisions which may be made to any forward-looking statement to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Overview

General

Hemispherx Biopharma, Inc. and its subsidiaries (collectively, “Hemispherx”, “Company”, “we" or “us”) are a specialty pharmaceutical company headquartered in Philadelphia, Pennsylvania and engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. We were founded in the early 1970s doing contract research for the National Institutes of Health. Since that time, we have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases. We have three domestic subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp., all of which are incorporated in Delaware and are dormant. Our foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A. which was established in Belgium in 1998.

-15-

We have been reexamining our fundamental priorities in terms of direction, corporate culture and our ability to fund operations. As a result, there have been significant changes at the Company in the past few months. As noted above, we have made several changes to the Company’s executive management team to provide effective and competent leadership that, management believes, will properly position the Company to achieve its commercial goals and increase stockholder value. Recent actions include aggressively pursuing international sales of clinical grade materials and implementing a strong financial austerity plan. We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and expertise needed to commercialize the many potential therapeutic aspects of our experimental drug and our approved drug Alferon®. Management’s primary objectives are to create stockholder value and deliver much needed therapies to patients.

We have made several significant changes in the past few months. On September 16, 2015, our Board appointed Mr. Peter Rodino as Lead Director. In addition, Mr. Rodino and William Mitchell, M.D., Ph.D. were each appointed to the Compensation Committee and Corporate Governance and Nominating Committee. Mr. Rodino, Dr. Mitchell and Iraj E. Kiani were each appointed to the Audit Committee.

On February 17, 2016, our Board, by majority vote, terminated the employment of Dr. Carter, our Chairman of the Board, Chief Executive Officer and Chief Scientific Officer. As a result, Dr. Carter also is no longer a director. Dr. Mitchell, one of our independent directors, was appointed Chairman of the Board.

On February 19, 2016, our Board of Directors also made several changes to our executive management team in light of the termination of Dr. Carter, to provide effective and competent leadership that will properly position us to achieve our commercial goals and increase stockholder value. In this regard, Adam Pascale was named Chief Financial Officer in addition to his current responsibilities as Chief Accounting Officer. Mr. Pascale has been employed us for 18 years, with more than two decades of public accounting experience and prior public company experience. He earned a Bachelor of Arts degree in Accounting and Finance from Rutgers University. Mr. Pascale served for several years as a CPA prior to joining the Company, and is a member of both the American and the Pennsylvania Institutes of Certified Public Accountants. Mr. Equels, our Chief Executive Officer (“CEO”) and President, resigned as Chief Financial Officer to make way for Mr. Pascale.

On February 25, 2016, our Board appointed Thomas K. Equels, our current President, as our CEO. In that capacity, he is the principal executive officer of the Company. On June 16, 2016, Iraj Kiani resigned as a member of the Board of Directors of the Company.

Our flagship products include Alferon N Injection® and the experimental therapeutic Ampligen®. Alferon N Injection® is approved for a category of STD infection, and Ampligen® represents an experimental RNA being developed for globally important viral diseases and disorders of the immune system. Hemispherx' platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Alferon® LDO (Low Dose Oral) is a formulation under development targeting influenza.

The below chart provides a summary of the clinical indications for both Ampligen® and Alferon® currently under development.

-16-

We own and operate a 43,000 sq. ft. FDA approved facility in New Brunswick, NJ to produce Alferon® and Ampligen®, and completed the construction of our $8 million facility enhancement project in 2015 which, upon FDA approval, should provide for a higher capacity, more cost effective manufacturing process for the production of Alferon N Injection®. As part of our objectives to achieve our commercial goals and increase stockholder value, we are in the process of selling an underutilized building adjacent to our New Jersey manufacturing facility site. We do not believe that the sale of this building will have an impact on the production of our products. We also are exploring the possibility of selling the primary facility if we can obtain a long term lease back of the facility on acceptable terms. Please see “Manufacturing” section below.

On February 1, 2013, we received a Complete Response Letter (“CRL”) from the FDA declining to approve our NDA for Ampligen® for Chronic Fatigue Syndrome ("CFS"). Please see the discussion in "Our Products - Ampligen®" below for more detail.

On April 20, 2016, the Company executed a consulting agreement with Huron Consulting Group, a global consultancy with decades of experience in the life sciences market, to advance the company’s strategic plan to capitalize on business opportunities in the United States and in target countries around the world.

Our principal executive office is located at One Penn Center, 1617 JFK Boulevard, Philadelphia, Pennsylvania 19103, and our telephone number is 215-988-0080.

OUR PRODUCTS

Our primary pharmaceutical product platform consists of our experimental compound, Ampligen®, our FDA approved natural interferon product, Alferon N Injection®, and our experimental liquid natural interferon for oral administration, Alferon® LDO (Low Dose Oral).

Ampligen®

Ampligen® is an experimental drug currently undergoing clinical development for the treatment of CFS. As noted above and discussed below, the FDA in its CRL declined to approve our NDA for the treatment of CFS with Ampligen®. Over its developmental history, Ampligen® has received various designations, including Orphan Drug Product Designation (FDA), Treatment protocol (e.g., “Expanded Access” or “Compassionate” use authorization) with Cost Recovery Authorization (FDA) and “promising” clinical outcome recognition based on the evaluation of certain summary clinical reports (“AHRQ” or Agency for Healthcare Research and Quality). Ampligen® represents the first drug in the class of large (macromolecular) RNA (nucleic acid) molecules to apply for NDA review. Based on the results of published, peer reviewed pre-clinical studies and clinical trials, we believe that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties.

-17-

We believe that nucleic acid compounds represent a potential new class of pharmaceutical products as they are designed to act at the molecular level for treatment of human diseases. There are two forms of nucleic acids, DNA and RNA. DNA is a group of naturally occurring molecules found in chromosomes, the cell's genetic machinery. RNA is a group of naturally occurring informational molecules which orchestrate a cell's behavior which, in turn, regulates the action of groups of cells, including the cells which compromise the body's immune system. RNA directs the production of proteins and regulates certain cell activities including the activation of an otherwise dormant cellular defense against viruses and tumors. Our drug technology utilizes specifically-configured RNA. Our double-stranded RNA drug product, trademarked Ampligen®, is an experimental, unapproved drug, that would be administered intravenously. Ampligen® has been assigned the generic name rintatolimod by the United States Adopted Names Council (USANC) and has the chemical designation poly(I) poly(C12U).

Clinical trials of Ampligen® already conducted by us include studies of the potential treatment of CFS, Hepatitis B, HIV and cancer patients with renal cell carcinoma and malignant melanoma. All of these potential uses will require additional clinical trials to generate the safety and effectiveness data necessary to support regulatory approval.

On February 1, 2013, we received a CRL from the FDA declining to approve our New Drug Application (“NDA”) for Ampligen® for CFS. In its CRL, the FDA communicated that Hemispherx should conduct at least one additional clinical trial, complete various nonclinical studies and perform a number of data analyses. The additional clinical study should address, among other things, Ampligen®'s efficacy in treating CFS patients, be of sufficient size and duration to assess the safety of Ampligen® and be sufficient to determine appropriate dosing. The FDA set forth the reasons for this action and provided recommendations to address certain of the outstanding issues. The FDA stated that the submitted data does not provide substantial evidence of efficacy of Ampligen® for the treatment of CFS and that the data does not provide sufficient information to determine whether the product is safe for use in CFS due to the limited size of the safety database and multiple discrepancies within the submitted data. In addition to the safety and effectiveness issues recommended to be addressed in at least one additional clinical trial, the CRL states that Hemispherx should conduct complete rodent carcinogenicity studies in two species prior to approval and also conduct additional animal toxicology studies providing more comprehensive evaluation of Ampligen® fragments and degradation products. The CRL also requests evaluation of variation between lots of Ampligen® tested in the development process and recommends tighter control of the Ampligen® manufacturing process.

In response to the CRL, we continue to plan to avail ourselves of the opportunity for an “end-of-review” meeting with representatives of the Office of Drug Evaluation II which issued the CRL, in order to clarify and seek to narrow the outstanding issues regarding the further development of Ampligen® for the treatment of CFS.

FDA regulations provide a formal dispute resolution process to obtain review of any FDA decision, including a decision not to approve an NDA, by raising the matter with the supervisor of the FDA office that made the decision. The formal dispute resolution process exists to encourage open, prompt discussion of scientific (including medical) disputes and procedural (including administrative) disputes that arise during the drug development, new drug review, and post-marketing oversight processes of the FDA. Depending on the outcome of a number of initiatives in the CFS community, including the FDA’s Patient Focused Drug Development Initiatives, forthcoming drug guidance and other scientific initiatives by the Institute of Medicine, Center for Disease Control and National Institute of Health, we will continue to examine the opportunity for an “end-of-review” meeting. Depending on the results of these initiatives, we may request an "end-of-review" conference with the FDA as a precursor to a possible submission of a formal appeal to the Office of New Drugs within the FDA's Center for Drug Evaluation and Research regarding the FDA's decision. Please see “Risks Associated with Our Business” in Part I; Item 1A. Risk Factors below.

-18-

Until we undertake the end-of-review conference(s) with the FDA, we are unable to reasonably estimate the nature, costs, necessary efforts to obtain FDA clearance or anticipated completion dates of any additional clinical study or studies. Utilizing the industry norms for undertaking a Phase III clinical study, we estimate upon acceptance of the study's design that it would take approximately 18 months to three years to complete a new well-controlled Ampligen® clinical study for resubmission to the FDA. Industry norms suggest that it will require three to six months to initiate the study, one to two years to accrue and test patients, three to six months to close-out the study and file the necessary documents with the FDA. The actual duration to complete the clinical study may be different based on the length of time it takes to design the study and obtain FDA's acceptance of the design, the final design of an acceptable Phase III clinical study, availability of suitable participants and clinical sites along with other factors that could impact the implementation of the study, analysis of results or requirements of the FDA and/or other governmental organizations. We anticipate that the time and cost to undertake clinical trial(s), studies and data analysis are beyond our current financial resources without gaining access to additional funding. Please see "Part I; Item 1A, Risk Factors: "We may require additional financing which may not be available."

In May 1997, the FDA authorized an open-label treatment protocol, (“AMP 511”), allowing patient access to Ampligen® for treatment in an open-label safety study under which severely debilitated CFS patients have the opportunity to be on Ampligen® to treat this very serious and chronic condition. The data collected from the AMP 511 protocol through a consortium group of clinical sites provide safety information regarding the use of Ampligen® in patients with CFS. As of June 30, 2016, there were 27 patients participating in this open label treatment protocol taking treatment. We are establishing an enlarged data base of clinical safety information which we believe will provide further documentation regarding the absence of autoimmune disease associated with Ampligen® treatment. We believe that continued efforts to understand existing data, and to advance the development of new data and information, will ultimately support our future filings for Ampligen® and/or the design of future clinical studies. In 1997, we calculated the cost per dose (400mg) of Ampligen® to be $150 per dose consistent with the regulatory guidelines; however, we recently engaged an independent certified public accountant to recalculate the cost per dose consistent with the current guidelines, utilizing the costs to produce a vial in 2015. The independent analysis disclosed a cost per 400 mg dose of Ampligen® of $400, $200 per vial. We have requested authorization from the FDA to implement the new cost.

On July 12, 2012, we filed a new drug application for Ampligen® with the ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica), the agency responsible for the national regulation of drugs, foods and medical technology in Argentina, under the ANMAT’s Orphan Drug regulations. We believe that the approval of Ampligen® as an Orphan Drug may allow reimbursement by the Health Services Authority (SSS), the central health authority in Argentina for patients seeking treatment for CFS.

In January 2015, we reported that we have conducted new in vitro studies of natural killer (NK) cells obtained from CFS patients in conjunction with a comprehensive review of the medical literature to determine the relative incidence of NK cell functional deficiencies in CFS disease. This review indicates that low NK cell cytotoxicity (NKCC) has been consistently reported in CFS patients compared to normal controls. In the new laboratory studies, Ampligen® was found to increase in vitro NK activity utilizing cells from CFS patient donors. The authors of the new report are all affiliated with Hemispherx.

Alferon N Injection®

Alferon N Injection® is the registered trademark for our injectable formulation of natural alpha interferon, which was approved by the FDA in 1989 for the treatment of certain categories of genital warts. Alferon® is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional (within lesions) treatment of refractory (resistant to other treatment) or recurring external genital warts in patients 18 years of age or older. Certain types of human papilloma viruses (“HPV”) cause genital warts, a sexually transmitted disease (“STD”). The U.S. Centers for Disease Control and Prevention (“CDC”) estimates that “approximately twenty million Americans are currently infected with HPV with another six million becoming newly infected each year. HPV is so common that at least 50% of sexually active men and women get it at some point in their lives.” Although they do not usually result in death, genital warts commonly recur, causing significant morbidity and entail substantial health care costs.

Interferons are a group of proteins produced and secreted by cells to combat diseases. Researchers have identified four major classes of human interferon: alpha, beta, gamma and omega. Alferon N Injection® contains a multi-species form of alpha interferon. The world-wide market for injectable alpha interferon-based products has experienced rapid growth and various alpha interferon injectable products are approved for many major medical uses worldwide. Alpha interferons are manufactured commercially in three ways: by genetic engineering, by cell culture, and from human white blood cells. All three of these types of alpha interferon are or were approved for commercial sale in the U.S. Our natural alpha interferon is produced from human white blood cells.

-19-

The potential advantages of natural alpha interferon over recombinant (synthetic) interferon produced and marketed by other pharmaceutical firms may be based upon their respective molecular compositions. Natural alpha interferon is composed of a family of proteins containing many molecular species of interferon. In contrast, commercial recombinant alpha interferon products each contain only a single species. Researchers have reported that the various species of interferons may have differing antiviral activity depending upon the type of virus. Natural alpha interferon presents a broad complement of species, which we believe may account for its higher activity in laboratory studies. Natural alpha interferon is also glycosylated (partially covered with sugar molecules). Such glycosylation is not present on the currently U.S. marketed recombinant alpha interferons. We believe that the absence of glycosylation may be, in part, responsible for the production of interferon-neutralizing antibodies seen in patients treated with recombinant alpha interferon. Although cell culture-derived interferon is also composed of multiple glycosylated alpha interferon species, the types and relative quantity of these species are different from our natural alpha interferon.

Alferon N Injection® [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product. There are essentially no neutralizing antibodies observed against Alferon N Injection® to date and the product has a relatively low side-effect profile. The recombinant DNA derived alpha interferon formulations have been reported to have decreased effectiveness after one year, probably due to neutralizing antibody formation.

See "Manufacturing" and "Marketing/Distribution" sections below for more details on the manufacture and marketing/distribution of Alferon N Injection®.

Alferon® LDO (Low Dose Oral)

Alferon® LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)] is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection®, should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic believed to work by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa. Oral interferon could be economically feasible for patients and logistically manageable globally for development programs for prevention and, or treatment of pandemic influenza, seasonal influenza and other emerging viruses. Oral administration of Alferon® LDO, with its anticipated affordability, low toxicity, no production of antibodies, and broad range of potential bioactivity, could be a breakthrough treatment or preventative for viral diseases.

Hemispherx currently has an FDA authorized protocol to conduct a Phase II, double-blind, adaptive-design, randomized, placebo-controlled, dose-ranging study of Alferon® LDO for the prophylaxis and treatment of seasonal influenza of more than 200 subjects. Our Phase II study has continued to be delayed as we had redirected many of our resources to complete the upgrades in the New Brunswick facility.

Other Diseases

In July 2011, we received FDA authorization to proceed with the initiation of a new clinical trial of intranasal Ampligen® to be used in conjunction with commercially approved seasonal influenza vaccine. On April 16, 2012, a clinical trial was initiated in which Ampligen® is nasally administered in conjunction with FluMist® to healthy human volunteers at the University of Alabama at Birmingham under the auspices of Dr. Paul Goepfert, Associate Professor of Medicine in the Division of Infectious Diseases and Director of the Alabama Vaccine Research Clinic. This study is a first use of Ampligen® with a seasonal vaccine in humans to assess the safety of Ampligen® when nasally delivered as a vaccine adjuvant. Another objective of this study is to determine the extent to which Ampligen® mobilizes potential protections against pandemic influenza by utilization of a seasonal flu vaccine. The study will evaluate the potential immunologic enhancement of Ampligen® by comparing immune parameters in the group receiving Ampligen® plus FluMist® with another group receiving FluMist® plus placebo. Twenty-five subjects have been enrolled; twelve in Stage 1 and thirteen subjects in Stage 2. The study is currently on hold pending the safety data on these 25 subjects being reviewed by the Data Monitoring Committee and authorization from the FDA is received to proceed with enrollment. As of June 30, 2016, there are no active subjects in the study.

-20-

In December 2013, we announced that we are supporting the University of Pittsburgh’s National Institutes of Health funded study (grant 1PO1CA132714) currently underway as part of the University’s Chemokine Modulation Research initiative which includes Ampligen® as an adjuvant. As part of this collaboration, Hemispherx has supplied clinical grade Ampligen® (rintatolimod) to the University. The study, under the leadership of professor of surgery Pawel Kalinski, M.D., Ph.D. and involves the Chemokine Modulatory regimen developed by Dr. Kalinski’s group, has successfully completed the dose escalation in patients with resectable colorectal cancer under the clinical leadership of Dr. Amer Zureikat, an assistant professor of surgery. To date, 15 patients have been treated in this study. In addition, the University has initiated enrollment in an additional cancer study of peritoneal surface malignancies which includes Ampligen® as an immune enhancer. To date, 43 patients have been treated. The University has initiated enrollment into another cancer study of recurrent ovarian cancer patients which includes Ampligen® as a component of the treatment regimen. To date, 3 patients have been treated. The University has received Institutional Review Board approval for another cancer study of subjects with chemo-refractory metastatic colorectal cancer which also includes Ampligen® as an immune enhancer. Enrollment into this study has not yet been initiated.

In May 2014, we announced that one of our advanced stage biological products, Alferon® N, significantly inhibited the replication of the MERS virus in vitro. MERS-CoV is a recently emerged human coronavirus responsible for the lethal pulmonary syndrome known as MERS (Middle East Respiratory Syndrome). Recent testing in laboratories of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has revealed that Alferon® N was inhibitory to MERS-CoV both when used before test cells were exposed to MERS-CoV, as well as after the cells were exposed to the deadly virus. NIAID researchers led the Alferon® N MERS-CoV experiments. They treated monkey kidney cells with Alferon® N either 18 hours prior to infection with MERS-CoV ("pre-treatment") or 1 hour following infection with MERS-CoV ("post-treatment"). At Day 1 and Day 3, supernatants were collected from cells and virus titers were thereafter measured. In both cases, Alferon® N showed significant dose-dependent inhibitory effects, thus suggesting the potential of Alferon® N both as a preventive and a potential treatment. Laboratory (in vitro) studies of potential antiviral agents are not necessarily predictive of clinical benefits. The Company was not involved in the conduct of the experimentation.

In June 2014, we announced that we have confirmed that Alferon® N inhibits replication of the MERS virus in vitro. Chien-Te (Kent) Tseng, Ph.D., Associate Professor, Microbiology & Immunology at the University of Texas Medical Branch at Galveston, led the Alferon® N MERS-CoV experiments. Calu-3 cells were treated with Alferon® N 24 hours prior to infection with MERS-CoV. At 36 hours, supernatants were collected from cells and the virus titers were thereafter measured. Alferon® N showed significant dose-dependent inhibitory effects, thus suggesting the potential of Alferon® N as a preventative. Laboratory (in vitro) studies of potential antiviral agents are not necessarily predictive of clinical benefits. The Company supplied the Alferon® N, but was not directly involved in the conduct of the experimentation.

In July 2015, we submitted an application for orphan drug designation to the European Medicines Agency (EMA) for Alferon® N to treat MERS and on January 6, 2016, the EMA forwarded to us both its Public Summary of Opinion and its record designation approving the Orphan Medicinal Products Designation for Alferon® N Injection, also known as interferon alfa-n3, as a potential treatment of MERS.

On March 3, 2016, we entered into a Sales, Marketing, Distribution and Supply Agreement (the “Scien Agreement”) with Scientific Products Pharmaceutical Co. LTD, a Saudi Arabia based pharmaceutical company (“Scien”). Pursuant to the Scien Agreement, we granted Scien an exclusive license to sell, market and distribute human leukocyte derived Interferon alfa-n3 (the “Product”) for refractory/recurrent genital warts, recombinant interferon refractory patients and patients with other infectious diseases, e.g., Middle East Respiratory Syndrome (“MERS”), influenza, West Nile Virus and cancer (the “Field”) within the Gulf Cooperation Council states (the “Territory”) for Direct Access/EAP and Regulatory Agency-Approved purposes. A condition precedent to the granting of the license is the successful completion of a clinical study to be performed by the Saudi Ministry of Health on at least five persons in Saudi Arabia treating early onset patients infected with MERS. Scien will purchase the Product to be used in this study. Pursuant to the Scien Agreement, Scien will, among other things, prepare a business plan to make aware and educate physicians and patients about the Product both prior to and following approval of the Product, assist us to gain regulatory approval of Product in the Field in the Territory and, if needed, assist in recruiting clinical trial sites and principal investigators in the Field in the Territory. We have recently been informed by the Saudi Ministry of Health that they will not pursue treating patients infected with MERS with human leukocyte derived Interferon and are now looking to explore other options to conduct a clinical study to treat MERS before seeking regulatory approval.

-21-

Ebola

We announced, in September 2014, a series of collaborations designed to determine the potential effectiveness of Alferon® N and Ampligen® as potential preventative and/or therapeutic treatments for Ebola related disorders. Our two platform drugs Alferon® N and Ampligen®, have certain unique structural attributes and developmental histories which suggest potential incremental value with respect to inclusion in various Ebola therapeutic cocktails under development. These collaborations have resulted in the following reports being issued:

November 2014 - We received a report from the United States Army Medical Research Institute of Infectious Diseases ("USAMRIID") scientists that they have in-vitro data indicating that Alferon®, the only multi-species, natural alpha interferon commercially approved in the U.S., successfully protected human cells against the Ebola virus (EBOV).

November 2014 - We announced that we had received a new research report from Professor Tramontano in the Department of Life and Environmental Sciences, University of Cagliari, Italy. The biochemical study demonstrates Ampligen® can successfully bind to the lethal Ebola Virus protein designated VP35. VP35 protein normally inactivates a patient's immune/antiviral system by binding to viral dsRNA thereby sequestering a critical antiviral/immune activator of the body, which leads to high morbidity and death rates. Ampligen® competes with viral dsRNA for VP35 binding and this finding is consistent with recent studies at USAMRIID demonstrating that Ampligen® inhibits Ebola virus infectivity in vitro.

December 2014 - We announced that we received a new research report from researchers at Howard University, Washington DC. The report describes a study in which Ampligen® strongly inhibited the Ebola minigenome in the human embryonic kidney cell system.

February 2015 - We announced results of a new efficacy study of Ampligen® in a mouse model of EBOV infection performed by scientists at the USAMRIID. Ampligen® was utilized with a mouse adapted Ebola virus using multiple groups of mice with varying dosage schedules of Ampligen® given every other day. The most effective dose, resulting in 100% percent survival at Day 21, corresponded to a human dose of approximately 400 mg, which has been used clinically approximately 50,000 times and has been generally well-tolerated when administered twice weekly. When higher doses of Ampligen® were used in the Ebola-infected mice, the survival rate dropped to 90%. The Ebola-infected mice treated with placebo had a 100% death rate by Day 7 post-infection. The EBOV data obtained from the in vitro and mouse infection studies using Ampligen® suggest a potential prophylactic and/or early onset therapeutic role in EVD. Previously published experimental results of animal studies using models of other lethal viral infections indicate possible similar applications to other lethal viral diseases. However, in vitro and animal testing is no assurance of human safety or efficacy for viral diseases. Clinical studies would be necessary to establish human efficacy and safety of Ampligen® for any treatment and/or prevention indication.

Positive results from a non-human primate ("NHP") study in all probability may be required before initiation of human clinical testing of Ampligen® in patients with Ebola Virus Disease ("EVD"). Clinical studies would also be necessary to establish human safety and efficacy of Ampligen® for either treatment and/or prevention of EVD. Clinical safety and tolerability data obtained for one indication, for example, CFS, may be different for another disorder like EVD. Currently, because of increased demand and the limited number of facilities that can conduct EBOV studies in NHP, the scheduling of a NHP study may be delayed; however, the Company is actively seeking such a study.

-22-

Our European subsidiary, Hemispherx Biopharma Europe N.V./S.A., has been formally notified of a positive opinion from the COMP (Committee on Medical Products) regarding its Orphan Medicinal Product Application for Ampligen®, an experimental therapeutic, to treat Ebola Virus Disease (EVD). The European Medicines Agency (EMA) published on May 22, 2015 both its Public Opinion Summary and its record designation approving the Orphan Medicinal Product Designation for Ampligen®, also known as rintatolimod experimental therapeutic, to treat Ebola Virus Disease (EVD).

Our overall objectives include plans to continue seeking approval for commercialization of Ampligen® in the United States and abroad as well as to widen existing commercial therapeutic indications of Alferon N Injection® presently approved in the United States and Argentina. In addition, we have formed collaborations with multiple research laboratories around the world to examine Ampligen®, an experimental therapeutic, for the treatment of Ebola Virus Disease (EVD) among others. Our ability to commercialize our products, widen commercial therapeutic indications of Alferon N Injection® and/or capitalize on our collaborations with research laboratories to examine our products as potential preventatives for, and treatments of, MERS, among others, are subject to a number of significant risks and uncertainties including, but not limited to our ability to enter into more definitive agreements with some of the research laboratories and others that we are collaborating with, to fund and conduct additional testing and studies, whether or not such testing is successful or requires additional testing and meets the requirements of the FDA and comparable foreign regulatory agencies. We do not know when, if ever, our products will be generally available for commercial sale for any indication.

Manufacturing

On October 2, 2011, the Company finalized their Fourth Amendment to a Supply Agreement, effective through March 11, 2014, with Jubilant Hollister-Stier Laboratories LLC of Spokane, Washington (“Hollister-Stier”), pursuant to which Hollister-Stier would formulate and package Ampligen® from the key raw materials that Hemispherx would supply to them. This Supply Agreement expired March 11, 2014. The Company is working towards an amendment to the existing Supply Agreement, which may contain additional fees as part of entering into the extension. In October 2014, we entered into a purchase commitment with Hollister-Stier for approximately $700,000 for the manufacture of clinical batches of Ampligen®. The Company is in discusssion with Hollister-Stier about this purchase commitment.

On July 27, 2016, the Company reached an agreement with Avrio Biopharmaceuticals ("Avrio"), Irvine California, to serve as an additional contract manufacturer of Hemispherx's experimental drug, Ampligen®. Avrio, an FDA inspected facility, has the capabilities for the compounding and fill/finish of sterile clinical and commercial grade Ampligen® to satisfy the Company's ongoing domestic clinical studies as well as the recently initiated Early Access Program (EAP) in Europe and Turkey. We believe that Avrio will be able to meet our immediate requirements until we are able to amend our agreement with Hollister-Stier and, regardless, will be a good source of manufactured product. The Company has initiated the transfer of the key raw materials and has made an initial payment of $246,000 to Avrio for the manufacture of Ampligen®. Please see “Risks Associated with Our Business” in Part II. Item 1A. Risk Factors below - There are no long-term agreements with suppliers of required materials and services for Ampligen® and there are a limited number of raw material suppliers. If we are unable to obtain the required raw materials and/or services, we may not be able to manufacture Ampligen®.

-23-

We also are exploring the possibility of selling the facility if we can obtain a long term lease back of the facility on acceptable terms.

To formulate, fill, finish and package (“fill and finish”) Alferon N Injection® Drug Product, we require a FDA approved third party Contract Manufacturing Organization (“CMO”). In January 2012, we agreed to a Technology, Transfer, Validation and Commercial Supply Agreement with Althea Technologies, Inc. (“Althea”) of San Diego, CA, regarding the fill and finish process for Alferon N Injection®. In November 2014, we entered into a purchase commitment with Althea for approximately $622,000 for the production of validation batches of Alferon® N Injection for emergency use and/or commercial sale. The Company has paid approximately $210,000 to Althea with regard to this open purchase commitment as of June 30, 2016 and has recorded this amount within work-in-process inventory.

Marketing/Distribution

Our marketing strategy for Ampligen® reflects the differing health care systems around the world along with the different marketing and distribution systems that are used to supply pharmaceutical products to those systems. We expect that, subject to receipt of FDA, ANMAT and/or other regulatory approval, Ampligen® may be utilized in four medical arenas: physicians’ offices; clinics; hospitals; and the home treatment setting. In preparation for the FDA’s consideration of our Ampligen® NDA, we undertook early stage development of pre-launch and launch driven marketing plans focusing on audience development, medical support and payer reimbursement initiatives which could facilitate product acceptance and utilization at the time of regulatory approval, if obtained. Similarly, we continued to consider distribution scenarios for the Specialty Pharmacy/Infusion channel which could provide market access, offer 3PL (third party logistics) capabilities and provide the requisite risk management control mechanisms. It is our intent to utilize third party service providers to execute elements of both the marketing/sales and distribution plans. As a possible option, we considered a plan to utilize a small group of Managed Market account managers to introduce the product to payor, employer and government account audiences. We believe that this approach could establish a market presence and facilitate the generation of revenue without incurring the substantial costs associated with a traditional sales force. Furthermore, Management believes that any approach considered should enable us to retain multiple options for future marketing strategies.

-24-

In January 2010, we engaged an Argentinean regulatory and business design entity to explore the possibility of initiating clinical trials of Alferon N Injection®, Ampligen® and Alferon® LDO during the influenza season in Argentina. On June 14, 2010, we executed a five year exclusive Sales, Marketing, Distribution and Supply Agreement for Argentina with GP Pharm Latinoamerica (“GP Pharm”), an affiliate company of Spanish GP Pharm SA. Under this Agreement, GP Pharm will be responsible for gaining regulatory approval in Argentina for Ampligen® to treat CFS in Argentina and for commercializing Ampligen® for this indication in Argentina. We granted GP Pharm the right to expand rights to sell this experimental therapeutic into other Latin America countries based upon GP Pharm achieving certain performance milestones. We also granted GP Pharm an option to market Alferon N Injection® in Argentina and other Latin America countries. Under these agreements, we will manufacture and supply Ampligen® and Alferon N Injection® to GP Pharm. On November 15, 2010, we amended our June 15, 2010 agreement with GP Pharm to include Mexico in the Territory under the Sales, Marketing, Distribution and Supply Agreement. Under this Agreement, GP Pharm Mexico will be responsible for seeking regulatory approval in Mexico for Ampligen®, an experimental therapeutic, to treat CFS in Mexico and, if approval is obtained, for commercializing Ampligen® for this indication in Mexico. On May 24, 2016, we entered into a five year exclusive Renewed Sales, Marketing, Distribution and Supply Agreement (the “Agreement”) with GP Pharma whereby all material provisions within the Agreement remained consistent with the original agreement.

In January 2012, the ANMAT approved the sale and distribution of Alferon N Injection® (under the brand name “Naturaferon”) in Argentina. The receipt of the ANMAT approval for HPV is the first step of a regulatory process towards the commercial sales of Naturaferon. On September 20, 2012, we filed with ANMAT an amended NDA for the use of Alferon N Injection® in patients with chronic hepatitis C who have become refractory to recombinant interferon as a result of the appearance of neutralizing antibodies against recombinant interferon. On February 6, 2013, we received the ANMAT approval for the treatment of refractory patients that failed or were intolerant to the treatment with Interferon recombinant with Naturaferon in Argentina.

On September 6, 2011, we executed an amended agreement with Armada Healthcare, LLC (“Armada”) to undertake the marketing, education and sales of Alferon N Injection® throughout the United States. This agreement also provides start-up along with ongoing sales and marketing support to the Company. On July 31, 2015, it was mutually agreed upon to extend this agreement through August 14, 2017 subject to the same terms and conditions. We previously extended this agreement for the previous three years also under the same terms and conditions.

On September 6, 2011, we executed a new agreement with specialty distributor, BioRidge Pharma, LLC (“BioRidge”) to warehouse, ship, and distribute Alferon N Injection® on an exclusive basis in support of U.S. sales. On July 31, 2015, it was mutually agreed upon to extend this agreement through August 14, 2017 subject to the same terms and conditions. We previously extended this agreement for the previous three years also under the same terms and conditions.

On March 9, 2015, we executed an agreement with Emerge Health Pty Ltd. ("Emerge") to seek approval of Ampligen® for CFS in Australia and New Zealand and to commence distribution of Ampligen® in both countries on a named-patient basis, where deemed appropriate. The parties intend to collaborate on seeking regulatory approval from Australia's Therapeutic Goods Administration ("TGA") and New Zealand's Medicines and Medical Devices Safety Authority ("Medsafe"). Under this five-year exclusive license to sell, market, and distribute Ampligen in Australia and New Zealand to treat CFS, Emerge will implement regulatory-compliant programs to educate physicians about Ampligen® for CFS and seek orphan drug designation and approval of Ampligen® to treat CFS. Hemispherx will support these efforts and will supply Ampligen® at a predetermined transfer price. We have the right to buy out of the agreement at a price equal to three times Ampligen® sales for the preceding 12 months if exercised within the first two years or two times such sales if exercised after year three.

-25-

On August 3, 2015, we executed a multi-year agreement with Impatients, N.V. ("Impatients"), a Netherlands based company doing business as myTomorrows, for the commencement and management of an Early Access Program (“EAP”) in Europe, Turkey and Canada (the “Territory”) related to Chronic Fatigue Syndrome. Pursuant to the agreement, MyTomorrows, as Hemispherx’ exclusive service provider and distributor in the Territory, would perform EAP activities. These activities would be directed to (a) the education of physicians and patients regarding the possibility of early access to innovative medical treatments not yet the subject of a Marketing Authorization (regulatory approval) through named-patient use, compassionate use, expanded access and hospital exemption (b) patient and physician outreach related to a patient-physician platform, (c) the securing of Early Access Approvals (exemptions and/or waivers required by regulatory authorities for medical treatments prior to Marketing Authorization) for the use of such treatments, (d) the distribution and sale of such treatments pursuant to such Early Access Approvals, (e) pharmacovigilance (drug safety) activities and/or (f) the collection of data such as patient-reported outcomes, doctor-reported experiences and registry data. Hemispherx would support these efforts and supply Ampligen to myTomorrows at a predetermined transfer price. In the event that we receive Marketing Authorization in any country in the Territory, we would pay myTomorrows a royalty on products sold. The parties would establish a Joint Steering Committee composes of representative of both parties to oversee the EAP. On October 16, 2015, we amended the agreement with Impatients to include Alferon N® as part of the EAP as well as the inclusion of Brazil, Columbia and Chile within the definition of Territory which may provide access to our natural alpha interferon for patients that have become intolerant to treatment with recombinant interferon or where such treatment fails. We currently have inventory available for sale comprising of approximately 1,200 vials of clinical grade natural interferon Alpha-n3. The aforementioned agreement was terminated on April 20^th, 2016, to rectify certain aspects of the original agreement. On May 24, 2016, we entered into an amended and restated agreement with Impatients to reinstate the EAP agreement that covers an EAP to treat Chronic Fatigue Syndrome patients in the territories of the European Union and Turkey. International sales through this agreement are anticipated in 2016.

On August 6, 2015, we executed an agreement with Emerge to seek approval of Alferon N Injection® in Australia and New Zealand and to commence distribution of Alferon® in both countries on a named-patient basis, for treating genital warts and other infections and diseases to which patients in Australia and New Zealand have become refractory to recombinant interferon. Hemispherx and Emerge will collaborate on seeking regulatory approval from Australia’s TGA and New Zealand’s Medsafe. Under a five-year exclusive license to sell, market, and distribute Alferon N Injection® in Australia and New Zealand, Emerge will implement regulatory-compliant programs to educate physicians about Alferon®. Hemispherx will support these efforts and will supply Alferon® at a predetermined transfer price. We have the right to buy out of the agreement at a price equal to three times Alferon® sales for the preceding 12 months if exercised within the first two years or two times such sales if exercised after year three.

401(k) Plan

Each participant immediately vests in his or her deferred salary contributions, while Company contributions will vest over one year. The 6% Company matching contribution was terminated effective January 1, 2016. For the six months ended June 30, 2016, the Company did not make any contributions towards the 401(k) Plan.

New Accounting Pronouncements

See “Note 10: Recent Accounting Pronouncements”.

Disclosure About Off-Balance Sheet Arrangements

None.

-26-

Critical Accounting Policies

There have been no material changes in our critical accounting policies and estimates from those disclosed in Part II; Item 7: “Management's Discussion and Analysis of Financial Condition and Results of Operations; Critical Accounting Policies” contained in our Annual Report on Form 10-K for the year ended December 31, 2015.

RESULTS OF OPERATIONS

Three months ended June 30, 2016 versus three months ended June 30, 2015

Net Loss

Our net loss was approximately $1,303,000 and $4,845,000 for the three months ended June 30, 2016 and 2015, respectively, representing a decrease in loss of approximately $3,542,000 or 73% when compared to the same period in 2015. This decrease in loss for these three months was primarily due to the following:

a decrease in research and development expense of $1,539,000 or 63%;

a decrease in production costs of approximately $217,000 or 43%; and

an insurance settlement, net of litigation expenses of $2,100,000 recorded as other income of $1,436,000; offset by

Net loss per share was $(0.01) and $(0.02) for the three months ended June 30, 2016 and 2015, respectively. The weighted average number of shares of our common stock outstanding as of June 30, 2016 was 248,008,113 as compared to 236,149,999 as of June 30, 2015.

Revenues

Revenues from our Ampligen® Cost Recovery Program were $15,000 and $47,000 for the three months ended June 30, 2016 and 2015, respectively. For the three months ended June 30, 2016 and 2015, we had no Alferon N Injection® finished good product to commercially sell and all revenue was generated from the FDA approved open-label treatment protocol, (“AMP 511”), that allows patient access to Ampligen® for treatment in an open-label safety study.

Production Costs

Production costs were approximately $290,000 and $507,000, respectively, for the three months ended June 30, 2016 and 2015. This decrease of approximately $217,000 or 43% was primarily due to: 1) a decrease of approximately $163,000 in stability testing and pre-production costs related to the flood that occurred on the afternoon of January 5, 2016, caused by a malfunctioning water supply pipe for the sprinkler system, and 2) insurance claim proceeds of approximately $31,000 received during the current quarter towards damages caused by the flood.

Research and Development Costs

Overall Research and Development (“R&D”) costs for the three months ended June 30, 2016 were approximately $900,000 as compared to $2,439,000 for the same period a year ago, reflecting a decrease of approximately $1,539,000 or 63%. The primary reason for the decrease in research and development costs was due to: 1) a decrease in general R&D of approximately $55,000 associated with Ampligen®, 2) a decrease in executive salaries and wages of approximately $605,000, and 3) a decrease of approximately $872,000 in general R&D expenses including Alferon N Injection® compliance testing and clinical work. These decreases were mainly the result of implementing a strong financial austerity plan whereby we conducted an analysis of our research and development programs and our staffing levels within our New Jersey manufacturing facility as well as the flood caused by the malfunctioning water supply pipe for the sprinkler system mentioned above.

-27-

General and Administrative Expenses

General and Administrative (“G&A”) expenses for the three months ended June 30, 2016 and 2015, were approximately $1,639,000 and $2,002,000, respectively, reflecting a decrease of approximately $363,000 or 18%. The decrease in G&A expenses in 2016 was mainly due to lower executive salaries and wages and director fees of approximately $299,000 in the current quarter resulting from a reduction in staffing levels and lower professional fees of approximately $115,000.

Interest and Other Income

Interest and other income for the three months ended June 30, 2016 and 2015 were approximately $75,000 and $56,000, respectively, representing an increase of approximately $19,000 or 34%. The primary cause for the increase in investment income during the current quarter was primarily due to realized gains of approximately $20,000 during the current period as compared to the prior period.

Insurance settlement net of litigation expenses

The Company recorded a net insurance settlement of $1,436,000 during the three months ended June 30, 2016 which resulted from the legal settlements of various class action lawsuits during the current period. Insurance proceeds received of $3,536,000 were offset by litigation settlement expenses of $2,100,000. There were no such expenses in the prior period (see "Part II - Other Information; Item 1: Legal Proceedings" for details).

Six months ended June 30, 2016 versus six months ended June 30, 2015

Net Loss

Our net loss was approximately $3,467,000 and $8,290,000 for the six months ended June 30, 2016 and 2015, respectively, representing a decrease in loss of approximately $4,823,000 or 58% when compared to the same period in 2015. This decrease in loss for these six months was primarily due to the following:

a decrease in research and development expense of $3,211,000 or 63%;

a decrease in production costs of approximately $321,000 or 37%;

an insurance settlement net of litigation expenses recorded as other income of $1,436,000;

an increase in the gain from sale of income tax net operating losses of $187,000 or 14%; offset by

an increase in general and administrative expense of $172,000 or 4%;

a net loss on sale of short term marketable securities of approximately $87,000; and

a decrease in interest and other income of approximately $46,000 or 28%.

Net loss per share was $(0.01) and $(0.04) for the six months ended June 30, 2016 and 2015, respectively. The weighted average number of shares of our common stock outstanding as of June 30, 2016 was 247,786,026 as compared to 224,954,200 as of June 30, 2015.

Revenues

Revenues from our Ampligen® Cost Recovery Program were $54,000 and $83,000 for the six months ended June 30, 2016 and 2015, respectively. For the six months ended June 30, 2016 and 2015, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the FDA approved open-label treatment protocol, (“AMP 511”), that allows patient access to Ampligen® for treatment in an open-label safety study.

-28-

Production Costs

Production costs were approximately $558,000 and $879,000, respectively, for the six months ended June 30, 2016 and 2015. This decrease of approximately $321,000 or 37% was primarily due to a decrease in stability testing and pre-production costs related to the flood that occurred on the afternoon of January 5, 2016, caused by a malfunctioning water supply pipe for the sprinkler system.

Research and Development Costs

Overall Research and Development (“R&D”) costs for the six months ended June 30, 2016 were approximately $1,902,000 as compared to $5,113,000 for the same period a year ago, reflecting a decrease of approximately $3,211,000 or 63%. The primary reason for the decrease in research and development costs was due to: 1) a decrease in general R&D of approximately $1,319,000 associated with Ampligen®, and 2) a decrease of approximately $1,892,000 in general R&D expenses related to Alferon N Injection® compliance testing and clinical work. These decreases were mainly the result of implementing a strong financial austerity plan whereby we conducted an analysis of our research and development programs and our staffing levels within our New Jersey manufacturing facility as well as the flood caused by the malfunctioning water supply pipe for the sprinkler system mentioned above.

General and Administrative Expenses

General and Administrative (“G&A”) expenses for the six months ended June 30, 2016 and 2015, were approximately $4,087,000 and $3,915,000, respectively, reflecting an increase of approximately $172,000 or 4%. The increase in G&A expenses in 2016 was mainly due to: 1) a one-time charge for executive compensation severance pay due to the termination of an executive officer of $850,000, and 2) higher legal fees in the current period of $305,000 associated with various legal settlements (see "Part II - Other Information; Item 1: Legal Proceedings" for details). These increases were offset by lower executive salaries and wages and director fees of approximately $723,000 in the current period and lower professional fees of approximately $172,000.

-29-

Interest and Other Income

Interest and other income for the six months ended June 30, 2016 and 2015 were approximately $116,000 and $162,000, respectively, representing a decrease of approximately $46,000 or 16%. The primary cause for the decrease in investment income during the current period was primarily due to lower balances available to invest in the current period as compared to the prior period.

Insurance settlement net of litigation expenses

The Company recorded a net insurance settlement of $1,436,000 during the six months ended June 30, 2016 which resulted from the legal settlements of various class action lawsuits during the current period. Insurance proceeds received of $3,536,000 were offset by litigation settlement expenses of $2,100,000. There were no such expenses in the prior period (see "Part II - Other Information; Item 1: Legal Proceedings" for details).

Loss on Sale of Marketable Securities

Loss on sale of marketable securities was $87,000 and $0, respectively, for the six months ended June 30, 2016 and 2015. Our securities sold during the current period resulted in net realized losses. There were no such sales that incurred losses in 2015 for the same period.

Sale of New Jersey Tax Net Operating Loss

In January 2016, the Company effectively sold $16,000,000 of its approximately $29,000,000 of New Jersey state net operating loss carryforwards (for the year 2014) for approximately $1,320,000 and sold research credits for $241,000. In January 2015, the Company effectively sold $14,291,000 of its approximately $28,000,000 of New Jersey state net operating loss carryforwards (for the year 2013) for approximately $1,374,000, representing an increase in cash gain of $187,000 or 14% (see “Note 11: Funds Received from Sale of Income Tax Net Operating Losses”) for the six months ended June 30, 2016 as compared to the same period in 2015.

Liquidity and Capital Resources

Cash used in operating activities for the six months ended June 30, 2016 was approximately $2,292,000 compared to approximately $9,237,000 for the same period in 2015, a decrease of $6,945,000 or 75%. The primary reason for this decrease in cash used in operations in 2016 was due to lower operating expenses whereby we conducted an analysis of our research and development programs as well as our staffing levels within our New Jersey manufacturing facility which resulted in a decrease in cash flow used in operations in 2016. In addition, the Company received proceeds from an insurance settlement of $3,536,000 which resulted from the legal settlements of various class action lawsuits during the current period. Also, the Company paid the 2014 executive incentive bonuses in January 2015 for approximately $1,232,000 reflected in accrued expenses and also paid for work in process inventory of $1,090,000 in 2015. Lastly, the Company has restricted $1,750,000 in an escrow account which is designated for litigation settlement.

Cash provided by investing activities for the six months ended June 30, 2016 was approximately $1,553,000 compared to approximately $355,000 in cash used in investing activities for the same period in 2015, an increase of $1,908,000. The primary reason for the increase can be attributable to sales and maturities of marketable securities during the current period of $1,918,000.

Cash provided by financing activities for the six months ended June 30, 2016 was approximately $162,000 compared to approximately $9,278,000 for the same period in 2015, a decrease of $9,117,000. The primary reason for the decrease can be attributable to the Company receiving net proceeds of $9,293,000 from the sale of 38,919,883 shares sold pursuant to the ATM during the six months ended June 30, 2015 (see "Note 8: Stockholders' Equity”).

-30-

As of June 30, 2016, we had approximately $6,512,000 in cash, cash equivalents and marketable securities, inclusive of approximately $4,974,000 in Marketable Securities, representing a decrease of approximately $648,000 from December 31, 2015. The Company has restricted $1,750,000 in an escrow account which is designated for litigation settlement. In an effort to conserve cash, we conducted an analysis of our research and development programs as well as our staffing levels within our New Jersey manufacturing facility. Our analysis disclosed an ability to gain efficiencies and eliminate redundancies within our staffing which will result in a decrease in cash flow used in operations in 2016 and beyond. If we are unable to commercialize and sell Ampligen® or Alferon® LDO and/or recommence material sales of Alferon N Injection®, our operations, financial position and liquidity may be adversely impacted, and additional financing may be required. In this regard, due to the repair issues mentioned above within our NJ facility and the high cost estimates to bring the facility back online, we most likely will need additional funds to finance the revalidation process in our facility to initiate commercial manufacturing, thereby readying ourselves for an FDA Pre-Approval Inspection. However, there is no assurance that such financing will be available.

On March 15, 2016, we received written notice from the NYSE MKT LLC that we were not in compliance with the continued listing standards set forth in Section 1003(f)(v) of the NYSE MKT Company Guide because the Company’s common stock has been selling for a low price per share for a substantial period of time. The NYSE MKT has determined that the continued listing of our common stock is predicated on the Company affecting a reverse stock split of its common stock or otherwise demonstrating sustained price improvement within a reasonable period of time. We have until September 15, 2016 to demonstrate compliance.

We have been reexamining our fundamental priorities in terms of direction, corporate culture and our ability to fund operations. As a result, there have been significant changes at the Company in the past few months. The CEO of the Company was terminated and the Board of Directors has made several changes to the Company’s executive management team to provide effective and competent leadership that, management believes, will properly position the Company to achieve its commercial goals and increase stockholder value. Recent actions include aggressively pursuing international sales of clinical grade materials and implementing a strong financial austerity plan. We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and expertise needed to commercialize the many potential therapeutic aspects of its experimental drug and its approved drug Alferon®. A co-development partner may help in the acceleration of the commercialization of many of our potential experimental drugs as they have access to additional resources and capital; however, there can be no assurance that such co-development partnerships will be on acceptable terms, or that such partnerships, will be acceptable from a profitability standpoint. Management’s primary objectives are to create stockholder value and deliver much needed therapies to patients. There is no immediate impact on the listing of the Company’s common stock, which will continue to trade on the NYSE MKT, subject to the Company’s compliance with other listing standards. See “Part II; Item 1A-Risk Factors; The trading price of our common stock has decreased significantly over the past year and, as a result, the NYSE MKT has informed us that we are not in compliance with the standards for continued listing on the NYSE MKT. If we are unable to raise the trading price, the market for our common stock most likely will be adversely affected”.

-31-

In 2015, Mr. Equels waived his right under his employment agreement to any future payment of any incentive bonus related to the sale of the Company’s stock or other securities by, or on behalf of, the Company pursuant to the Maxim Equity Distribution Agreement or any similar or successor ATM equity distribution agreement. Mr. Equels voluntarily provided this waiver in an effort to preserve cash and to help the Company to ensure its short term commercialization goals.

The Company maintains a record of the number of shares of stock represented by each Incentive Right issued out of the 2016 Voluntary Incentive Stock Award Plan. During the six months ended June 30, 2016, The Company issued 1,477,201 incentive shares associated with the Plan and recorded $192,000 in equity-based compensation. For a more detailed subscription of these plans, please see Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Liquidity and Capital Resources section within the Company’s 2015 Form 10-K filed with the SEC on March 29, 2016.

Equity Distribution Agreement

On December 15, 2015, we entered into an Equity Distribution Agreement with Chardan Capital Markets, LLC (the “Chardan Agreement”) to create an at-the-market equity program under which we may sell shares of our common stock from time to time through Chardan Capital Markets, LLC, as sales agent (“Chardan”). Under the Chardan Agreement, Chardan will be entitled to a commission at a fixed commission rate of 3.0% of the gross sales price of Shares sold under the Chardan Agreement. Sales of the Shares, if any, under the Chardan Agreement may be made in transactions that are deemed to be “at-the-market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers’ transactions, including on the NYSE MKT, at market prices or as otherwise agreed with Chardan. The Company has no obligation to sell any of the Shares, and may at any time suspend offers under the Chardan Agreement or terminate the Chardan Agreement.

The Shares will be issued pursuant to the Company’s previously filed and effective Registration Statement on Form S-3 (File No. 333-205228). On December 16, 2015, the Company filed a Prospectus Supplement relating to the Chardan offering with the Securities and Exchange Commission. In 2015, no shares were sold under the Chardan Agreement. For the period ended June 30, 2016, the Company sold an aggregate of 1,270,233 shares that resulted in net cash proceeds of approximately $163,000 after commissions paid to Chardan for $5,000. The impact of the fund raising effort through the EDA is reflected in the "Consolidated Statements of Cash Flows" comparing the various financing activities for the six months ended June 30, 2016 and 2015, respectively. Unless and until the market price of our common stock increases significantly our ability to raise substantial funds from the sale of shares under the Chardan offering or other sales of our equity is hindered (see Part II; Item 1A. Risk Factors - “The trading price of our common stock has decreased significantly over the past year. If we are unable to raise the trading price, the market for our common stock most likely will be adversely affected”).

-32-

There can be no assurances that, if needed, we will be able to raise adequate funds from these or other sources or enter into licensing, partnering or other arrangements to advance our business goals. Our inability to raise such funds or enter into such arrangements, if needed, could have a material adverse effect on our ability to develop our products. Also, we have the ability to curtail discretionary spending, including some research and development activities, if required to conserve cash. Because of our long-term capital requirements, we may seek to access the public equity market whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. We are unable to estimate the amount, timing or nature of future sales of outstanding common stock or instruments convertible into or exercisable for our common stock. Any additional funding may result in significant dilution and could involve the issuance of securities with rights, which are senior to those of existing stockholders. We may also need additional funding earlier than anticipated, and our cash requirements, in general, may vary materially from those now planned, for reasons including, but not limited to, changes in our research and development programs, clinical trials, acquisitions of intellectual property or assets, enhancements to the manufacturing process, competitive and technological advances, the regulatory processes including the commercializing of Ampligen® products or new utilization of Alferon® products. See Part II, Item 1A. Risk Factors; “We may require additional financing which may not be available."

The proceeds from our financing have been used to fund infrastructure growth including manufacturing, regulatory compliance and market development along with our efforts regarding the Ampligen® NDA and preparedness for the FDA pre-approval inspections of the New Brunswick manufacturing facility. There can be no assurances that, if needed, we will raise adequate funds from these or other sources, which may have a material adverse effect on our ability to develop our products. Also, we have the ability to curtail discretionary spending, including some research and development activities, if required to conserve cash.

ITEM 3:

Quantitative and Qualitative Disclosures About Market Risk

We had approximately $6,512,000 in cash, cash equivalents and marketable securities, inclusive of approximately $4,974,000 in Marketable Securities, representing a decrease of approximately $2,398,000 from December 31, 2015. The Company has restricted $1,750,000 in an escrow account which is designated for litigation settlement.

To the extent that our cash and cash equivalents exceed our near term funding needs, we intend to invest the excess cash in money market accounts, high-grade corporate bonds or fixed-income type bond funds. We employ established conservative policies and procedures to manage any risks with respect to investment exposure.

ITEM 4:

Controls and Procedures

Our Chief Executive Officer and our Chief Financial Officer performed an evaluation of the effectiveness of our disclosure controls and procedures, which have been designed to permit us to effectively identify and timely disclose important information. In designing and evaluating the disclosure controls and procedures, Management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and Management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that the controls and procedures were effective as of June 30, 2016, to ensure that material information was accumulated and communicated to our Management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

During the six months ended June 30, 2016, we have made no change in our internal controls over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

-33-

Part II – OTHER INFORMATION

ITEM 1:

Legal Proceedings

(a)

Stephanie A. Frater v. Hemispherx Biopharma, Inc., William A. Carter, David Strayer and Wayne Pambianchi, U.S. District Court for Eastern District of Pennsylvania, Case No. 2:12-cv-07152-WY.

(b)

Mark Zicherman v. Hemispherx Biopharma, Inc., William A. Carter, Thomas K. Equels, Iraj E. Kiani, William M. Mitchell, Richard C. Piani, David Strayer and Charles T. Bernhardt, U.S. District Court for Eastern District of Pennsylvania, Case No. 2:13-cv-00243-WY.

(c)

Michael Desclos v. Hemispherx Biopharma, Inc., William A. Carter, Charles T. Bernhardt, Thomas K. Equels, David R. Strayer, Richard C. Piani, William M. Mitchell, and Iraj E. Kiani, First Judicial District of Pennsylvania, Court of Common Pleas of Philadelphia, March 2013 Term, No. 110.

(d)

Richard J. Sussman and Douglas T. Lowe v. Hemispherx Biopharma, Inc., William A. Carter, Charles T. Bernhardt, Thomas K. Equels, David R. Strayer, Richard C. Piani, William M. Mitchell, and Iraj E. Kiani, First Judicial District of Pennsylvania, Court of Common Pleas of Philadelphia, April 2013 Term, No. 3458.

(e)

Rena A. Kastis and James E. Conroy v. Hemispherx Biopharma, Inc., William A. Carter, Thomas K. Equels, Richard C. Piani, William M. Mitchell, Iraj E. Kiani and Robert E Peterson, Chancery Court of the State of Delaware, June 18, 2013, Case No. 8657.

(f)

Charles T. Bernhardt III v. Hemispherx Biopharma, Inc., Dr. William A. Carter, Thomas K. Equels, Esquire, Dr. Iraj Eqhbal Kiani, Dr. William M. Mitchell and Peter W. Rodino; Court of Common Pleas of Philadelphia County, Philadelphia, PA; Case: February Term, 2014 No. 000784.

(g)

Cato Capital, LLC v. Hemispherx Biopharma, Inc., U.S. District Court for the District of Delaware, Case No. 9-549-GMS.

(h)

William A. Carter v. Hemispherx Biopharma, Inc., U.S. District Court for the Southern District of Florida February 19, 2016 Case No. 1:16-cv-20597.

(a)

On December 21, 2012, a putative Federal Securities Class Action Complaint was filed against the Company and three of its Officers in the United States District Court for the Eastern District of Pennsylvania. This action, Stephanie A. Frater v. Hemispherx Biopharma, Inc., et al., was purportedly brought on behalf of a putative class of Hemispherx investors who purchased the Company's publicly traded securities between March 14, 2012 and December 17, 2012. The Complaint generally asserted that Defendants made material misrepresentations and omissions regarding the status of the Company's New Drug Application for Ampligen®, which had been filed with the United States Food and Drug Administration, in alleged violation of Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”), Rule 10b-5 promulgated thereunder, and Section 20(a) of the Exchange Act. On March 14, 2013, the Court appointed Hemispherx Investor Group as Lead Plaintiff pursuant to the Private Securities Litigation Reform Act of 1995 (“PSLRA”), 15 U.S.C. § 78u-4. Pursuant to the Court's March 29, 2013 scheduling order, Lead Plaintiff filed a Consolidated Amended Class Action Complaint (“Amended Complaint”) on May 20, 2013, and in its Amended Complaint, dropped Thomas K. Equels and Charles T. Bernhardt as Defendants and added David R. Strayer, M.D. and Wayne Pambianchi as Defendants. The Amended Complaint alleges an expanded Class Period of March 14, 2012 to December 20, 2012, which period encompasses statements made in the Company's 2011 Form 10-K filed on March 14, 2012, and at the FDA Advisory Committee Meeting on December 20, 2012. On July 19, 2013, Defendants filed a motion to dismiss the Amended Complaint. Lead Plaintiff filed its brief in opposition to Defendants' motion to dismiss is September 17, 2013, and Defendants filed their reply brief on October 17, 2013. On January 24, 2014, the court entered an order denying defendants' motion to dismiss the Amended Complaint, and on February 20, 2014, entered a scheduling order imposing, inter alia, a March 31, 2015 deadline for completion of all fact discovery. On February 25, 2014, defendants filed an answer and affirmative defenses to the Amended Compliant. Also on February 25, 2014, the Court entered a Stipulated Protective Order, which will govern all confidential documents produced in discovery. After conducting significant fact discovery, the parties reached an agreement in principle to settle all claims on December 31, 2014. However, the settlement is subject to the Court's issuance of an order finally approving the terms of the parties' settlement agreement in all material respects. On March 11, 2015, the parties filed a joint motion with the Court seeking an order, inter alia, granting preliminary approval of their settlement agreement, preliminarily certifying a class for settlement purposes, and setting a date for a final settlement hearing. On April 8, 2015, the Court granted the parties’ joint motion, and entered an Order preliminarily approving the parties’ settlement, preliminarily certifying a class for settlement purposes, directing issuance of notice, and scheduling the final approval hearing for July 22, 2015. On July 22, 2015, the Court held the final approval hearing to determine whether the parties’ settlement is fair, reasonable, adequate and should be approved, and on the same date entered an Order granting final approval of the parties’ settlement. No Company funds were used to pay the settlement, which was paid from the Company’s insurance coverage. The settlement did not contain any admission of fault or wrongdoing by Hemispherx or any of the individual defendants. No appeal was filed.

-34-

(b)

On January 15, 2013, a Shareholder Derivative Complaint was filed against the Company, as nominal defendant, and certain of its current and former Officers and Directors in the United States District Court for the Eastern District of Pennsylvania. Purporting to assert claims on behalf of the Company, the Complaint in this action, Mark Zicherman v. Hemispherx Biopharma, Inc., et al., alleges violations of state law, including breaches of fiduciary duties, waste of corporate assets, and unjust enrichment, arising from the alleged federal securities violations asserted in the securities class action. On February 22, 2013, the Court entered an order temporarily staying this case pending the outcome of the securities class action defendants' motion to dismiss that action. On July 3, 2013, Plaintiff filed an Amended Complaint, adding David R. Strayer, M.D., as a Defendant. On July 18, 2013, the Court entered an order staying the case as against Dr. Strayer pending the outcome of the motion to dismiss the securities class action. On January 24, 2014, the Court denied the defendants' motion to dismiss the securities class action. On March 26, 2014, the Court entered an order to continue the temporary stay, and on March 27, 2014, the Court entered an order placing the action in the Civil Suspense File. On April 11, 2014, the Court entered a Stipulated Protective Order, which will govern all confidential documents produced in discovery. On January 28, 2015, on request of the parties, the Court entered an Order continuing the temporary stay, subject to the requirement that the parties submit an updated joint status report within ten days of the court’s entry of an order granting or denying the securities class action parties’ motion for preliminary approval of their settlement agreement. On or about January 13, 2016, the parties agreed to attempt to resolve the action through mediation. On February 11, 2016, the parties engaged in a mediation and, at that mediation, reached an agreement in principle to settle all claims. On April 27, 2016, the parties executed a Stipulation and Agreement of Settlement (“Settlement”) which, if finally approved by the Court, will resolve all claims asserted in this action (“Zicherman”) and the two related consolidated state-court actions referenced below, Michael Desclos v. Hemispherx Biopharma, Inc. et al., and Richard J. Sussman and Douglas T. Lowe v. Hemispherx Biopharma, Inc., et al. On May 27, 2016, the Court entered an order preliminarily approving the parties’ Settlement of all three actions and scheduling the final approval hearing for September 27, 2016.

(c)

On March 4, 2013, a Shareholder Derivative Complaint was filed against the Company, as nominal defendant, and certain of its current and former Officers and Directors in the First Judicial District of Pennsylvania of the Court of Common Pleas of Philadelphia. Purporting to assert claims on behalf of the Company, the Complaint in this action, Michael Desclos v. Hemispherx Biopharma, Inc., et al., alleges violations of state law, including breaches of fiduciary duties, waste of corporate assets, and unjust enrichment, arising from the alleged federal securities violations asserted in the securities class action. On April 10, 2013, the Court entered an order temporarily staying this case pending the outcome of the securities class action defendants' motion to dismiss that action. On January 24, 2013, the court in the federal securities class action denied the defendants' motion to dismiss. On January 29, 2014, the court entered an order consolidating this action with the shareholder derivative action, Richard J. Sussman and Douglas T. Lowe v. Hemispherx Biopharma, Inc., et al., described below. On March 26, 2014, the Court entered an order to continue the temporary stay. On June 9, 2014, the Court entered a Stipulated Protective Order, which will govern all confidential documents produced in discovery. On or about January 13, 2016, the parties agreed to attempt to resolve the action through mediation. On February 11, 2016, the parties engaged in a mediation and, at that mediation, reached an agreement in principle to settle all claims. On April 27, 2016, the parties executed a Stipulation and Agreement of Settlement (“Settlement”) which, if finally approved by the Court, will resolve all claims asserted in this action (“Desclos”) and the two related actions, Zicherman, referenced above, and the state court action referenced below, Richard J. Sussman and Douglas T. Lowe v. Hemispherx Biopharma, Inc., et al. On May 27, 2016, the Court in Zicherman entered an order preliminarily approving the parties’ Settlement of all three actions and scheduling the final approval hearing for September 27, 2016.

-35-

(d)

On April 23, 2013, a Shareholder Derivative Complaint was filed against the Company, as nominal defendant, and certain of its current and former Officers and Directors in the First Judicial District of Pennsylvania of the Court of Common Pleas of Philadelphia. Purporting to assert claims on behalf of the Company, the Complaint in this action, Richard J. Sussman and Douglas T. Lowe v. Hemispherx Biopharma, Inc., et al., alleges violations of state law, including breaches of fiduciary duties, abuse of control, gross mismanagement, waste of corporate assets, and unjust enrichment, arising from the alleged federal securities violations asserted in the securities class action. On May 10, 2013, the Court entered an order staying this case pending the outcome of the ruling on the Federal Securities Class Action Defendants' motion to dismiss. On January 24, 2014, the court in the federal securities class action denied the defendants' motion to dismiss. On January 29, 2014, the Court entered an order consolidating this action with the shareholder derivative action, Michael Desclos v. Hemispherx Biopharma, Inc., et al., described above. On March 26, 2014, the Court entered an order to continue the temporary stay. On June 9, 2014, the Court entered a Stipulated Protective Order, which will govern all confidential documents produced in discovery. On or about January 13, 2016, the parties agreed to attempt to resolve the action through mediation. On February 11, 2016, the parties engaged in a mediation and, at that mediation, reached an agreement to settle all claims. On April 27, 2016, the parties executed a Stipulation and Agreement of Settlement (“Settlement”) which, if finally approved by the Court, will resolve all claims asserted in this action and the two related actions, Zicherman and Desclos, referenced above. On May 27, 2016, the Court in Zicherman entered an order preliminarily approving the parties’ Settlement of all three actions and scheduling the final approval hearing for September 27, 2016.

(e)

On June 18, 2013, a Stockholder Derivative Complaint was filed against the Company, as nominal defendant, and certain of its current and former Officers and Directors in the Court of Chancery of the State of Delaware. The Complaint in this action, Rena A. Kastis and James E. Conroy v. Hemispherx Biopharma, Inc., et al., alleges breaches of fiduciary duties, waste of corporate assets and unjust enrichment. The Company's Board of Directors appointed a Special Litigation Committee (“SLC”) to review the allegations set forth in the Complaint. On September 10, 2013, the Court entered a Stipulation and Order staying all proceedings in this action pending the SLC’s review and recommendation concerning the allegations contained in the Complaint. On December 20, 2013, the SLC issued its Report, in which it concluded that dismissing the Complaint would be in the best interests of Hemispherx and its stockholders. On January 20, 2014, the SLC moved to dismiss the Complaint. Following briefing and oral argument on the motion to dismiss, the Court denied the SLC’s motion on August 18, 2015, but did dismiss the claims against former officer Robert E. Peterson. On October 13, 2015, Plaintiffs filed a Verified Amended Derivative and Class Action Complaint (the “Amended Complaint”), asserting additional claims for breach of fiduciary duty against Board member Peter W. Rodino, declaratory judgment with respect to certain bonuses paid to officers of the Company, and a class action claim for breach of fiduciary duty against the current Board in connection with the solicitation of votes in advance of the Company’s 2015 annual meeting. The Amended Complaint also removed all of the dismissed claims against Mr. Peterson. The Company and all individual defendants except former Board member Richard C. Piani answered the Amended Compliant on November 19, 2015. The Court entered a scheduling order on December 2, 2015, and the Company anticipates discovery will continue through the second quarter of 2016. On January 5, 2016, the parties agreed to suspend all litigation for 60 days and to attempt to resolve the action through mediation. The parties engaged in a mediation on February 10, 2016, and reached an agreement in principle to settle all claims on April 27, 2016, and memorialized that agreement in a Stipulation and Agreement of Settlement (the “Settlement Stipulation”) which was filed with the Court on June 8, 2016. However, the settlement is subject to the Court's issuance of an order finally approving the terms of the parties’ settlement agreement in all material respects. On June 8, 2016, concurrent with the filing of the Settlement Stipulation, the parties filed a joint proposed scheduling order, which the Court entered the same day (the “Scheduling Order”). The Scheduling Order preliminarily certified the class for settlement purposes, directed the Company to issue notice (in the form approved by the Court) to Company stockholders and members of the putative class, and scheduled a settlement approval hearing (the “Settlement Approval Hearing”) to occur on September 9, 2016. At the Settlement Approval Hearing, the Court will determine whether the parties’ settlement is fair, reasonable, adequate and should be approved, and if the Court so determines, will enter an Order granting final approval of the parties’ settlement.

The Company believes that the claims asserted in the shareholder derivative litigation are without merit, and is vigorously defending these actions. While the Company also believes that the claims asserted in the securities litigation are without merit, the Company has reached a settlement agreement in principle that is satisfactory to the Company. If the Court does not issue an order finally approving the terms of the parties’ settlement agreement in all material respects, however, the Company intends to resume its vigorous defense of the securities litigation. The potential impact of these actions, which seek unspecified damages, equitable relief, attorneys' fees and expenses, is uncertain. There can be no assurance that an adverse result in these proceedings would not have a potentially material adverse effect on the Company's business, results of operations and financial condition.

-36-

(f)

On February 7, 2014, Charles T. Bernhardt III (“Bernhardt”) filed a Complaint in the Philadelphia Court of Common Pleas asserting that under an employment agreement dated December 6, 2011, the Company owed Bernhardt certain wages, fringe benefits and severance payments by reason of his resignation from employment as Chief Financial Officer of the Company. In October 2015, all parties to the suit agreed to a full and final settlement of the action. The settlement agreement has been fully executed by all parties and the Court action has been dismissed as settled. The Parties have agreed to a full and amicable resolution of all claims.

(g)

Cato Capital, LLC ("Cato") brought suit against the Company on July 31, 2009, in the United States District Court for the District of Delaware (the "Court"), alleging that under a November 2008 agreement between Cato and Hemispherx, Hemispherx owed Cato a placement fee arising from subsequent Hemispherx financing and investment transactions. Hemispherx disputed these allegations, asserting that Cato failed to comply with the provisions of its own contract. The Amended Complaint sought damages in the amount of $9,830,000.00 plus attorneys' fees and punitive damages. Pursuant to an indemnification responsibility, Hemispherx has also retained this firm to undertake the defense of the Sage Group.

The Parties had a Non-Jury trial on March 4, 5 and 6, 2013 before the United States District Court for the District of Delaware. On September 29, 2014, the Court found in favor of Hemispherx and Sage on all counts, and dismissed Cato’s claims in their entirety. On January 13, 2015, the Court granted the Company’s motion for attorney’s fees and costs and awarded the Company $770,852.76.

On October 24, 2014, Cato filed a notice of appeal of the Court’s September 29, 2014 decision in the United States Court of Appeals for the Third Circuit (the “Third Circuit”). On March 3, 2015, Cato filed its Brief in the Third Circuit. The Company’s Brief in Response was filed on April 6, 2015, with a Reply Brief by Cato filed on April 19, 2015. The Court of Appeals conducted Oral Argument on July 16, 2015. On August 21, 2015 the Court of Appeals affirmed the judgment of the District Court. On September 9, 2015 Cato sought reconsideration of the decision through re-argument or re-hearing by the en banc Court of Appeals. On September 17, 2015 the Court of Appeals denied Cato’s requests. On October 1, 2015 Hemispherx filed for additional costs and fees to be added to its existing judgment. On February 10, 2016 the Court increased Hemispherx’ judgment by an additional $48,725.75 to reflect the costs of defending the Cato appeal. On February 11, 2016 the Court of Appeals returned the mandate to the District Court. The Company is pursuing collection of its judgment in the amount of $829,578.51.

(h)

On February 19, 2016, a complaint was filed against the Company by William A. Carter in the United States District Court for the Southern District of Florida. The Complaint seeks damages against the Company for the alleged wrongful termination of the Plaintiff, the former Chief Executive Officer and Chairman of the Board of Directors of the Company, pursuant to an Engagement Agreement and an Employment Agreement, breach of each such agreement, and for unpaid wages and unlawful retaliation. The Complaint was served on February 26, 2016. The Response was due on March 17, 2016. A scheduling order was entered by the Court on February 25, 2016, setting the deadline for the submission of a Joint Scheduling Report and a Joint Proposed Scheduling Order within twenty (20) days of the appearance of the Defendant. No other orders have been entered by the Court. The Company believes that the claims asserted in the Complaint are without merit, and intends to vigorously defend these actions. The Parties have resolved all outstanding issues and have executed a comprehensive Settlement Agreement. The Court has dismissed the filed litigation in accordance with the parties' agreed resolution.

Summation.

In reference to Contingencies identified above, there can be no assurance that an adverse result in these proceedings would not have a potentially material adverse effect on our business, results of operations, and financial condition. The Company believes it has meritorious defenses and is vigorously defending against the claims identified in Contingency (b), (c), (d), (e), (f) and (h). There is currently no projection as to the likely outcome of the cases and the Company has not recorded any gain or loss contingencies as a result of the above matters for the six months ended June 30, 2016 and 2015. Also, with regards to Contingency (a), (b), (c), (d) and (e), the Company maintains a Directors and Officers Insurance Policy that provides coverage for claims and retention of legal counsel.

-37-

ITEM 1A:

Risk Factors

The following cautionary statements identify important factors that could cause our actual results to differ materially from those projected in the forward-looking statements made in this Form 10-Q. Among the key factors that have a direct bearing on our results of operations are:

Risks Associated with Our Business

No assurance of successful product development and finding co-development partners.

Ampligen® and related products. The development of Ampligen® and our other related products is subject to a number of significant risks. Ampligen® may be found to be ineffective or to have adverse side effects, fail to receive necessary regulatory clearances, be difficult to manufacture on a commercial scale, be uneconomical to market or be precluded from commercialization by proprietary right of third parties. Our investigational products are in various stages of clinical and pre-clinical development and require further clinical studies and appropriate regulatory approval processes before any such products can be marketed. We do not know when, if ever, Ampligen® or our other products will be generally available for commercial sale for any indication. Generally, only a small percentage of potential therapeutic products are eventually approved by the FDA for commercial sale (Please see the next Risk Factor and Part 1, Item II: “Management's Discussion and Analysis of Financial Condition and Results of Operations Business; Our Products; Ampligen®” above for more information).

Alferon N Injection®. Although Alferon N Injection® is approved for marketing in the United States for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older, to date it has not been approved for other indications. We face many of the risks discussed above, with regard to developing this product for use to treat other ailments (Please see the next Risk Factor and Part 1, Item II: “Management's Discussion and Analysis of Financial Condition and Results of Operations Business; Our Products; “Alferon N Injection®” above for more information).

We are committed to a focused business plan oriented toward finding co-development partners with the necessary capital and expertise required to commercialize the many therapeutic aspects of our experimental drugs and our FDA approved drug Alferon N®. If we are unable to find a suitable co-development partner to assist in the product development and commercialization of our experimental drugs and our FDA approved drug Alferon N®, we may be unable to continue or complete our development and commercialization of our products. In addition, there can be no assurance that such co-development partnerships would be on acceptable terms, or that such partnerships, will be acceptable from a profitability standpoint.

Our drug and related technologies are investigational and subject to regulatory approval. If we are unable to obtain regulatory approval in a timely manner, or at all, our operations will be materially harmed and our stock adversely affected.

All of our drugs and associated technologies, other than Alferon N Injection®, are investigational and must receive prior regulatory approval by appropriate regulatory authorities for commercial distribution and sale and are currently legally available only through clinical trials with specified disorders. At present, Alferon N Injection® is approved for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older. Use of Alferon N Injection® for other indications will require regulatory approval.

Our products, including Ampligen®, are subject to extensive regulation by numerous governmental authorities in the United States (“U.S.”) and other countries, including, but not limited to, the FDA in the U.S., the Health Protection Branch (“HPB”) of Canada, the Agency for the European Medicines Agency (“EMA”) in Europe and the Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (“ANMAT”) in Argentina. Obtaining regulatory approvals is a rigorous and lengthy process and requires the expenditure of substantial resources. In order to obtain final regulatory approval of a new drug, we must demonstrate to the satisfaction of the regulatory agency that the product is safe and effective for its intended uses and that we are capable of manufacturing the product to the applicable regulatory standards. We require regulatory approval in order to market Ampligen® or any other proposed product and receive product revenues or royalties. We cannot assure you that Ampligen® will ultimately be demonstrated to be safe and efficacious. While Ampligen® is authorized for use in clinical trials in the U.S., we cannot assure you that additional clinical trial approvals will be authorized in the United States or in other countries, in a timely fashion or at all, or that we will complete these clinical trials. In addition, although Ampligen® has been authorized by the FDA for treatment use under certain conditions, including provision for cost recovery, there can be no assurance that such authorization will continue in effect.

-38-

On February 1, 2013, we received a CRL from the FDA declining to approve our Ampligen® NDA for the treatment of CFS. The FDA communicated that we should conduct at least one additional clinical trial, complete various nonclinical studies and perform a number of data analysis. For more detailed information about the current status of our Ampligen® NDA please see Part 1, Item II: “Management's Discussion and Analysis of Financial Condition and Results of Operations Business; Our Products; Ampligen®” above.

The FDA's regulatory review and approval process is extensive, lengthy, expensive and inherently uncertain. To receive approval for a product candidate, we must, among other things, demonstrate to the FDA's satisfaction with substantial evidence from well-controlled pre-clinical and clinical trials that the product candidate is both safe and effective for each indication for which approval is sought. Before we can sell Ampligen® for any use, or promote Alferon® for any use other than as Alferon N Injection® for treatment of refractory or recurring genital warts, we will need to file the appropriate NDA with the FDA in the U.S. and the appropriate regulatory agency outside of the U.S. where we intend to market and sell such products. At present the only NDA we have filed with the FDA is the NDA for the use of Ampligen® to treat CFS. As discussed in the prior paragraph, the FDA declined to approve this NDA and indicated that we needed to conduct additional work. Therefore, ultimate FDA approval, if any, may be delayed by several years and may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our future applications for approval, which might significantly harm our business and prospects. As a result, we cannot predict if or when we might receive regulatory approval for the use of Ampligen® to treat CFS or for the use of any other products. Even if regulatory approval from the FDA is received for the use of Ampligen® to treat CFS or eventually, for the use of any other product, any approvals that we obtain could contain significant limitations in the form of narrow indications, patient populations, warnings, precautions or contra-indications or other conditions of use, or the requirement that we implement a risk evaluation and mitigation strategy. In such an event, our ability to generate revenues from such products could be greatly reduced and our business could be harmed.

Even if we believe that data collected from our preclinical studies and clinical trials of our product candidate are promising, this data has not been, and may not be in the future, sufficient to support marketing approval by the FDA, and regulatory interpretation of these data and procedures may continue to be unfavorable.

To the extent that we are required by the FDA pursuant to the Ampligen® NDA to conduct additional studies and take additional actions, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our future applications for approval, which might significantly harm our business and prospects. As a result, we cannot predict when or whether regulatory approval will be obtained for any product candidate we develop.

Obtaining approval of a NDA by the FDA, or a comparable foreign regulatory authority, is inherently uncertain. Even after completing clinical trials and other studies, a product candidate could fail to receive regulatory approval for many reasons, including the following:

•

not be able to demonstrate to the satisfaction of the FDA that our product candidate is safe and effective for any indication;

•

the FDA may disagree with the design or implementation of our clinical trials or other studies;

•

the results of the clinical trials or other studies may not demonstrate that a product candidate's clinical and other benefits outweigh its safety risks;

•

the FDA may disagree with our interpretation of data from clinical trials or other studies;

•

the data collected from clinical trials and other studies of a product candidate may not be sufficient to support the submission of a NDA;

-39-

•

the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical and other study data insufficient for approval; and

•

the FDA may not approve the proposed manufacturing processes and facilities for a product candidate.

In 2012, FDA reviewers raised certain questions about the status of our existing lots of older Work-In-Process Alferon® materials and Alferon® Active Pharmaceutical Product (“API”), which would need to be released by the FDA before those materials could be used in commercial product. After conducting all of the appropriate tests on samples of the inventory during 2013, we concluded that we could not alleviate certain questions the FDA had about the older Work-In-Process Alferon N Injection®. Accordingly, these lots were not submitted to the FDA to request release for commercial sale and their remaining dollar value was written-off. In the absence of FDA approvals for product manufactured from existing inventory, commercial sales of Alferon® will not resume until new batches of Alferon® inventory and API can be produced, filled and finished, and released by the FDA for commercial sale. (Please see Part 1, Item II: “Management's Discussion and Analysis of Financial Condition and Results of Operations Business; Our Products; Manufacturing” above for more information).

Alferon® LDO has been approved for pre-clinical testing for possible use as prophylaxis and treatment against influenza. While the studies to date have been encouraging, preliminary testing in the laboratory and in animal models is not necessarily predictive of successful results in clinical testing or human treatment. No assurance can be given that similar results will be observed in clinical trials. Use of Alferon® as a possible treatment of influenza requires prior regulatory approval. In October 2009, we originally submitted a protocol to the FDA proposing to conduct a Phase II, double-blind, adaptive-design, randomized, placebo-controlled, dose-ranging study of Alferon® LDO for the prophylaxis and treatment of seasonal and pandemic influenza of more than 200 subjects. In December 2010, the FDA authorized this Phase II, double-blind, adaptive-design, randomized, placebo-controlled, dose-ranging study of Alferon® LDO for the prophylaxis and treatment of seasonal and pandemic influenza of more than 200 subjects. Our Phase II study has been delayed. The outcome of this confirmatory study, if and when resumed, will allow us to better evaluate the potential effectiveness of this product and to proceed with this study of seasonal and pandemic influenza. We are unable to provide any assurances that the Phase II Alferon® LDO study for the prophylaxis and treatment of seasonal and pandemic influenza will be undertaken.

If we are unable to gain necessary FDA approvals related to Ampligen® and Alferon® on a timely basis, our operations most likely will be materially and/or adversely affected. Additionally, if we are unable to generate the additional data, successfully complete inspections or obtain approvals as required by the FDA on a timely manner, or at all, or determine that any of our clinical studies are not cost/justified to undertake or if, for that or any other reason, Ampligen®, Alferon® or one of our other products or production processes do not receive necessary regulatory approval in the U.S. or elsewhere:

•

our ability to generate revenues to sustain our operations will be substantially impaired, which would increase the likelihood that we would need to obtain additional financing for our other development efforts;

•

our reputation among investors might be harmed, which might make it more difficult for us to obtain equity capital on attractive terms or at all; and

•

our profitability would be delayed, our business will be materially harmed and our stock price may be adversely affected.

Biotechnology stock prices, including our stock price, have declined significantly in certain instances where companies have failed to meet expectations with respect to FDA approval or the timing for FDA approval.

-40-

We may continue to incur substantial losses and our future profitability is uncertain.

We last reported net profit from 1985 through 1987. Since 1987, with a major emphasis on new drug diagnostic and development, we have incurred substantial operating losses, as we pursued our clinical trial effort to get our experimental drug, Ampligen®, approved. As of June 30, 2016, our accumulated deficit was approximately $296,466,000. We have not yet generated significant revenues from our products and may incur substantial and increased losses in the future. We cannot assure that we will ever achieve significant revenues from product sales or become profitable. We require, and will continue to require, the commitment of substantial resources to develop our products. We cannot assure that our product development efforts will be successfully completed or that required regulatory approvals will be obtained or that any products will be manufactured and marketed successfully, or be profitable.

We most likely will require additional financing which may not be available.

The development of our products requires the commitment of substantial resources to conduct the time consuming research, preclinical development, and clinical trials that are necessary to bring pharmaceutical products to market. As of June 30, 2016, we had approximately $6,512,000 in cash, cash equivalents and marketable securities (inclusive of approximately $4,974,000 in Marketable Securities). However, if we are unable to commercialize and sell Ampligen® or Alferon® LDO and/or recommence material sales of Alferon N Injection®, our operations, financial position and liquidity may be adversely impacted.

In its CRL, the FDA communicated that Hemispherx should conduct at least one additional clinical trial, complete various nonclinical studies and perform a number of data analyses. Until we undertake the end-of-review conference(s) with the FDA, we are unable to reasonably estimate the nature, costs, necessary efforts to obtain FDA clearance or anticipated completion dates of any additional clinical study or studies. Utilizing the industry norms for undertaking a Phase III clinical study, we estimate upon acceptance of the study's design that it would take approximately 18 months to three years to complete a new well-controlled Ampligen® clinical study for resubmission to the FDA. It can be reasonably anticipated that the time and cost to undertake clinical trial(s), studies and data analysis are beyond our current financial resources without gaining access to additional funding. The actual duration to complete the clinical study may be different based on the length of time it takes to design the study and obtain FDA's acceptance of the design, the final design of an acceptable Phase III clinical study design, availability of suitable participants and clinical sites along with other factors that could impact the implementation of the study, analysis of results or requirements of the FDA and/or other governmental organizations.

Given the challenging economic conditions, we continue to review every aspect of our operations for cost and spending reductions to assure our long-term financial stability while maintaining the resources necessary to achieve our primary objectives of obtaining NDA approval of Ampligen® along with the manufacturing, marketing and distribution of our products, including Alferon N Injection®. Due to the repair issues mentioned above within our NJ facility and the high cost estimates to bring the facility back online, we most likely will need additional funds to finance the revalidation process in our facility to initiate commercial manufacturing, thereby readying ourselves for an FDA Pre-Approval Inspection. We may also need additional capital to eventually commercialize and sell Ampligen® or Alferon® LDO and/or recommence and increase sales of Alferon N Injection® or our other products. We anticipate considering multiple options in an attempt to secure funding, including but not limited to such methods as the sales of additional equity, licensing agreements, partnering with other organizations, debt financing or other sources of capital. We may also review the possibility of selling the remaining work-in-process inventory through the EAP; however, this inventory has yet to go through the fill and finish process.

In December 2015, Hemispherx entered into an Equity Distribution Agreement with Chardan Capital Markets, LLC (the “Chardan Agreement”) to create an at-the-market equity program under which it may sell shares of its common stock from time to time through Chardan Capital Markets, LLC, as sales agent (“Chardan”). On December 15, 2015, prior to the filing the Prospectus Supplement for sales under the Chardan Agreement, the Company filed a Prospectus Supplement reducing all offerings pursuant to its existing equity distribution agreement with Maxim Group LLC to $0. Please see Part 1, Item II: “Management's Discussion and Analysis of Financial Condition and Results of Operations Business; Liquidity and Capital Resources” and the Risk Factor “The trading price of our common stock has decreased significantly over the past year. If we are unable to raise the trading price, the market for our common stock most likely will be adversely affected” below.

-41-

As recently announced in the Company’s November 23, 2015 Current Report on Form 8-K, Dr. William A. Carter, the Company’s then Chairman of the Board, Chief Executive Officer and Chief Scientific Officer, and Thomas K. Equels, the Company’s current CEO, President, Executive Vice Chairman of the Board, Secretary and General Counsel, waived their rights under their respective employment agreements to any future payment of any incentive bonus related to the sale of the Company’s stock under any ATM equity distribution agreements. Dr. Carter and Mr. Equels voluntarily provided these waivers in an effort to preserve cash and to help the Company to ensure its short term commercialization goals.

If we are unable to obtain additional funding, through the EDA or otherwise, our ability to develop our products, commercially produce inventory or continue our operations may be materially adversely affected.

Our Alferon N Injection® Commercial Sales were halted due to lack of finished goods inventory. If we are unable to gain the necessary FDA approvals related to Alferon®, our operations most likely will be materially and/or adversely affected.

Commercial sales of Alferon N Injection® were halted in March 2008 when our finished goods inventory expired. The production of Alferon N Injection® from the Work-In-Process Inventory was restarted in May 2010, continued into January 2011 with its conversion into API.

In April 2012, FDA reviewers raised certain questions about the status of our existing lots of older Work-In-Process Alferon® materials and Alferon® API, which would need to be released by the FDA before those materials could be used in commercial product. After conducting all of the appropriate tests on samples of the inventory during 2013, we concluded that we could not alleviate certain questions the FDA had about the older Work-In-Process Alferon N Injection® and their remaining dollar value has been written-off. Commercial sales of Alferon® will not resume until new batches of Alferon® inventory and API can be produced, filled and finished, and released by the FDA for commercial sale.

While our facility is FDA approved under the BLA by the FDA for Alferon®, this status will need to be reaffirmed upon the completion of the facility's upgrades for Alferon®. We cannot provide any guarantee that the facility will necessarily pass a FDA pre-approval inspection for Ampligen® or Alferon® manufacture, which are conducted in separately dedicated areas within the overall New Brunswick manufacturing complex. Please see the Risk Factor “There is no assurance that our manufacturing facility will again be granted a BLA certification by the FDA upon completion of the manufacturing enhancements or return to commercial, large-scale production. In addition, our inability to timely fix the issues caused by the recent flood in our manufacturing facility could hinder our ability sustain sales of our products, if and when such sales commence.” below for more information.

If we are unable to gain the necessary FDA approvals related to the manufacturing process and/or final product of new Alferon® inventory, our operations most likely will be materially and/or adversely affected. For more information on Alferon N Injection® regarding potential commercial sales, please see Part 1, Item II: “Management's Discussion and Analysis of Financial Condition and Results of Operations Business; Manufacturing”.

In light of these contingencies, there can be no assurances that the approved Alferon N Injection® product will be returned to production on a timely basis, if at all, or that if and when it is again made commercially available, it will return to prior sales levels.

-42-

We may not be profitable unless we can protect our patents and/or receive approval for additional pending patents.

We need to preserve and acquire enforceable patents covering the use of Ampligen® for a particular disease in order to obtain exclusive rights for the commercial sale of Ampligen® for such disease. We obtained all rights to Alferon N Injection®, and we plan to preserve and acquire enforceable patents covering its use for existing and potentially new diseases. Our success depends, in large part, on our ability to preserve and obtain patent protection for our products and to obtain and preserve our trade secrets and expertise. Certain of our know-how and technology is not patentable, particularly the procedures for the manufacture of our experimental drug, Ampligen®. We also have been issued a patent which affords protection on the use of Ampligen® in patients with Chronic Fatigue Syndrome. We have not yet been issued any patents in the United States for the use of Ampligen® as a sole treatment for any of the cancers which we have sought to target. For more information on Patents, please see 2015 Form 10-K, PART I, Item I – “Business; Patents”.

We cannot assure that our competitors will not seek and obtain patents regarding the use of similar products in combination with various other agents, for a particular target indication prior to our doing so. If we cannot protect our patents covering the use of our products for a particular disease, or obtain additional patents, we may not be able to successfully market our products.

The patent position of biotechnology and pharmaceutical firms is highly uncertain and involves complex legal and factual questions.

To date, no consistent policy has emerged regarding the breadth of protection afforded by pharmaceutical and biotechnology patents. There can be no assurance that new patent applications relating to our products, process or technology will result in patents being issued or that, if issued, such patents will afford meaningful protection against competitors with similar technology. It is generally anticipated that there may be significant litigation in the industry regarding patent and intellectual property rights. Such litigation could require substantial resources from us and we may not have the financial resources necessary to enforce the patent rights that we hold. No assurance can be made that our patents will provide competitive advantages for our products, process and technology or will not be successfully challenged by competitors. No assurance can be given that patents do not exist or could not be filed which would have a materially adverse effect on our ability to develop or market our products or to obtain or maintain any competitive position that we may achieve with respect to our products. Our patents also may not prevent others from developing competitive products or process using related technology.

There can be no assurance that we will be able to obtain necessary licenses if we cannot enforce patent rights we may hold. In addition, the failure of third parties from whom we currently license certain proprietary information or from whom we may be required to obtain such licenses in the future, to adequately enforce their rights to such proprietary information, could adversely affect the value of such licenses to us.

If we cannot enforce the patent rights we currently hold we may be required to obtain licenses from others to develop, manufacture or market our products. There can be no assurance that we would be able to obtain any such licenses on commercially reasonable terms, if at all. We currently license certain proprietary information from third parties, some of which may have been developed with government grants under circumstances where the government maintained certain rights with respect to the proprietary information developed. No assurances can be given that such third parties will adequately enforce any rights they may have or that the rights, if any, retained by the government will not adversely affect the value of our license.

There is no guarantee that our trade secrets will not be disclosed or known by our competitors.

To protect our rights, we require all employees and certain consultants to enter into confidentiality agreements with us. There can be no assurance that these agreements will not be breached, that we would have adequate and enforceable remedies for any breach, or that any trade secrets of ours will not otherwise become known or be independently developed by competitors.

-43-

We have limited marketing and sales capability. If we are unable to obtain additional distributors and our current and future distributors do not market our products successfully, we may not generate significant revenues or become profitable.

We have limited marketing and sales capability. We are dependent upon existing and, possibly future, marketing agreements and third party distribution agreements for our products in order to generate significant revenues and become profitable. As a result, any revenues received by us will be dependent in large part on the efforts of third parties, and there is no assurance that these efforts will be successful.

Our commercialization strategy for Ampligen® for CFS, if and when it is approved for marketing and sale by the FDA, may include licensing/co-marketing agreements utilizing the resources and capacities of a strategic partner(s). We continue to seek a world-wide marketing partner with the goal of having a relationship in place before approval is obtained. In parallel to partnering discussions, appropriate pre-marketing activities will be undertaken. It is our current intention to control manufacturing of Ampligen® on a world-wide basis.

Our commercialization strategy for Alferon N Injection® may include the utilization of internal functions and/or licensing/co-marketing agreements that would utilize the resources and capacities of one or more strategic partners. Accordingly, we have engaged Armada Healthcare to undertake the marketing, education and sales of Alferon N Injection® throughout the United States along with GP Pharm for both Ampligen® and Alferon® in Argentina along with other South and Latin American countries.

We cannot assure that our U.S. or foreign marketing strategy will be successful or that we will be able to establish future marketing or third party distribution agreements on terms acceptable to us, or that the cost of establishing these arrangements will not exceed any product revenues. Our inability to establish viable marketing and sales capabilities would most likely have a materially adverse effect on us. There can be no assurances that the approved Alferon N Injection® product will be returned to prior sales levels.

There are no long-term agreements with suppliers of required materials and services for Ampligen® and there are a limited number of raw material/reagent suppliers for Ampligen® and Alferon®. If we are unable to obtain the required raw materials/Reagents and/or services, we may not be able to manufacture Ampligen® and Alferon®.

A number of essential raw materials are used in the production of Ampligen® as well as packaging materials utilized in the fill and finish process. We do not have, but continue to work towards having long-term agreements for the supply of such materials, when possible. There can be no assurance we can enter into long-term supply agreements covering essential materials on commercially reasonable terms, if at all.

There are a limited number of suppliers in the United States and abroad available to provide the raw and packaging materials/reagents for use in manufacturing Ampligen® and Alferon®. At present, we do not have any agreements with third parties for the supply of any of these materials or we are relying on a limited source of reagent suppliers necessary for the manufacture of Alferon®. We have established relevant manufacturing operations within our New Brunswick, New Jersey facility for the production of Ampligen® polymers from raw materials in order to obtain a more consistent manufacturing basis in the quantities necessary for clinical testing. In September 2011 and similar to our prior agreements, Hollister-Stier has agreed to undertake the manufacturing sets to formulate, fill, finish and package Ampligen® from the key polymers that we would supply. Hollister-Stier would have the right of first refusal to manufacture certain Ampligen® related products. In July 2016, we reached an agreement with Avrio Biopharmaceuticals ("Avrio") to serve as an additional contract manufacturer of Ampligen® for use with clinical studies as well as the recently initiated Early Access Program (EAP) in Europe and Turkey. We believe that we have sufficient quantities of Ampligen® to meet our limited near term projected needs until we start receiving product from Avrio. Should there be an unanticipated delay in receiving new product from Avrio or should we experience an unexpected demand for Ampligen® in our clinical studies or pursuant to the EAP, our ability to supply Ampligen® most likely will be adversely affected. Although the Company has engaged Avrio, we will continue to work towards an amended agreement with Hollister-Stier. In addition, during the final stage of the manufacturing process for Alferon®, we encountered issues regarding a change in both the contract supplier of leukocytes and the long term supply availability related to a reagent used in the formulation of Alferon®. We have substantially resolved these issues through engaging in multiple agreements with suppliers of leukocytes as well as entering into a licensing agreement with a foreign multinational chemicals and biotechnology company that has been in business for over a century for the sourcing of the primary reagent allowing us to manufacture Alferon®. However, due to the interruption of the required flow of leukocytes, production ceased, causing parts to malfunction in the upstream process when the system was restarted for testing. We were working diligently to make the necessary repairs to be able to restart the validation process; however, in the process of obtaining time estimates for the repairs we experienced a flood within portions our manufacturing facility. As a result, we will be constrained in our ability to manufacture product in the near future due to this flood in the upstream processing cleanroom that contains the bioreactor. The flood occurred on the afternoon of January 5, 2016, caused by a malfunctioning water supply pipe for the sprinkler system covering a large amount of the cleanroom in stagnant water and silt from the sprinkler system. Our facility insurer has been proactive in addressing and covering the loss. While repairs have required preapproval by our insurer, activity has moved forward quickly. The repairs noted below required special action because of the need to keep this critical manufacturing room within International Organization for Standardization (ISO) classifications and the need to certify that all the equipment that was exposed, or submerged, is in proper condition and operating effectively following the corrective actions. All HEPA filters affected by the flood were tested by an outside contractor and have passed all required tests. The flooring that was damaged has been repaired using a special epoxy that is used in cleanrooms. A large portion of the walls in the ISO classified area were damaged. We had a damage mitigation company come in to stop any moisture from seeping further into the ISO classified areas. Subsequently, all damaged walls and ceilings have been replaced with cleanroom grade materials and need no further work. Six pumps that were affected by the flood were sent back to the manufacturer for inspection and repair. Repairs that were required have been completed on the pumps and they were reinstalled in the Alferon manufacturing facility after the floor repair work was completed. All pumps will need to be qualified for use in the manufacturing process prior to the validation process for a Pre-Approval Inspection. All air ducts supplying the Alferon manufacturing area needed to be cleaned and insulation replaced along with ceiling tiles. The duct insulation and ceiling tile replacement will be performed after the duct cleaning work is completed. All smaller pieces of machinery and equipment that could not be salvaged have been replaced. The final repair step required to be performed will be HVAC air balancing and qualification.

-44-

Currently, the manufacturing process is on hold and there is no definitive timetable to have the facility back online. If we are unable to gain the necessary FDA approvals related to the manufacturing process and/or final product of new Alferon® inventory, our operations most likely will be materially and/or adversely affected. In light of these contingencies, there can be no assurances that the approved Alferon N Injection® product will be returned to production on a timely basis, if at all, or that if and when it is again made commercially available, it will return to prior sales levels.

If we are unable to obtain or manufacture the required materials/reagents, and/or procure services needed in the final steps in the manufacturing process, we may be unable to manufacture Ampligen®. The costs and availability of products and materials we need for the production of Ampligen® are subject to fluctuation depending on a variety of factors beyond our control, including competitive factors, changes in technology, ownership of intellectual property, FDA and other governmental regulations. There can be no assurance that we will be able to obtain such products and materials on terms acceptable to us or at all. For more information on Ampligen® manufacturing, please see Part 1, Item II: “Management's Discussion and Analysis of Financial Condition and Results of Operations Business; Our Products; Manufacturing” above.

There are a limited number of organizations in the United States available to provide the final manufacturing steps of formulation, fill, finish and packing sets for Alferon N Injection® and Ampligen®.

There are a limited number of organizations in the United States available to provide the final steps in the manufacturing for Alferon N Injection® and Ampligen®. To formulate, fill, finish and package our products (“fill and finish”), we require a FDA approved third party CMO.

In January 2012, we agreed to a Technology, Transfer, Validation and Commercial Supply Agreement with Althea Technologies, Inc. regarding the fill and finish process for Alferon N Injection®. As we no longer have any existing inventory, commercial sales of Alferon® will not resume until new batches of Alferon® inventory and API can be produced, filled and finished, and released by the FDA for commercial sale.

Pursuant our Supply Agreement with Hollister-Stier, they will formulate, fill, finish and package Ampligen® from the key raw materials that we would supply. We are unable to provide any assurances that the FDA will approve the inventory manufactured by us or produced by Hollister-Stier. If this finish goods inventory is not granted approval by the FDA, our operations may be materially adversely affected. This Supply Agreement expired on March 11, 2014. The Company is working towards an amendment to the existing Supply Agreement which may contain additional fees as part of entering into the extension. In October 2014, we entered into a purchase commitment with a contract manufacturer (Hollister Stier) for approximately $700,000 for the manufacture of clinical batches of Ampligen®. We are in discussion with Hollister-Stier about this purchase commitment. In July 2016, we reached an agreement with Avrio to serve as an additional contract manufacturer of Ampligen® for use with clinical studies as well as the recently initiated Early Access Program (EAP) in Europe and Turkey. Avrio should be able to meet our immediate requirements. We believe that we have sufficient quantities of Ampligen® to meet our limited near term projected needs until we start receiving product from Avrio. Should there be an unanticipated delay in receiving new product from Avrio or should we experience an unexpected demand for Ampligen® in our clinical studies or pursuant to the EAP, our ability to supply Ampligen® most likely will be adversely affected.

-45-

If we are unable to procure services needed in the final steps in the manufacturing process, we may be unable to manufacture Alferon N Injection® and/or Ampligen®. The costs and availability of products and materials we need for the production of Ampligen® and the commercial production of Alferon N Injection® and other products which we may commercially produce are subject to fluctuation depending on a variety of factors beyond our control, including competitive factors, changes in technology, and FDA and other governmental regulations and there can be no assurance that we will be able to obtain such products and materials on terms acceptable to us or at all. For more information on Ampligen® and Alferon N Injection® manufacturing, please see Part 1, Item II: “Management's Discussion and Analysis of Financial Condition and Results of Operations Business; Our Products; Manufacturing” above.

There is no assurance that our manufacturing facility will again be granted a BLA certification by the FDA or return to commercial, large-scale production. In addition, our inability to timely fix the issues caused by the recent flood in our manufacturing facility could hinder our ability sustain sales of our products, if and when such sales commence.

We completed the construction of our $8 million facility enhancement project in 2015 which, upon FDA approval, should provide for a higher capacity, more cost effective manufacturing process for the production of Alferon N Injection®. The production of new Alferon® API inventory commenced in February 2015. While the facility is approved by FDA under the BLA for Alferon®, this status will need to be reaffirmed upon the completion of the facility's enhancements prior to commercial sale of newly produced inventory product. If and when we obtain a reaffirmation of FDA BLA status, we will need FDA approval to release the final product confirming the quality and stability to allow commercial sales to resume. For more information, please see Part 1, Item II: “Management's Discussion and Analysis of Financial Condition and Results of Operations Business; Our Products; Manufacturing” above for more information. There can be no assurance the BLA status will be recertified by the FDA upon the completion of the enhancement process or that the manufacturing facility will return to commercial, large-scale production for Alferon®. Additionally, there can be no assurance that any given product will be determined to be safe and effective, or capable of being manufactured under applicable quality standards.

Only if and when our BLA status is recertified by the FDA to produce Alferon® API at our enhanced manufacturing facility and Althea gains FDA’s approval to formulate, fill and finish Alferon, can batches of Alferon® be released by the FDA for commercial sales. We are unable to provide any assurances that the FDA will approve our enhanced manufacturing process and/or newly created finish product lots formulated, filled and finished at Althea. Without FDA approval, our Alferon N Injection® will not be considered suitable for commercial sales.

Our ability to manufacture at our manufacturing facility is also hampered and delayed by the recent flood. See Part 1, Item II: “Management's Discussion and Analysis of Financial Condition and Results of Operations Business; “Marketing”.

In light of these contingencies, there can be no assurances that the approved Alferon N Injection® product will be returned to commercial production or sale on a timely basis, if at all, or that if and when it is again made commercially available, it will return to prior sales levels.

There is no assurance that upon successful manufacture of a drug on a limited scale basis for investigational use will lead to a successful transition to commercial, large-scale production.

Changes in methods of manufacturing, including commercial scale-up, may affect the chemical structure of Ampligen® and other RNA drugs, as well as their safety and efficacy. The transition from limited production of pre-clinical and clinical research quantities to production of commercial quantities of our products will involve distinct management and technical challenges and may require additional management, technical personnel and capital to the extent such manufacturing is not handled by third parties. While we believe that the Company could successfully upgrade our production capability at our New Brunswick, NJ facility in a commercial scale-up of Ampligen®, there can be no assurance that our manufacturing will be successful or that any given product will be determined to be safe and effective, or capable of being manufactured under applicable quality standards, economically, and in commercial quantities, or successfully marketed.

-46-

We have limited manufacturing experience for Ampligen® and Alferon®. We may not be profitable unless we can produce Ampligen®, Alferon® or other products in commercial quantities at costs acceptable to us.

Satisfactory inspection by the FDA of both our Ampligen® and Alferon® manufacturing process is required before commercial sale of project would be allowed. The CRL from the FDA on February 1, 2013, requests evaluation of variation between lots of Ampligen® tested in the development process and recommends tighter control of the Ampligen® manufacturing process. We cannot provide any guarantee that the facility will pass a FDA pre-approval inspection for Ampligen® or Alferon® manufacture, which are conducted in separately dedicated areas within the overall New Brunswick manufacturing complex. The failure to obtain FDA approval for either of our manufacturing process areas would most likely have a materially adverse impact upon us.

Ampligen® has been produced to date in limited quantities for use in our clinical trials, and we are dependent upon a qualified third party supplier for the manufacturing, filling, finish and packaging process. The failure to continue these arrangements or to achieve other such arrangements on satisfactory terms could have a material adverse effect on us. In furtherance of the capital improvement program at our New Brunswick, NJ facility to upgrade our manufacturing capability to produce bulk quantities of Alferon N Injection® API, the validation phase of the Alferon® manufacturing project is currently underway. While the facility is approved by FDA under the BLA for Alferon®, this status will need to be reaffirmed upon the completion of the facility's enhancements prior to commercial sale of newly produced inventory product. If and when we obtain a reaffirmation of FDA BLA status, we will need FDA approval to release the final product confirming the quality and stability to allow commercial sales to resume. For more information, please see Part 1, Item II: “Management's Discussion and Analysis of Financial Condition and Results of Operations Business; Our Products; Manufacturing” above. In light of these contingencies, there can be no assurances that the approved Alferon N Injection® product will be returned to production on a timely basis, if at all. The failure to obtain FDA approval of any of our manufacturing process would most likely have a materially adverse impact upon us.

Also to be successful, our products must be manufactured in commercial quantities in compliance with regulatory requirements and at acceptable costs. We believe, but cannot assure, that our enhancements to our manufacturing facilities will be adequate for our future needs for the production of our proposed products for large-scale commercialization. We intend to ramp up our existing facility and/or utilize third party facilities if and when the need arises or, if we are unable to do so, to build or acquire commercial-scale manufacturing facilities. We will need to comply with regulatory requirements for such facilities, including those of the FDA pertaining to cGMP requirements or maintaining our BLA status. There can be no assurance that such facilities can be used, built, or acquired on commercially acceptable terms, or that such facilities, if used, built, or acquired, will be adequate for the production of our proposed products for large-scale commercialization or our long-term needs.

We have never produced Ampligen®, Alferon® or any other products in large commercial quantities. We must manufacture our products in compliance with regulatory requirements in large commercial quantities and at acceptable costs in order for us to be profitable. We intend to utilize third party manufacturers and/or facilities if and when the need arises or, if we are unable to do so, to build or acquire commercial-scale manufacturing facilities. If we cannot manufacture commercial quantities of Ampligen® and/or Alferon®, or continue to maintain third party agreements for its manufacture at costs acceptable to us, our operations will be significantly affected. If and when the Ampligen® NDA is approved, we may need to find an additional vendor to manufacture the product for commercial sales. Also, each production lot of Alferon N Injection® is subject to FDA review and approval prior to releasing the lots to be sold. This review and approval process could take considerable time, which would delay our having product in inventory to sell, nor can we provide any assurance as to the receipt of FDA approval of our finished inventory product. There can be no assurances that the Ampligen® and/or Alferon® can be commercially produced at costs acceptable to us.

Rapid technological change may render our products obsolete or non-competitive.

The pharmaceutical and biotechnology industries are subject to rapid and substantial technological change. Technological competition from pharmaceutical and biotechnology companies, universities, governmental entities and others diversifying into the field is intense and is expected to increase. Most of these entities have significantly greater research and development capabilities than us, as well as substantial marketing, financial and managerial resources, and represent significant competition for us. There can be no assurance that developments by others will not render our products or technologies obsolete or noncompetitive or that we will be able to keep pace with technological developments.

-47-

Our products may be subject to substantial competition.

Ampligen®. Competitors may be developing technologies that are, or in the future may be, the basis for competitive products. Some of these potential products may have an entirely different approach or means of accomplishing similar therapeutic effects to products being developed by us. These competing products may be more effective and less costly than our products. In addition, conventional drug therapy, surgery and other more familiar treatments may offer competition to our products. Furthermore, many of our competitors have significantly greater experience than we do in preclinical testing and human clinical trials of pharmaceutical products and in obtaining FDA, HPB and other regulatory approvals of products. Accordingly, our competitors may succeed in obtaining FDA, HPB or other regulatory product approvals more rapidly than us. There are no drugs approved for commercial sale with respect to treating CFS in the United States. The dominant competitors with drugs to treat disease indications in which we plan to address include Pfizer, GlaxoSmithKline, Merck & Co., Novartis and AstraZeneca. Biotech competitors include Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta. These potential competitors are among the largest pharmaceutical companies in the world, are well known to the public and the medical community, and have substantially greater financial resources, product development, and manufacturing and marketing capabilities than we have. Although we believe our principal advantage is the unique mechanism of action of Ampligen® on the immune system, we cannot assure that we will be able to compete.

Alferon N Injection®. Our competitors are among the largest pharmaceutical companies in the world, are well known to the public and the medical community, and have substantially greater financial resources, product development, and manufacturing and marketing capabilities than we have. Alferon N Injection® currently competes with Merck's injectable recombinant alpha interferon product (INTRON® A) for the treatment of genital warts. In addition, other pharmaceutical firms offer self-administered topical cream, for the treatment of external genital and perianal warts such as Graceway Pharmaceuticals (Aldara®), Watson Pharma (Condylox®) and MediGene (Veregen®). Alferon N Injection® also competes with surgical, chemical, and other methods of treating genital warts. We cannot assess the impact products developed by our competitors, or advances in other methods of the treatment of genital warts, will have on the commercial viability of Alferon N Injection®. If and when we obtain additional approvals of uses of this product, we expect to compete primarily on the basis of product performance. Our competitors have developed or may develop products (containing either alpha or beta interferon or other therapeutic compounds) or other treatment modalities for those uses. There can be no assurance that, if we are able to obtain regulatory approval of Alferon N Injection® for the treatment of new indications, we will be able to achieve any significant penetration into those markets. In addition, because certain competitive products are not dependent on a source of human blood cells, such products may be able to be produced in greater volume and at a lower cost than Alferon N Injection®. Currently, our wholesale price on a per unit basis of Alferon N Injection® is higher than that of the competitive recombinant alpha and beta interferon products. Please see risk factor “We may not be profitable unless we can protect our patents and/or receive approval for additional pending patents" above for additional information.

General. Other companies may succeed in developing products earlier than we do, obtaining approvals for such products from the FDA more rapidly than we do, or developing products that are more effective than those we may develop. While we will attempt to expand our technological capabilities in order to remain competitive, there can be no assurance that research and development by others or other medical advances will not render our technology or products obsolete or non-competitive or result in treatments or cures superior to any therapy we develop.

Possible side effects from the use of Ampligen® or Alferon N Injection® could adversely affect potential revenues and physician/patient acceptability of our product.

Ampligen®. We believe that Ampligen® has been generally well tolerated with a low incidence of clinical toxicity, particularly given the severely debilitating or life threatening diseases that have been treated. A mild flushing reaction has been observed in approximately 15-20% of patients treated in our various studies. This reaction is occasionally accompanied by a rapid heartbeat, a tightness of the chest, urticaria (swelling of the skin), anxiety, shortness of breath, subjective reports of “feeling hot”, sweating and nausea. The reaction is usually infusion-rate related and can generally be controlled by reducing the rate of infusion. Other adverse side effects include liver enzyme level elevations, diarrhea, itching, asthma, low blood pressure, photophobia, rash, visual disturbances, slow or irregular heart rate, decreases in platelets and white blood cell counts, anemia, dizziness, confusion, elevation of kidney function tests, occasional temporary hair loss and various flu-like symptoms, including fever, chills, fatigue, muscular aches, joint pains, headaches, nausea and vomiting. These flu-like side effects typically subside within several months.

The FDA in its February 1, 2013 CRL, set forth the reasons for not approving Ampligen® at this time and provided recommendations to address certain of the outstanding issues. The Agency stated that the submitted data do not provide substantial evidence of efficacy of Ampligen® for the treatment of CFS and that the data do not provide sufficient information to determine whether the product is safe for use in CFS due to the limited size of the safety database and multiple discrepancies within the submitted data.

-48-

If approved, one or more of the potential side effects of the drug might deter usage of Ampligen® in certain clinical situations and therefore, could adversely affect potential revenues and physician/patient acceptability of our product.

Alferon N Injection®. At present, Alferon N Injection® is approved for the intralesional (within the lesion) treatment of refractory or recurring external genital warts in adults. In clinical trials conducted for the treatment of genital warts with Alferon N Injection®, patients did not experience serious side effects; however, there can be no assurance that unexpected or unacceptable side effects will not be found in the future for this use or other potential uses of Alferon N Injection® which could threaten or limit such product's usefulness.

We may be subject to product liability claims from the use of Ampligen®, Alferon N Injection®, or other of our products which could negatively affect our future operations. We have limited product liability and clinical trial insurance.

We maintain a limited amount of Products Liability and Clinical Trial insurance coverage world-wide for Ampligen® and Alferon® due to the minimal amount of historical loss claims regarding these products in the marketplace. Any claims against our products, Ampligen®, Alferon N Injection® and Alferon® LDO, could have a materially adverse effect on our business and financial condition.

We face an inherent business risk of exposure to product liability claims in the event that the use of Ampligen®, Alferon N Injection® or other of our products results in adverse effects. This liability might result from claims made directly by patients, hospitals, clinics or other consumers, or by pharmaceutical companies or others manufacturing these products on our behalf. Our future operations may be negatively affected from the litigation costs, settlement expenses and lost product sales inherent to these claims. While we will continue to attempt to take appropriate precautions, we cannot assure that we will avoid significant product liability exposure.

With our recent development on the collaborative agreement with myTomorrows to provide access to our natural alpha interferon for patients that have become intolerant to treatment with recombinant interferon or where such treatment fails in South America and Europe, we have initiated the process of enhancing our insurance coverage for any potential sales that may arise from this arrangement.

The loss of services of key personnel could hurt our chances for success.

Our success is dependent on the continued efforts of our staff, especially certain doctors and researchers. The loss of the services of personnel key to our operations could have a material adverse effect on our operations and chances for success. The loss of key personnel or the failure to recruit additional personnel as needed could have a materially adverse effect on our ability to achieve our objectives. Mr. Equels is a key employee with reference to operational and financial management.

Uncertainty of health care reimbursement for our products.

Our ability to successfully commercialize our products will depend, in part, on the extent to which reimbursement for the cost of such products and related treatment will be available from government health administration authorities, private health coverage insurers and other organizations. Significant uncertainty exists as to the reimbursement status of newly approved health care products, and from time to time legislation is proposed, which, if adopted, could further restrict the prices charged by and/or amounts reimbursable to manufacturers of pharmaceutical products. We cannot predict what, if any, legislation will ultimately be adopted or the impact of such legislation on us. There can be no assurance that third party insurance companies will allow us to charge and receive payments for products sufficient to realize an appropriate return on our investment in product development.

-49-

There are risks of liabilities associated with handling and disposing of hazardous materials.

Our business involves the controlled use of hazardous materials, carcinogenic chemicals, flammable solvents and various radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply in all material respects with the standards prescribed by applicable regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident or the failure to comply with applicable regulations, we could be held liable for any damages that result, and any such liability could be significant. We do not maintain insurance coverage against such liabilities.

Four Shareholder Derivative Actions Have Been Filed Against Us and We May Be Subject to Civil Liabilities.

As described in Part I; Item 3. Legal Proceedings, four shareholder derivative actions have been filed alleging various state law breach of fiduciary duty, waste of corporate assets and unjust enrichment claims along with seeking monetary damages, costs, attorneys' fees, and equitable and injunctive relief. Defending against these suits, even if meritless, can result in substantial costs to us and could divert the attention of our management.

The existence of these proceedings could have a material adverse effect on our ability to access the capital markets to raise additional funds. While Management believes that the lawsuits are without merit, we cannot predict or determine the timing or final outcomes of the lawsuits and are unable to estimate the amount or range of loss that could result from unfavorable outcomes. Adverse results in some or all of these legal proceedings could be material to our results of operations, financial condition or cash flows.

We rely upon information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could harm our ability to operate our business effectively.

Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations, and could result in a material disruption of our business operations, in addition to possibly requiring substantial expenditures of resources to remedy. The loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate public disclosure of confidential or proprietary information, we could incur liability and our product development and commercialization efforts could be delayed.

Risks Associated with an Investment in Our Common Stock:

The market price of our stock may be adversely affected by market volatility.

The market price of our common stock has been and is likely to be volatile. This is especially true given the current significant instability in the financial markets. In addition to general economic, political and market conditions, the price and trading volume of our stock could fluctuate widely in response to many factors, including:

•

announcements of the results of clinical trials by us or our competitors;

•

announcements of availability or projections of our products for commercial sale;

•

announcements of legal actions against us and/or settlements or verdicts adverse to us;

•

adverse reactions to products;

•

governmental approvals, delays in expected governmental approvals or withdrawals of any prior governmental approvals or public or regulatory agency comments regarding the safety or effectiveness of our products, or the adequacy of the procedures, facilities or controls employed in the manufacture of our products;

•

changes in U.S. or foreign regulatory policy during the period of product development;

•

developments in patent or other proprietary rights, including any third party challenges of our intellectual property rights;

•

announcements of technological innovations by us or our competitors;

•

announcements of new products or new contracts by us or our competitors;

•

actual or anticipated variations in our operating results due to the level of development expenses and other factors;

-50-

•

changes in financial estimates by securities analysts and whether our earnings meet or exceed the estimates;

•

conditions and trends in the pharmaceutical and other industries;

•

new accounting standards;

•

overall investment market fluctuation;

•

restatement of prior financial results;

•

notice of NYSE MKT non-compliance with requirements; and

•

occurrence of any of the risks described in these "Risk Factors".

Our common stock is listed for quotation on the NYSE MKT. For the six months ended June 30, 2016, the trading price of our common stock has ranged from $0.20 to $0.07 per share. We expect the price of our common stock to remain volatile. The average daily trading volume of our common stock varies significantly. Please also see risk factor “The trading price of our common stock has decreased significantly over the past year and, as a result, the NYSE MKT has informed us that we are not in compliance with the standards for continued listing on the NYSE MKT. If we are unable to raise the trading price, the market for our common stock most likely will be adversely affected” below.

In the past, following periods of volatility in the market price of the securities of companies in our industry, securities class action litigation has often been instituted against companies in our industry. In this regard, please see risk factor “Four Shareholder Derivative Actions Have Been Filed Against Us and We May Be Subject to Civil Liabilities" above.

Our stock price may be adversely affected if a significant amount of shares is sold in the public market.

We may issue shares to be used to meet our capital requirements or use shares to compensate employees, consultants and/or Directors. In this regard, we have registered 77,849,014 of securities for public sale pursuant to a universal shelf registration statement and we have been selling shares under this shelf registration statement and the EDA with Maxim. Effective December 15, 2015, we halted all future offers and sales of our Common Stock under the EDA with Maxim and reduced the amount of potential future offers and sales under the EDA to $0.00. Between July 23, 2012, the date of the EDA, and December 15, 2015, we sold an aggregate of 106,581,461 shares of Common Stock pursuant to the EDA for aggregate gross proceeds of $47,453,220. On December 15, 2015, we filed a prospectus supplement to the issuance and sale of up to $7,941,000 of our common stock from time to time through our sales agent, Chardan Capital Markets, LLC. Please see Part I, Item II - Management’s Discussion and Analysis of Financial Condition and Result of Operations; Liquidity and Capital Resources” above for more information.

We are unable to estimate the amount, timing or nature of future sales of outstanding common stock or instruments convertible into or exercisable for our common stock. Sales of substantial amounts of our common stock in the public market, including additional sale of securities pursuant to the EDA with Chardan or otherwise under the universal shelf registration statement or upon exercise of outstanding options, could cause the market price for our common stock to decrease. Furthermore, a decline in the price of our common stock would likely impede our ability to raise capital through the issuance of additional shares of common stock or other equity securities.

The trading price of our common stock has decreased significantly over the past year and, as a result, the NYSE MKT has informed us that we are not in compliance with the standards for continued listing on the NYSE MKT. If we are unable to raise the trading price, the market for our common stock most likely will be adversely affected.

Our stock price has fallen throughout 2015 from a closing price of $0.25 on January 2, 2015 to a closing price of $0.08 on December 31, 2015. This decrease in the trading price has hindered our ability to raise funds from the sale of shares under the Chardan Agreement or in other equity related funding transactions. In addition, as discussed below, if we are unable to raise the trading price, we risk delisting of our stock on the NYSE: MKT. Should our stock be so delisted, stockholders’ ability to sell their shares in the open market most likely will be adversely affected even if the shares are then quoted for trading on an interdealer quotation system such as the OTCBB or OTC Markets.

On March 15, 2016, we received written notice from the NYSE MKT LLC (the “NYSE MKT”) that we are not in compliance with the continued listing standards set forth in Section 1003(f)(v) of the NYSE MKT Company Guide because our common stock has been selling for a low price per share for a substantial period of time. The NYSE MKT has determined that the continued listing of our common stock is predicated on the Company affecting a reverse stock split of its common stock or otherwise demonstrating sustained price improvement within a reasonable period of time. We have until September 15, 2016 to demonstrate compliance.

-51-

We plan to seek stockholder approval of a reverse stock split at the Annual Stockholders’ Meeting which we anticipate holding on August 17, 2016. We cannot assure that the reverse stock split will be approved by stockholders that, if approved, it and other of our actions will demonstrate compliance with the NYS MKT. If our common stock is delisted from trading on the NYSE MKT the market for our common stock most likely will be adversely affected.

Provisions of our Certificate of Incorporation and Delaware law could defer a change of our Management which could discourage or delay offers to acquire us.

Provisions of our Certificate of Incorporation and Delaware law may make it more difficult for someone to acquire control of us or for our stockholders to remove existing management, and might discourage a third party from offering to acquire us, even if a change in control or in Management would be beneficial to our stockholders. For example, our Certificate of Incorporation allows us to issue shares of preferred stock without any vote or further action by our stockholders. Our Board of Directors has the authority to fix and determine the relative rights and preferences of preferred stock. Our Board of Directors also has the authority to issue preferred stock without further stockholder approval. As a result, our Board of Directors could authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares, together with a premium, prior to the redemption of our common stock. In this regard, on November 2, 2012, we amended and restated our Stockholder Rights Plan (“Rights Plan”) and, under the Rights Plan, our Board of Directors declared a dividend distribution of one Right for each outstanding share of Common Stock to stockholders of record at the close of business on November 29, 2002. Each Right initially entitles holders to buy one-hundredth unit of preferred stock for $30.00 and may be redeemed prior to November 19, 2017, the expiration date, at $0.001 per Right under certain circumstances. The Rights generally are not transferable apart from the common stock and will not be exercisable unless and until a person or group acquires or commences a tender or exchange offer to acquire, beneficial ownership of 15% or more of our common stock.

Special Note Regarding Forward Looking Statements

Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us, you should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made and we undertake no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Our research in clinical efforts may continue for the next several years and we may continue to incur losses due to clinical costs incurred in the development of Ampligen® for commercial application. Possible losses may fluctuate from quarter to quarter as a result of differences in the timing of significant expenses incurred and receipt of licensing fees and/or cost recovery treatment revenue.

ITEM 2:

Unregistered Sales of Equity Securities and Use of Proceeds

We did not have any unregistered sales nor repurchase any of our securities during the six months ended June 30, 2016.

ITEM 3:

Defaults upon Senior Securities

None.

-52-

ITEM 4:

Mine Safety Disclosures

Not Applicable.

ITEM 5:

Other Information

None.

ITEM 6:

Exhibits

(a)

Exhibits

10.1		July 20, 2016 Agreement between Avrio Biopharmaceuticals (“Avrio”) and the Company. Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

31.1		Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company's Chief Executive Officer.

31.2		Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company's Chief Financial Officer.

32.1		Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company's Chief Executive Officer.

32.2		Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company's Chief Financial Officer.

101		The following materials from Hemispherx’ Quarterly Report on Form 10-Q for the period ended June 30, 2016 formatted in eXtensible Business Reporting Language (“XBRL”): (i) Condensed Balance Sheets; (ii) Condensed Consolidated Statements of Comprehensive Loss; (iii) Changes in Stockholders' Equity; (iv) Condensed Consolidated Statements of Cash Flows; and (v) Notes to Condensed Consolidated Financial Statements.

-53-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	HEMISPHERX BIOPHARMA, INC.

	/s/ Thomas K. Equels
	Thomas K. Equels, Esq.
	Chief Executive Officer & President

	/s/ Adam Pascale
	Adam Pascale
	Chief Financial Officer

Date: August 15, 2016

-54-

EX-10.1 2 s103890_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

{***}

Fill/Finish of Ampligen^®Bulk Drug

Proposal Prepared for

Hemispherx Biopharma, Inc.

June 20, 2016August 12, 2016

Avrio Biopharmaceuticals | 4 Chrysler, Irvine California 92618

Phone 866.982.8746 | Fax 949.462.0821 |

{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Confidential

Table of Contents

1.0	Contact Information	2
2.0	Scope of Work Summary	3
3.0	Fee and Schedule Summary Estimate	3
4.0	Payment Schedule	5
5.0	Analytical Activities	6
6.0	Drug Product Manufacturing	7
7.0	Supporting Services	8
8.0	Storage and Shipping	10
9.0	Key Assumptions	10
10.0	Change in Scope Management	10
11.0	Authorizations	11
12.0	Terms and Conditions	12

1.0

Contact Information

Hemispherx Biopharma, Inc.
Contact:	Wayne Springate	Carol Smith, Ph.D.
Title:	VP of Operations	VP of Manufacturing Quality and Process Development
Address:	One Penn Center, 1617 JFK Blvd, Philadelphia, PA 19103	One Penn Center, 1617 JFK Blvd, Philadelphia, PA 19103
Phone No.:	(215) 988-0080	(215) 988-0080
Email:	Wayne.Springate@hemispherx.net	carol.smith@Hemispherx.net

Avrio Biopharmaceuticals, LLC
Contact:	Jack Wright	Laman Alani
Title:	VP, Business Development and Marketing	COO
Address:	10 Vanderbilt, Irvine, CA 92618	4 Chrysler, Irvine, CA 92618
Phone No.:	(949) 547-7333	(949) 462-0814 x334
Email:	jack.wright@irvinepharma.com	laman.alani@avriobiopharma.com

{***}

Confidential
Page 2 of 17

2.0

Scope of Work Summary

Avrio Biopharmaceuticals LLC (“Avrio”) is pleased to present this proposal to Hemispherx Biopharma, Inc. (“Client”) for product fill and finish of a liquid presentation. Avrio will manufacture Phase 3 clinical trial material supply of Ampligen drug product.

Included in the scope of work is analytical method transfer and validation to support drug product testing, raw material release testing, manufacturing compatibility studies, filter validation, engineering run, media fill, clinical batch production, and finished product release.

This proposal is based on the technical information as provided by Client. The proposed work will be conducted by Avrio located in Irvine, California.

3.0

Fee and Schedule Summary Estimate

	Task	Deliverables	Time Estimate	Cost Estimate*
	Analytical Activities
1a	Release Testing of Excipients (ID only)
	{*}	Certificate of Analysis	{*}	{*}
	{*}			{*}
	{*}			{*}
	{*}			{*}
1b	Release Testing of Polymers (ID only)
	{*}	Certificate of Analysis	{*}	{*}
	{*}			{*}
2a	{*}	Validation Report	{*}	{*}
2b	{*}	Validation Report	{*}	{*}
2c	{*}	Validation Report	{*}	{*}
2d	{*}	Validation Report	{*}	{*}
			Subtotal	{*}
Tech Transfer and Qualifications
3a	{*}	Protocol and Report	{*}	{*}
3b	{*}	Protocol and Report	{*}	{*}
4a	{*}	Protocol and Report	{*}	{*}
4b	{*}	Protocol and Report	{*}	{*}
5	{*}	Report	{*}	{*}
6	{*}	Final Report	{*}	{*}
7	{*}	Final Report	{*}	{*}

{***}

Confidential
Page 3 of 17

	Task	Deliverables	Time Estimate	Cost Estimate*
8	{*}	Final Report	{*}	{*}
			Subtotal	{*}
		Drug Product Manufacturing
9	{*}	Protocol and Report	{*}	{*}
10	{*}	Protocol and Report	{*}	{*}
11	{*}	Final Report	{*}	{*}
12	{*}	Batch Record, Material Specifications (Raw Material, Components, In Process & Final Product)	{*}	{*}
13	{*}	Executed Batch Records	{*}	{*}
14	{*}	Executed Batch Records	{*}	{*}
15	{*}	Executed Batch Records	{*}	{*}
16	{*}	Media Qualification Protocol and Report	{*}	{*}
	GMP Batch Production for Registration Batches
17	{*}	Executed Batch Records	{*}	{*}
18a	{*}	Executed Batch Records, Units	{*}	{*}
18b	{*}	Executed Batch Records, Units	{*}	{*}
19	{*}	Certificate of Analysis	{*} (after date of fill)	{*}
	Subtotal (liquid formulation manufacturing)			{*}
		Additional Support and Fees
	Project Management	{*}	6 months	{*}
	Materials and Components*	Project specific materials and components purchased by Avrio will be billed to Client at cost {*}		{*}
	Shipping Preparation of Finished Batch	Preparation of product, verification of shipment, documentation preparation		{*}
	Shipping of Finished Batch			{*}

{***}

Confidential
Page 4 of 17

Task	Deliverables	Time Estimate	Cost Estimate*
Storage Chamber for 2-8⁰C storage of Finished Product¹			{*}
Monthly Storage for Finished Batch (after 60 days following release)	{*}/month {*})		{*}
Subtotal			{*}
Estimated Grand Total			{*}

*An estimated ${***} has been accounted for pass through costs and will only be billed for project specific materials which are purchased by Avrio. Pass through costs are subject to a 10% handling fee. Client will supply {***}.

For formulations and processes developed by Avrio, and for which an engineering run was performed by Avrio, Avrio shall be responsible for the successful manufacture of the cGMP Batch. For formulations and/or processes developed by another party and transferred to Avrio, Avrio will manufacture the batches as outlined in the Batch Record as approved by Client. Avrio shall be responsible for the manufacture of the batch in accordance with the approved procedures.

4.0

Payment Schedule

Payments for the above listed scope will be made in accordance with the following milestones:

Prepayment:

{***}% of the grand total is due upon signature

{***} months of PM fees included in prepayment. The remaining will be billed monthly

Excludes shipping and storage. No activities will begin until upfront payment is received.

Analytical Method Feasibility:

{***}% upon submittal of data summary (per method)

Analytical Method Validation/Verification

{***}% upon submittal of draft protocol (per method)

{***}% upon submittal of draft report (per method)

Micro Validation:

{***}% upon submittal of validation reports (per method)

Tanks IQ/OQ and CIP/SIP Validations:

{***}% upon completion of validation reports

{***}

Confidential
Page 5 of 17

Release of Raw Materials:

{***}% upon completion

Manufacturing Activities:

{***}% upon completion of manufacturing

{***}% upon release of batch

Additional Supporting Services:

Billed on a month by month basis

Payment terms are NET 30 days from date of invoice except for the first payment which is due when received.

5.0

Analytical Activities

Task 1: Release Testing of Drug Product and Components

Avrio’s affiliate, Irvine Pharmaceutical Services, Inc. (“Irvine”), shall perform testing for the release of {***} in accordance with approved specifications provided by Client.

{***}

Avrio shall release {***} based on Certificate of Analysis (CofA) as client supplied components.

Irvine will perform identity testing by USP on the following excipients for {***} formulation:

{***}

II.

{***}

III.

{***}

IV.

{***}

Upon completion, a Certificate of Analysis approved by Quality Assurance (QA) will be generated for Client for each of the above materials in accordance with cGMP requirements.

Task 2: Microbiological Methods Validation

Avrio will perform the {***} to support routine testing:

{***}

Upon completion of each microbial method validation, Avrio will generate a validation report for Client review.

{***}

Confidential
Page 6 of 17

6.0

Tech Transfer Activities

Task 3: Method Feasibility

Avrio will perform the method feasibility for the following methods:

(a)

{***}

(b)

{***}

Avrio will generate a feasibility report upon completion of the feasibility work.

Task 4: Method Validation of Ampligen ID

Avrio will perform the method validation for the following methods:

(a)

{***}

(b)

{***}

Avrio will conduct method validation {***}. Upon completion of method validation, Avrio will issue a summary report for Client review.

If the existing methods as provided or directed by Client are not suitable for cGMP support (as mutually agreed in good faith by Avrio and Client), additional development of the method(s) may be required at additional cost.

Task 5: Tank IQ/OQ

Avrio will perform IQ/OQ of three compounding tanks provided by Hemispherx. {***}

Task 6: CIP Validation

Avrio will perform one CIP process confirmation run and three CIP validation runs per tank based on process parameters provided by Hemispherx. Cleaning validation protocol will be based on {***}.

Task 7: SIP Validation

Avrio will perform one SIP process confirmation run and three SIP validation runs per {***}.

Task 8: Mixing Studies

Avrio will perform mixing studies during engineering run based {***}.

{***}

Confidential
Page 7 of 17

7.0

Drug Product Manufacturing

Task 9: Machine Modification and Validation for {***}

{***}. Upon completion of the validation, Avrio will generate a validation report for Client review.

Task 10: Manufacturing Compatibility Studies

A compatibility study of the formulation with manufacturing components shall be designed and performed as required to ensure that the contact surfaces of the process (lines, filters, bags or vessels) do not adsorb the active compound or other ingredients of the formulation or produce higher than allowed levels of degradants or leachables.

Task 11: Filter Validations

Avrio assumes the filters used in the filter assembly provided by client can be used in a new assembly customized to work with Avrio equipment. Filter validation studies are assumed to be previously completed by client and are not included in this proposal.

Task 12: Manufacturing Preparation

Client will provide {***} and container closure components required for manufacturing. All Avrio purchased materials and components will be charged to Client as pass-through costs. Materials and components supplied by client will be received and released per Task 1. All other materials and components will be received and released per Avrio Standard Operating Procedures and charged to Client as pass-through costs.

The manufacturing batch record will be prepared by Avrio and approved by both parties. Avrio will include the product specification limits (provided by the Client) in the protocol.

Task 13: Engineering Formulation

Formulation tanks will be cleaned and sterilized {***}. Bulk Ampligen will be formulated for engineering run based on {***}.

Task 14: Engineering Batch – Liquid Formulation

Avrio will manufacture an Engineering Batch of {***} vials of the final formulation of Ampligen drug product (liquid).

Fill volume shall consist of {***}.

Avrio will conduct the following tests of the bulk compounded product:

•

{***}

•

{***}

•

{***}

Confidential
Page 8 of 17

Upon completion of fill and finish, Avrio will provide a copy of batch records for Client’s review. All documentation is reviewed by manufacturing.

Task 15: Media Formulation

Formulation tanks will be cleaned and sterilized {***}. Bulk media will be formulated for media fill based on client procedures.

Task 16: Media Fills

{***}

Task 17: Fill/Finish Formulation

Formulation tanks will be cleaned and sterilized {***}. Bulk Ampligen will be formulated for cGMP batch based on {***}.

Task 18: Fill/Finish Batch

Avrio will manufacture {***} of the final formulation of Ampligen in support of clinical studies.

{***}

Upon completion of fill and finish, Avrio will provide a copy of batch records for Client’s review. All documentation is reviewed by QA and manufacturing teams.

Task 19: GMP Batch Release

Avrio will perform release of the one (1) GMP batch of Ampligen for Injection according to final specification sheet approved by Client.

The release tests to be performed on the product shall be:

{***}

Upon completion of testing for each lot Avrio will furnish a QA approved CofA, in support of releasing the product to the Client.

{***}

Confidential
Page 9 of 17

8.0

Supporting Services

Project Management

Upon the client's approval of a proposal, a Project Manager (PM) will be assigned. Based on the timeline outlined in the proposal, the dedicated PM would identify tasks, timelines, and resources required.

The designated PM will then coordinate a formal kick-off meeting with the client and appropriate laboratory personnel to review and discuss the project scope, resources, and timelines. A technical writer would draft a technology (method) protocol for each required task and provide this to the client for their review and approval.

Analysts are selected based on their education, background, and work experience to support specific projects and tasks. The designated PM would then, from start to finish, oversee the project, managing deadlines, mitigating program risks, and providing proactive communications to the client via emails/conference calls/Gantt charts/etc.

During development work, typically weekly teleconferences are held to discuss next steps, and progress, with an agenda provided. For manufacturing and during a batch release, email updates will be provided, as available.

Materials, Components, and Equipment

The services described in this agreement will comprise the following additional costs:

{***}

9.0

Storage and Shipping

Avrio will be responsible for storage of finished product packaged vials for up to 60 days from Date of Manufacture. Finished vials will be bulk packaged and shipped at ambient temperature or as requested by Client.

Note: The Client will be responsible for providing Avrio all information of where final product will be shipped. The cost of shipping is the responsibility of Client and not included in this proposal.

10.0

Key Assumptions

This proposal is based upon the key assumptions listed below. Changes to any of the following key assumptions may result in a change in scope:

{***}

Client will provide all applicable and required test and manufacturing material(s) and any available documents to Avrio in order to meet the requirements of the project timeline including but not limited to formulation and process information. Client will provide GMP {***}.

{***}

Confidential
Page 10 of 17

Client will provide a minimum of two (2) weeks advance notice for sample and documentation shipment(s). A completed Chain of Custody form must accompany all samples submitted to Irvine; otherwise samples will not be processed.

The protocol(s), report(s), and batch records will be generated in Avrio format and one revision of the protocol(s) and report(s) is included in the pricing.

Project specific materials/equipment purchased by Avrio {***} will be billed to Client {***}.

All analytical, microbiology testing will be performed at Avrio’s affiliate, Irvine Pharmaceutical Services.

Avrio will discard of material following 30 days of batch release unless otherwise specified by Client. Disposal fees will be charged as a pass through cost.

Charges for Out of Specification (OOS) investigations which are determined non-laboratory related shall be billed back to Client at {***}. A Change in Scope document will be prepared for Client’s approval to capture the associated costs of the investigation.

11.0

Change in Scope Management

Any modifications or amendments to the Project Scope will require an executed Change Order. All Change Orders must be signed by authorized representatives of Avrio and Client prior to the initiation of change.

Change Orders may be required for changes to the following project elements:

•

Change in one or more of the Key Assumptions listed in this quotation

•

Project Scope

•

Change in equipment or process (Client specified)

12.0

Authorizations

The costing and project schedule provided within this proposal is valid for one hundred and eighty (180) days after approval and issuance by Avrio. This quote is submitted under the Terms and Conditions attached to this proposal.

{***}

Confidential
Page 11 of 17

Client Acceptance of Proposal		Avrio Approval
Signature: s/		Signature: s/
Name: Wayne Springate		Name: Laman Alani
Title: VP of Operations		Title: COO
Date: 7/21/16		Date: 7/21/16
Purchase Order Number:

{***}

Confidential
Page 12 of 17

13.0

Terms and Conditions

1.0

Scope

1.1 Any services and / or sales of goods (“Services”) provided by Irvine Pharmaceutical Services, Inc. (“Irvine”) and Avrio Biopharmaceutical LLC. (“Avrio”; Irvine and Avrio are jointly referred to as “Provider”) to a customer (“Client”), and the entering into and execution of any contract or agreement of Services with a Client (“Order”), shall be subject to the terms and conditions contained herein (“Conditions”). These Conditions shall be deemed part of the Order.

1.2 Any terms by the Client, which are inconsistent with this document, and are not agreed to by Provider in writing, shall not apply. This shall apply even when the Client expressly orders the Services only subject to Client’s terms and conditions. No variation of Conditions will be binding upon Provider unless agreed to by Provider in writing and signed by its authorized representative. The terms “in writing” or “written” as used in these Conditions will also be satisfied by facsimile or other electronic transmission.

2.0

Order

2.1 Any Order of Services must be in writing and signed by an authorized representative of both the Client and Provider. The same shall apply to any amendments or changes to an Order.

2.2 In the case that any terms of these Conditions deviate from or are contradictory to terms of the Order, the terms and conditions of the duly signed Order shall govern.

3.0

Prices

All prices for Services are exclusive of any applicable shipping costs, shipping insurance, sales tax, and custom duties.

4.0

Payment

Terms of payment are net 30 days from the date of Provider’s invoice. Invoices shall be issued by Provider only after substantial completion of each respective group of tasks set forth in the Order including, without limitation, the delivery to Client of any deliverables associated with each group of tasks. In the event any payment for Services is not made when due, Provider shall be entitled to interest on any such payment at the rate of one and one quarter percent (1.25%) per month during the default period. In this case Provider is also entitled, among its other rights, to cease work and stop deliveries or any other activities with respect to the Order, until such payment, including any accrued interest, has been paid in full.

5.0

Limited Warranty

5.1 Provider warrants that (a) all Services performed hereunder will conform to the requirements of the Order, and (b) Provider will perform all Services according to good laboratory and manufacturing practices and in conformity with any and all federal, state and local regulations and requirements.

5.2 EXCEPT FOR THE FOREGOING WARRANTY, THERE IS NO OTHER WARRANTY OF PROVIDER OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

6.0

Limitation of Liability

6.1 IN THE EVENT PROVIDER FAILS TO PERFORM THE SERVICES HEREUNDER ON A TIMELY BASIS OR IN THE EVENT CLIENT REASONABLY REJECTS A DELIVERABLE BECAUSE IT DOES NOT COMPLY WITH THE ORDER OR THESE CONDITIONS, PROVIDER SHALL REPERFORM THE SERVICES. IF PROVIDER IS UNABLE TO CURE THE FAILURE, PROVIDER SHALL PAY THE CLIENT THE GREATER OF (A) ANY PAYMENTS PREVIOUSLY MADE BY CLIENT IN RESPECT OF SUCH SERVICES OR (B) THE COST OF A THIRD PARTY VENDOR TO PERFORM SUCH SERVICES BUT NOT TO EXCEED 125% OF THE AMOUNT OF PAYMENTS PROVIDED FOR IN (A) HEREOF.

{***}

Confidential
Page 13 of 17

6.2 PROVIDER, ITS AFFILIATES OR SUBSIDIARIES, OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES AND AGENTS, SHALL NOT BE LIABLE TO CLIENT FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE OR SPECIAL DAMAGES, INCLUDING LOST PROFITS, TO THE CLIENT AND/OR ANY THIRD PARTY, WHETHER ARISING FROM DEFECTIVE WORKMANSHIP OR MATERIALS OR DESIGN, BREACH OF WARRANTY, FAILURE OR DELAY IN DELIVERY OR OTHER BREACH OF CONTRACT, OR FROM ANY CAUSE WHATSOEVER, INCLUDING NEGLICENCE, EVEN IF THE CLIENT, OR THE THIRD PARTY, WAS ADVISED OF THE POSSIBILITY OF ANY SUCH DAMAGES AND EVEN IF ANY OTHER REMEDY FAILS OF ITS ESSENTIAL PURPOSE. IN NO EVENT SHALL THE LIABILITY OF PROVIDER TO CLIENT FOR ANY DAMAGES ARISING OUT OF THIS AGREEMENT, REGARDLESS OF THE LEGAL THEORY ON WHICH SUCH DAMAGES MAY BE BASED, EXCEED THE AMOUNT OF TWO TIMES THE AGREED UPON PRICE FOR SUCH SERVICES UNDER THE ORDER.

6.3 THE DISCLAIMERS AND LIMITATIONS OF LIABILITY SET FORTH IN THE FOREGOING SECTIONS 6.1 AND 6.2 SHALL NOT APPLY IN CASE OF GROSS NEGLIGENCE OR WILLFUL MISCONDUCT ON THE PART OF PROVIDER, AND SHALL NOT LIMIT OBLIGATIONS BY WAY OF INDEMNIFICATION UNDER SECTION 7.

7.0

Indemnification

Client will indemnify and hold harmless Provider and its affiliates and subsidiaries and their respective officers, directors, employees and agents from and against any and all third party claims, losses, damages, or liabilities (including but not limited to reasonable attorney’s fees), relating to or arising from or in connection with any third party allegations that the manufacture, use or sale of material by Provider for fulfilling its obligations under the Order infringes intellectual property or other rights of a third party, or the Client’s breach of any of Client’s representations, warranties, or covenants under the Order, in each case, except to the extent any such claim is based upon Provider’s gross negligence or intentional misconduct under the Order. Provider will indemnify and hold harmless Client and its affiliates and subsidiaries and their respective officers, directors, employees and agents from and against any and all third party claims, losses, damages or liabilities (including but not limited to reasonable attorney’s fees), relating to or arising from or in connection with the Provider’s breach of any of Provider’s representations, warranties or covenants under the Order, in each case, except to the extent any such claim is based upon Client’s gross negligence or intentional misconduct under the Order. The indemnified party shall promptly notify the indemnifying party of any third party claim giving rise to indemnification hereunder, and allow the indemnifying party to assume and control the defense of such claims through legal counsel reasonably acceptable to the indemnified party.

8.0

Assignment

The Order and these Conditions shall inure to the benefit of and are binding upon the parties hereto and their respective successors and assigns. Neither party shall assign its rights nor obligations under the Order without the written consent of the other party, which consent shall not be reasonably withheld; provided, however, that either party may assign its interests herein without the written consent of the other:

(A) to an entity which shall succeed to its rights and obligations by merger, consolidation or other reorganization or transfer by operation of law or by purchase of the business of or substantially all of the assets of the assignor; or

(B) to an entity controlling, under the control of or under common control with the assignor, where common control means more than fifty percent ownership of the equity interest of an entity.

Provider shall not subcontract any of the Services to a third party without the prior written consent of Client.

9.0

Force Majeure

Neither party shall be liable under an Order for any delay or failure in performance of the Services or its other obligations if such delay or failure is due to an act or other occurrence beyond its the reasonable control, including but not limited to, acts of nature, fire, flood, strikes, lockouts, labor troubles, inability to procure raw materials, failure or curtailment of power or any other utility service, restrictive governmental law or regulations, riots, insurrection, war or other reason of like nature (“Force Majeure”). Any party relying upon any event of Force Majeure to excuse its performance under this Agreement shall be required, as a condition of such reliance, to promptly notify the other party of such event and exercise its commercially reasonable efforts to remedy the circumstances creating such event.

{***}

Confidential
Page 14 of 17

10.0

Termination

10.1 Provider may terminate an Order at any time by written notice to Client, (i) if information provided by Client to Provider for the performance of the Services cannot be reduced to practice, or shall require any Services exceeding commercially reasonable efforts, or (ii) if Client is adjudicated insolvent, makes an assignment for the benefit of creditors, files a petition for bankruptcy, becomes the subject of a petition in bankruptcy, becomes the subject of any receivership proceeding or admits in writing its inability to pay its debts generally as they become due, or (iii) if Client breaches a material provision herein and Client fails to cure such breach within thirty (30) days after written notice thereof from Provider to Client. Client may terminate an Order in its discretion by giving ten (10) days written notice to Provider. Client may also terminate an Order at any time by written notice to Provider if Provider breaches a material provision herein and Provider fails to cure such breach within thirty (30) days after written notice thereof from Client to Provider.

10.2 If the Order is terminated by Client (other than a termination by Client by reason of the breach of an Order by Provider) or Provider according to one of the termination clauses in the foregoing Section 10.1, the Client agrees to reimburse Provider for the following under the terminated Order, subject to the right of Client to receive the results achieved by Provider under the Order up to the date of its termination, if so requested by Client:

- one hundred percent (100%) of authorized material costs and costs for outsourced work already incurred or irrevocably committed to;

- the portion of Services already provided, on a pro rata basis; and

- reasonable and unavoidable closing, documentation and clean-up fees. The foregoing provisions of this Section 10.2 shall not apply in case of a termination according to Section 10.1 (i) or if the termination occurred due to a material breach of Provider in the performance of its Services.

11.0

Severability

If any provision hereof or set out in the Order document shall be determined to be invalid or unenforceable, such determination shall not affect the validity of the remaining provisions, and the parties shall use all reasonable efforts to agree upon a substitute provision to achieve the same economic effect as the provision determined to be invalid or unenforceable.

12.0

Governing Law; Venue

The Order and these Conditions shall be governed by and construed in accordance with the laws of the State California, laws of the State of Pennsylvania if not laws of the State of Delaware, without regard for those laws relating to conflicts of law.

13.0

Compliance with Laws

Provider will conduct all Services in conformance with any and all applicable federal, state and local laws, regulations, and requirements. Such compliance includes, but is not limited to, the Food and Drug Administration regulations and United States’ regulations pertaining to good clinical and manufacturing practice requirements as may be established by applicable regulatory authorities in the United States from time to time; and such other federal, state and local laws and regulations in the United States and applicable to the conduct of the Services. Provider represents and warrants it has never been and, to the best of its knowledge after due inquiry, none of its employees, affiliates or agents has ever been threatened to be debarred or indicted for a crime or otherwise engaged in conduct for which a person can be debarred under Sections 306(a) or (b) of Federal Food, Drug and Cosmetic Act, and Provider will promptly notify Client upon learning of any such debarment, conviction, threat or indictment. Provider warrants that it will not employ the services of person which would result in a violation of the foregoing representation and warranty.

14.0

Retention of Documentation and Materials

Raw data, documentation, protocols, case report forms, source documents, interim reports and final reports (collectively Documentation) shall be retained by Provider for the period of time required or recommended by applicable United States’ regulatory requirements. During the above described retention periods, Documentation shall be available for inspection by the Client, the Client's authorized agents, and authorized government agencies.

15.0

Propriety Information

Client will own all data and written reports arising out of the Order or prepared for Client in this project upon payment for Services. Client acknowledges that Provider is required to maintain certain regulatory and scientific documents as required by regulatory authorities.

{***}

Confidential
Page 15 of 17

16.0

Nondisclosure

Provider agrees, during the term of performance of Services and for a period of five (5) years from the date of termination of this Order, that, except to the extent required by law, regulation, judicial requirement, or regulatory agency, it will not itself use, or provide or disclose to any third party, any information, data or documentation that were specifically developed or generated by Provider for Client.

17.0

Inspection

Both parties recognize that governmental agencies may request that Provider produce records, data, or materials related to Client products during the course of, or as subject of, an inspection. In such instances, Provider shall notify Client within one business day of any request for production or property inspections by any governmental agency specifically involving either the Services or the facility at which the Services are being performed, including, without limitation, any such planned inspections and have the opportunity to comment upon any related interactions with the governmental agency. Client may be present at inspections related to Provider’s Services hereunder. For all other inspections, Provider shall keep Client duly notified and informed of such inspection and any related activities associated with such inspection. Not more frequently than once per year and at other times upon reasonable request, Client may inspect Provider’s facilities and the performance of the Services.

18.0

Insurance

Provider shall maintain commercial product liability insurance (which insurance shall include professional errors and omissions insurance) at limits of not less than $5 million per occurrence and $5 million aggregate. Provider shall maintain commercial general liability insurance at limits of not less than $1 million per occurrence and $2 million aggregate and $4 million in excess umbrella liability (per occurrence and aggregate) insurance. If Provider terminates insurance coverage required hereunder, Provider shall obtain and maintain the maximum available extended discovery period insurance during the term of the Agreement. At the request of Client, Provider shall provide certificates evidencing such insurance.

19.0

Survival

The terms and provisions of Sections 4, 5, 6, 7, 8, 10, 11, 14, 15, 16, 17 and 19 of these Conditions shall survive the expiration, cancellation or termination of the Order.

{***}

Confidential
Page 16 of 17

PAYMENT FOR CANCELLATION OR POSTPONEMENT OF GMP MANUFACTURING

In the event of termination of this Agreement prior to GMP manufacturing, CLIENT shall reimburse Avrio for (a) all components ordered prior to termination and not cancelable at no cost to Avrio, (b) all work-in-process commenced by Avrio (“the Charges”). Charges would not include release costs or other costs which would not have occurred. In the event of cancellation or postponement by CLIENT of the GMP manufacturing phase described in this agreement or in the event of termination of this agreement, except for termination in the event of a default by Avrio, CLIENT shall pay a cancellation fee as shown in Schedule I. CLIENT shall make payment for all the Charges within thirty (30) days of the invoice date. If cancellation/postponement comes from Avrio, then CLIENT will be given the right to cancel/postpone with the same notice as given by Avrio. Avrio would use reasonable efforts to use the manufacturing window left vacant by CLIENT. In the case Avrio is able to use the window, no cancellation fees would be charged to CLIENT.

Schedule I. Cancellation/Postponement Fee Schedule

Postponement/Cancellation	Situation	Fee
	{*}	{*}
	{*}	{*}
Cancellation	{*}	{*}
	{*}	{*}
	{*}	{*}
Postponement	{*}	{*}
	{*}	{*}
	{*}	{*}

{***}

Confidential
Page 17 of 17

EX-31.1 3 s103890_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATIONS PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002

I, Thomas K. Equels certify that:

I have reviewed this quarterly report on Form 10-Q of Hemispherx Biopharma, Inc. (the “Registrant”);

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

The Registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

The Registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date: August 15, 2016
		/s/ Thomas K. Equels
		Thomas K. Equels, Esq.
		Chief Executive Officer

EX-31.2 4 s103890_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATIONS PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002

I, Adam Pascale, certify that:

I have reviewed this quarterly report on Form 10-Q of Hemispherx Biopharma, Inc. (the “Registrant”);

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date: August 15, 2016
		/s/ Adam Pascale
		Adam Pascale
		Chief Financial Officer

EX-32.1 5 s103890_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Hemispherx Biopharma, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended June 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas K. Equels, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 15, 2016
		/s/ Thomas K. Equels
		Thomas K. Equels, Esq.
		Chief Executive Officer

EX-32.2 6 s103890_ex32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Hemispherx Biopharma, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended June 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Adam Pascale, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 15, 2016
		/s/ Adam Pascale
		Adam Pascale
		Chief Financial Officer

GRAPHIC 7 tpg17.jpg GRAPHIC begin 644 tpg17.jpg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

43VM$_BB/KJC $]X.#=MG6DUS0+?5:C.\?C]3KPO.8YBY4=)LD'SM)(YQ+N(H MH4!W"(;,-8V?NK;ULEYKFGW=I:NV57EB9%+4K0$BE: FG<,.;#7M%U64P:;= M03SM2J.&(%:5(!K2O#%F-JWB6Q%>8^6"/ MKDI-28+&CXI)](K(HJ/WA6RADTBB)C%(8=VX!VE-(T35]?N_(:);37=[E+9 M(D+ME7M:B@F@JGUX9WVH6.F0>9U&:.&WS 9G8**GL%3Z3BNTAUNG_$QE>F M936)I\CXFVLY&0K$B\R576[.P,(F5^M1'( M"5)D6C '2#7B 10T]../_-+Z&8J' !W%5 AAW>S:L:IHFL:),+?6;6XM9CV++&\9/T9@^S$Q M9ZA8:C'S;"::/O1E8#Z:$TQU\GY6QKA2E2V2,NWJKXWH,"9D2:N%QEVD%7H MLTD]0C6!7TF^42;-Q>/W2:?$8.)0Y2AVB&W'3=,U'6+Q-.TJ"6YOYY8XU+ MNU 2:H)- "3ZAC]W=Y:V$#75[(D5LMLQ"JF@J3PXGAC@X:S[A/416W]PP M3E2BY;JT7,+5^1L% L4=98EE.-VS9XO%.7L:LN@D_1:O$E#)B/$!%"B(;A#; MOJVAZSH-P+36[6>TNF0,$E1D8J20& 8 T)!%?4<<[#4M/U2(SZ=-'/"&H61@ MPJ/14>GCB71$ 1$0 1$1$ #M$1$>P -HK#W$'L=3.G:4OQ\61.<<52 M^2$X^7E5J/$7FNRMF;QT T,^FWCF(CW[EVV1B69#.!47NR@(CNVC8=8TFX MOQI=O$]0&'LJ2")3G6BZ+DKV72(F!A445B8Z26DDT MTP/$84@ -W:.UOU;:^Y-!4-K5A>6J'L,L3H#[64#_QP^L=8TG4C33[F"9AZ M$=6/[@-<3]M!8DL+986%LL+%.>H!JAC-&VCW.VH1XN@67I=)?H4=DLHD49?( MMBX:_0XM)-7]8[^S2+V)=X[NL=O1@\N><J'T8 VQ-H'<>DZGJ%X"TTL M;11,?Y7[QG![\V45];#%Q_A@=4$C4[UG_0Q?EEXI\_6=Y5AV&-@9+= MR>[BRU]:C$[T?UAX9[K;ET2'!,B ^A@6+=2#P MC9KEM!R^/O>9M1FB/]+'0'OSG$%>J=B=21<,NG2R9O5RIC1Q_1O4_LC!\ M;=PW=MT';1=)RU=(I.6KE!0JJ+ANNF55!=%4@B11)5(X&8!$! =X;80964E M6!# T(]>-* @BHX@X"F^)3U"V#.6IS3_ "<6F5G'U5A9^>@X\3+#YFR\N MWKN/X)PBF8Q%7$'6'7B 0WI!,"(^S;9_P MVW[?0]M:CO[5)'&1&/U;> M9YF!_2.D2$$O8@R%;'5KGE.$A>):=L;MTZ,(]OYP $1W;7;H5 MN"YW38Z[N&Y)YMWK3N!^:O)3(OTH5?9BN]2M,AT:YTS2X0,D.GA?I/,.8^U MJGVXW3K?PQ&A>P5O3)\JZF&CZ;KD/**&2ME"41;NY+;.U!214QX/$DFLL/ M"0QA^KV"(^W8(7/S,[[M[N2$6VFE$D9?NY>(#$?RWJP1(>D&VI8%DYMV&9 ? M?3TBOYF,-]:NB34[T)]1&+LZZ>\QS,M2+5)NTZ!DQLQY&Y=2<0";^8Q+F:KL M5SP-@8RT3O.41 6LBUJ=--NN@(%-VS-Z[9ZZ[>NM!W%9HE_$@,D5
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end XML 17 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2

Document and Entity Information - shares
6 Months Ended

Jun. 30, 2016

Aug. 01, 2016

Document And Entity Information

Entity Registrant Name HEMISPHERX BIOPHARMA INC

Entity Central Index Key 0000946644

Document Type 10-Q

Trading Symbol HEB

Document Period End Date Jun. 30, 2016

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity a Well-known Seasoned Issuer No

Entity a Voluntary Filer No

Entity's Reporting Status Current Yes

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 248,932,220

Document Fiscal Period Focus Q2

Document Fiscal Year Focus 2016

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: heb_DocumentAndEntityInformationAbstract

Namespace Prefix: heb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2

Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands

Jun. 30, 2016

Dec. 31, 2015

Current assets:

Cash and cash equivalents $ 1,538 $ 2,115

Escrow account for litigation settlement 1,750

Marketable securities 4,974 6,795

Inventory-work in process 1,326 1,326

Assets held for sale 764

Prepaid expenses and other current assets 378 335

Total current assets 10,730 10,571

Property and equipment, net 10,057 11,237

Patent and trademark rights, net 899 862

Other assets 232 134

Total assets 21,918 22,804

Current liabilities:

Accounts payable 1,391 1,213

Accrued expenses 3,038 1,219

Current portion of capital lease 1

Total current liabilities 4,429 2,433

Commitments and contingencies (Note 6)

Stockholders' equity:

Preferred stock, par value $0.01 per share, authorized 5,000,000; issued and outstanding; none

Common stock, par value $0.001 per share, authorized 350,000,000 shares; issued and outstanding 248,829,720 and 247,559,487, respectively 249 247

Additional paid-in capital 313,619 313,220

Accumulated other comprehensive income (loss) 87 (97)

Accumulated deficit (296,466) (292,999)

Total stockholders' equity 17,489 20,371

Total liabilities and stockholders' equity $ 21,918 $ 22,804

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated appreciation or loss, net of tax, in value of the total of available-for-sale securities at the end of an accounting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669686-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 15
-Paragraph 4
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6390208&loc=d3e400-110220
+ Details

Name: us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26626-111562
+ Details

Name: us-gaap_AvailableForSaleSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of capital lease obligation due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45023-112735
+ Details

Name: us-gaap_CapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_EscrowDeposit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares

Jun. 30, 2016

Dec. 31, 2015

Statement of Financial Position [Abstract]

Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01

Preferred stock, authorized 5,000,000 5,000,000

Preferred stock, issued 0 0

Preferred stock, outstanding 0 0

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, authorized 350,000,000 350,000,000

Common stock, issued 248,829,720 247,559,487

Common stock, outstanding 248,829,720 247,559,487

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Jun. 30, 2016

Jun. 30, 2015

Revenues:

Clinical treatment programs $ 15 $ 47 $ 54 $ 83

Total revenues 15 47 54 83

Costs and expenses:

Production costs 290 507 558 879

Research and development 900 2,439 1,902 5,113

General and administrative 1,639 2,002 4,087 3,915

Total costs and expenses 2,829 4,948 6,547 9,907

Operating loss (2,814) (4,901) (6,493) (9,824)

Interest expense (2)

Interest and other income/expense 55 56 116 162

Insurance proceeds from legal settlement, net 1,436 1,436

Gain (Loss) on sales of short term marketable securities 20 (87)

Gain from sale of income tax net operating losses 1,561 1,374

Net loss (1,303) (4,845) (3,467) (8,290)

Other comprehensive income (loss):

Reclassification adjustments for loss on sales of short term marketable securities included in net loss 87

Unrealized gain (loss) on marketable securities 38 (137) 97 (26)

Net comprehensive loss $ (1,265) $ (4,982) $ (3,283) $ (8,316)

Basic and diluted loss per share (in dollars per share) $ (0.01) $ (0.02) $ (0.01) $ (0.04)

Weighted average shares outstanding, basic and diluted (in shares) 248,008,113 236,149,999 247,786,026 224,954,200

X

- Definition
Funds received from sale of income tax net operating losses.
+ References
No definition available.
+ Details

Name: heb_GainFromSaleOfIncomeTaxOperatingLosses

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenues recognized by the entity from providing services to in-patients, outpatients, residents in facilities owned or operated by the entity, from insurance premiums, or from goods provided or services performed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_HealthCareOrganizationRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).
+ References
No definition available.
+ Details

Name: us-gaap_InterestAndOtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred in the production of goods for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_ManufacturingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(c)-(e)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(c))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27405-111563
+ Details

Name: us-gaap_MarketableSecuritiesGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the amounts received by the insured under the terms of an insurance contract settlement. This element pertains only to insurance proceeds related to investments, for example fixed assets. It excludes insurance settlements classified as operating cash flows.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromInsuranceSettlementInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 21 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2

Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - 6 months ended Jun. 30, 2016 - USD ($)
$ in Thousands

Common Stock [Member]

Additional Paid-In Capital [Member]

Accumulated Other Comprehensive Income (Loss) [Member]

Accumulated Deficit [Member]

Total

Balance, at beginning at Dec. 31, 2015 $ 247 $ 313,220 $ (97) $ (292,999) $ 20,371

Balance, at beginning (in shares) at Dec. 31, 2015 247,559,487

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Equity-based compensation 238 238

Shares sold at the market $ 2 161 163

Shares sold at the market (in shares) 1,270,233

Net comprehensive loss 184 (3,467) (3,283)

Balance, at end at Jun. 30, 2016 $ 249 $ 313,619 $ 87 $ (296,466) $ 17,489

Balance, at end (in shares) at Jun. 30, 2016 248,829,720

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Value, after forfeitures, of stock or other type of equity granted of any equity-based compensation plan other than an employee stock ownership plan (ESOP).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 30
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64840991&loc=d3e3913-113898

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 30
-Section 35
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418191&loc=d3e15009-113911
+ Details

Name: us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2

Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Cash flows from operating activities:

Net loss $ (3,467) $ (8,290)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation of property and equipment 576 458

Amortization and abandonment of patent and trademark rights 70 79

Equity-based compensation 238 111

Realized loss on sale of marketable securities 87

Change in assets and liabilities:

Escrow account for litigation settlement (1,750)

Inventories (1,009)

Prepaid expenses and other current assets (43) 61

Accounts payable 178 189

Accrued expenses 1,819 (836)

Net cash used in operating activities (2,292) (9,237)

Cash flows from investing activities:

Purchase of property, equipment and construction in progress (160) (240)

Additions to patent, trademark and licensing rights (207) (169)

Deposits on capital leases refunded 2

Sales and maturities of short-term and long-term marketable securities 1,918 54

Net cash provided by (used in) investing activities 1,553 (355)

Cash flows from financing activities:

Payments on capital leases (1) (15)

Proceeds from sale of stock, net of issuance costs 163 9,293

Net cash provided by financing activities 162 9,278

Net decrease in cash and cash equivalents (577) (314)

Cash and cash equivalents at beginning of period 2,115 2,156

Cash and cash equivalents at end of period 1,538 1,842

Supplemental disclosures of non-cash investing and financing cash flow information:

Issuance of common stock for accounts payable 672

Unrealized (loss) gain on marketable securities 184 (26)

Supplemental disclosure of cash flow information:

Cash paid for interest expense (2)

Insurance proceeds from legal settlement $ 3,536

X

- Definition
Cash inflow of value of amortization and abandonment of patent and tradmark rights during the period.
+ References
No definition available.
+ Details

Name: heb_AmortizationAndAbandonmentOfIntagibleAssets

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of deposits on capital leases refundend during the period.
+ References
No definition available.
+ Details

Name: heb_DepositsOnCapitalLeasesRefunded

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the amount of escrow account for the settlement of litigation.
+ References
No definition available.
+ Details

Name: heb_EscrowAccountForLitigationSettlement

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the amount of insurance proceeds from settlement of legal matters.
+ References
No definition available.
+ Details

Name: heb_InsuranceProceedsFromLegalSettlement

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).
+ References
No definition available.
+ Details

Name: heb_PaymentsOnCapitalLeases

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This item represents the total realized gain (loss) included in earnings for the period as a result of selling marketable securities categorized as trading, available-for-sale, or held-to-maturity. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(c))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27405-111563
+ Details

Name: us-gaap_MarketableSecuritiesRealizedGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The fair value of stock issued in noncash financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586
+ Details

Name: us-gaap_StockIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of unrealized gain (loss) recognized in the income statement on unsold other securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_UnrealizedGainLossOnSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 23 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2

Basis of Presentation
6 Months Ended

Jun. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation
Note 1: Basis of Presentation

The consolidated financial statements include the financial statements of Hemispherx Biopharma, Inc. and its wholly-owned subsidiaries (“Company”). The Company has three domestic subsidiaries: BioPro Corp., BioAegean Corp. and Core Biotech Corp., all of which are incorporated in Delaware and are dormant. The Company also has a foreign subsidiary, Hemispherx Biopharma Europe N.V./S.A., which was established in Belgium in 1998. All significant intercompany balances and transactions have been eliminated in consolidation.

In the opinion of Management, all adjustments necessary for a fair presentation of such consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year.

The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto.

These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2015 and 2014, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

X

- Definition
The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccounting

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2

Net Loss Per Share
6 Months Ended

Jun. 30, 2016

Earnings Per Share [Abstract]

Net Loss Per Share
Note 2: Net Loss Per Share

Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 18,814,995 and 17,228,280 shares for the six months ended June 30, 2016 and 2015, respectively, are excluded from the calculation of diluted net loss per share since their effect is anti-dilutive.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2

Equity-Based Compensation
6 Months Ended

Jun. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Equity-Based Compensation
Note 3: Equity-Based Compensation

The fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, expected life and forfeiture rates. There were 2,225,000 and 800,000 options or equity warrants granted in the six months ended June 30, 2016 and 2015, respectively.



Stock option for employees' activity during the six months ended June 30, 2016 is as follows:

Stock option activity for employees:

Number of
Options Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Term
(Years) Aggregate
Intrinsic
Value

Outstanding January 1, 2016 10,725,248 $ 1.58 4.02 $ —

Granted 2,225,000 .13 — —

Forfeited (851,650 ) .85 — —

Outstanding June 30, 2016 12,098,598 $ 1.37 4.84 $ —

Vested and expected to vest June 30, 2016 12,098,598 $ 1.37 4.84 $ —

Exercisable June 30, 2016 9,898,598 $ 1.39 3.56 $ —

Unvested stock option activity for employees:

Number of
Options Weighted
Average
Exercise
Price Average
Remaining
Contractual
Term
(Years) Aggregate
Intrinsic
Value

Outstanding January 1, 2016 333,333 $ 0.29 7.82 $ —

Granted 2,225,000 .13 — —

Vested (358,333 ) .24 —

Forfeited — — — —

Outstanding June 30, 2016 2,200,000 $ .14 9.74 $ —

Stock option activity for non-employees:



Number of
Options Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Term (Years) Aggregate
Intrinsic
Value

Outstanding January 1, 2016 3,303,000 $ 1.29 4.31 $ —

Granted 550,000 .13 — —

Exercised — — — —

Forfeited (380,000 ) 3.73 — —

Outstanding June 30, 2016 3,473,000 $ .84 5.21 $ —

Vested and expected to vest June 30, 2016 3,473,000 $ .84 5.21 $ —

Exercisable June 30, 2016 2,923,000 $ .97 4.31 $ —



Unvested stock option activity for non-employees during the year:

Number of
Options Weighted
Average
Exercise
Price Average
Remaining
Contractual
Term
(Years) Aggregate
Intrinsic
Value

Outstanding January 1, 2016 — $ — — $ —

Granted 550,000 .13 — —

Vested — — — —

Forfeited — — — —

Outstanding June 30, 2016 550,000 $ .13 10.00 $ —

The impact on the Company’s results of operations of recording equity-based compensation for the six months ended June 30, 2016 and 2015 was to increase costs and expenses by approximately $238,000 and $111,000, respectively, which had no impact on earnings per share.

As of June 30, 2016 and 2015, respectively, there was $380,000 and $269,000 of unrecognized equity-based compensation cost related to options granted under the Equity Incentive Plan.

On January 26, 2016, the Board, based on the recommendation of its Compensation Committee, established two programs - the 2016 Senior Executive Deferred Cash Performance Award Plan for Dr. William A. Carter and Thomas K. Equels, the Company’s two primary executive officers, and the 2016 Voluntary Incentive Stock Award Plan for Company employees and Board members other than Dr. Carter and Mr. Equels. Both Plans include a Base Pay Supplement provision.

The Company maintains a record of the number of shares of stock represented by each Incentive Right issued out of the 2016 Voluntary Incentive Stock Award Plan. During the six months ended June 30, 2016, The Company granted rights to 1,477,201 incentive shares and recorded $192,000 in equity-based compensation under this Plan.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65895303&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2

Inventories
6 Months Ended

Jun. 30, 2016

Inventory Disclosure [Abstract]

Inventories
Note 4: Inventories

The Company uses the lower of first-in, first-out (“FIFO”) cost or market method of accounting for inventory.

Inventories consist of the following: (in thousands)

June 30, December 31,

2016 2015

Inventory work-in-process, January 1 $ 1,326 $ —

Production⁽¹⁾ — 1,443

Spoilage — (117 )

Inventory work-in-process, end of period $ 1,326 $ 1,326

(1) Commercial sales of Alferon® will not resume until new batches of commercial filled and finished product are produced and released by the FDA. The Company is continuing the validation of Alferon® production and production of new Alferon® API inventory commenced in February 2015. While the facility is approved by the FDA under the Biological License Application (“BLA”) for Alferon®, this status will need to be reaffirmed by an FDA pre-approval inspection. The Company will also need the FDA’s approval to release commercial product once it has submitted satisfactory stability and quality release data.

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2

Marketable Securities
6 Months Ended

Jun. 30, 2016

Marketable Securities [Abstract]

Marketable Securities
Note 5: Marketable Securities

Marketable securities consist of mutual funds. For the six months ended June 30, 2016 and 2015, it was determined that none of the marketable securities had other-than-temporary impairments. At June 30, 2016 and December 31, 2015, all securities were classified as available for sale investments and were measured as Level 1 instruments of the fair value measurements standard.

Securities classified as available for sale consisted of:

June 30, 2016

(in thousands)

Securities Amortized
Cost Gross
Unrealized
Gains Gross
Unrealized
Losses Fair Value Short-Term
Investments Long Term
Investments

Mutual Funds $ 4,887 $ 87 $ — $ 4,974 $ 4,974 $ —

Totals $ 4,887 $ 87 $ — $ 4,974 $ 4,974 $ —

December 31, 2015

(in thousands)

Securities Amortized
Cost Gross
Unrealized
Gains Gross
Unrealized
Losses Fair Value Short-Term
Investments Long Term
Investments

Mutual Funds $ 6,892 $ — $ (97 ) $ 6,795 $ 6,795 $ —

Totals $ 6,892 $ — $ (97 ) $ 6,795 $ 6,795 $ —

Unrealized losses on investments

Investments with continuous unrealized losses for less than 12 months and 12 months or greater and their related fair values were as follows:

June 30, 2016

As of June 30, 2016 there were no investments in a loss position.

December 31, 2015

(in thousands)

Less Than 12 Months 12 Months or Greater Totals

Securities Total
number
in loss
position Fair
Values Unrealized
Losses Fair
Values Unrealized
Losses Total
Fair
Value Total
Unrealized
Losses

Mutual Funds 2 $ 2,834 $ (159 ) $ 2,041 $ (21 ) $ 4,875 $ (180 )

Totals 2 $ 2,834 $ (159 ) $ 2,041 $ (21 ) $ 4,875 $ (180 )

X

- Definition
The entire disclosure for investments in certain debt and equity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-Glossary Debt Security
-URI http://asc.fasb.org/extlink&oid=6509901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-Glossary Equity Security
-URI http://asc.fasb.org/extlink&oid=6511694

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27405-111563
+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_MarketableSecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2

Accrued Expenses
6 Months Ended

Jun. 30, 2016

Payables and Accruals [Abstract]

Accrued Expenses
Note 6: Accrued Expenses

Accrued expenses consist of the following:

(in thousands)

June 30,
2016 December 31,
2015

Compensation, including severance $ 558 $ 229

Professional fees 2,085 619

Clinical trial expenses 107 143

Other expenses 288 228

$ 3,038 $ 1,219

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2

Property and Equipment
6 Months Ended

Jun. 30, 2016

Property, Plant and Equipment [Abstract]

Property and Equipment
Note 7: Property and Equipment

(in thousands)

June 30,
2016 December 31,
2015

Land, buildings and improvements $ 10,530 $ 11,603

Furniture, fixtures, and equipment 5,630 5,490

Leasehold improvements — 85

Total property and equipment 16,160 17,178

Less: accumulated depreciation and amortization (6,103 ) (5,941 )

Property and equipment, net $ 10,057 $ 11,237

Property and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, ranging from three to thirty-nine years.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13-14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2921-110230

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2

Stockholders' Equity
6 Months Ended

Jun. 30, 2016

Stockholders' equity:

Stockholders' Equity
Note 8: Stockholders’ Equity

The Equity Incentive Plan of 2009, effective June 24, 2009, authorizes the grant of non-qualified and incentive stock options, stock appreciation rights, restricted stock and other stock awards. A maximum of 15,000,000 shares of common stock is reserved for potential issuance pursuant to awards under the Equity Incentive Plan of 2009. In September 2015, the Company's shareholders approved the following amendments to the 2009 Plan: (1) increased the number of shares authorized to be issued under the Equity Incentive Plan from 15,000,000 to 22,000,000; (2) required a gradual vesting period of options issued under the Equity Incentive Plan over a three year period; (3) revised the definition of “change in control” to make it less “liberal” by amending the provision that a change in control occurs upon stockholder approval of a merger, consolidation or sale or disposition by the Company of all or substantially all of its assets (a “Business Combination”) to state that such a change in control occurs upon the consummation of the Business Combination; and (4) clarified that the definition of change in control has a double trigger. For a Participant to get the benefit resulting from a change in control, such Participant must have been terminated other than for cause within a two year period. Unless sooner terminated, the Equity Incentive Plan of 2009 will continue in effect for a period of 10 years from its effective date. For the six months ended June 30, 2016 and 2015, there were 2,775,000 and 800,000 options granted by the Company, respectively.

On December 15, 2015, the Company entered into an Equity Distribution Agreement with Chardan Capital Markets, LLC (the “Chardan Agreement”) to create an at-the-market equity program under which it may sell shares of its common stock (the “Shares”) from time to time through Chardan Capital Markets, LLC, as sales agent (“Chardan”). Under the Chardan Agreement, Chardan will be entitled to a commission at a fixed commission rate of 3.0% of the gross sales price of Shares sold under the Chardan Agreement.



Sales of the Shares, if any, under the Chardan Agreement may be made in transactions that are deemed to be “at-the-market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers’ transactions, including on the NYSE MKT, at market prices or as otherwise agreed with Chardan. The Company has no obligation to sell any of the Shares, and may at any time suspend offers under the Chardan Agreement or terminate the Chardan Agreement.

The Shares will be issued pursuant to the Company’s previously filed and effective Registration Statement on Form S-3 (File No. 333-205228). On December 16, 2015, the Company filed a Prospectus Supplement relating to the Chardan offering with the Securities and Exchange Commission. In 2015, no shares were sold under the Chardan Agreement. For the period ended June 30, 2016, the Company sold an aggregate of 1,270,233 shares that resulted in net cash proceeds of approximately $163,000 after commissions paid to Chardan for approximately $5,000.

The Company’s plans to allocate the net proceeds from the offering towards research and development, operations and general and administrative purposes related to the commercialization of Ampligen® and Alferon® related products, including, but not limited to, the following: (1) costs to maintain the Alferon N Injection® manufacturing facility and to prepare for the FDA pre-approval inspections of the Ampligen® facility, (2) manufacture of commercial product, (3) potential new preclinical and/or clinical studies in order to gain commercial approval for Ampligen® and broader approvals for Alferon® and Alferon LDO®, (4) working capital to build and maintain sufficient inventory by procuring raw materials, supplies and other items for the New Brunswick manufacturing facility, as well as to remunerate outside contractors for necessary services, such as, final filling and finishing operations in order to meet any anticipated demand from normal operations as well as through the possible pursuit of other disease areas and/or geographic regions that may present themselves, (5) pursuit of potential partnering opportunities for Ampligen®, (6) potential establishment of sales and marketing capabilities, as well as consideration towards the expansion of our manufacturing capacity, and (7) working capital for general and administrative expenses.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2

Cash and Cash Equivalents
6 Months Ended

Jun. 30, 2016

Cash and Cash Equivalents [Abstract]

Cash and Cash Equivalents
Note 9: Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. The Company has restricted $1,750,000 of these funds in an escrow account which is designated for litigation expenses pursuant to the terms of a litigation settlement agreement.

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 6.H.3)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13728-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951
+ Details

Name: us-gaap_CashAndCashEquivalentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2

Recent Accounting Pronouncements
6 Months Ended

Jun. 30, 2016

Accounting Changes and Error Corrections [Abstract]

Recent Accounting Pronouncements
Note 10: Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2017, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Upon the Company realizing operating revenues from the sale of commercialized product, the Company’s adoption of this guidance may have an impact on the Company’s financial statement presentation or disclosures.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 explicitly requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist which raise substantial doubt about an entity's ability to continue as a going concern and to provide related disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and annual and interim periods thereafter, with early adoption permitted. The Company will continue to evaluate and monitor at each annual or interim reporting period whether there are conditions or events that exist pertaining to this guidance.



In January 2016, the (“FASB”) has issued Accounting Standards Update (ASU) No. 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new guidance is intended to improve the recognition and measurement of financial instruments. The new guidance is effective for public companies for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The new guidance permits early adoption of the own credit provision. The Company believes that the adoption of the guidance may have an impact on the Company’s financial statement presentation or disclosures.

In February 2016, the FASB issued ASU 2016-02 - Leases,* which amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective for annual reporting periods beginning after December 15, 2018, and early adoption of is permitted as of the standard’s issuance date. “ASU 2016-02” requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company has not adopted ASU 2016-02 and believes such adoption may have an impact on the Company’s financial statement presentation or disclosures.

In 2016, the FASB also issued Accounting Standards Updates (“ASU”) 2016-03 through 2016-13. These updates did not have a significant impact on the financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2

Funds Received from Sale of Income Tax Net Operating Losses
6 Months Ended

Jun. 30, 2016

Income Tax Disclosure [Abstract]

Funds Received from Sale of Income Tax Net Operating Losses
Note 11: Funds Received from Sale of Income Tax Net Operating Losses

As of December 31, 2015, the Company has approximately $166,000,000 of federal net operating loss carryforwards (expiring in the years 2018 through 2035) available to offset future federal taxable income. The Company also has approximately $36,000,000 of Pennsylvania state net operating loss carryforwards (expiring in the years 2018 through 2033) and approximately $29,000,000 of New Jersey state net operating loss carryforwards (expiring in the years 2034 and 2035) available to offset future state taxable income.

In January 2016, the Company effectively sold $16,000,000 of its New Jersey state net operating loss carryforward for the year 2014 for approximately $1,320,000, and also sold New Jersey research and development credits for $241,000. The utilization of certain state net operating loss carry-forwards may be subject to annual limitations. With no tax due for the foreseeable future, the Company has determined that the accounting for interest or penalties related to the payment of tax is not necessary at this time.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2

Assets held for sale
6 Months Ended

Jun. 30, 2016

Receivables [Abstract]

Assets held for sale
Note 12: Assets held for sale

The assets held for sale consists of the net book value of an underutilized building located adjacent to the site of the Company’s New Jersey manufacturing facility. As part of the Company’s objectives to achieve its commercial goals and increase stockholder value, the Company has initiated the sale of underutilized assets. As a result, the Company is in the process of selling this building at its current market value and has reclassified it as held for sale at its net book value of $764,000.

X

- Definition
Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230
+ Details

Name: us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2

Subsequent Events
6 Months Ended

Jun. 30, 2016

Subsequent Events [Abstract]

Subsequent Events
Note 13: Subsequent Events

The Company evaluated subsequent events through the date on which these financial statements were issued and determined that no subsequent event constituted a matter that required adjustment to the financial statements for the six months ended June 30, 2016.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2

Equity-Based Compensation (Tables)
6 Months Ended

Jun. 30, 2016

Employees [Member]

Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]

Schedule of stock option activity

Stock option activity for employees:

Number of
Options Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Term
(Years) Aggregate
Intrinsic
Value

Outstanding January 1, 2016 10,725,248 $ 1.58 4.02 $ —

Granted 2,225,000 .13 — —

Forfeited (851,650 ) .85 — —

Outstanding June 30, 2016 12,098,598 $ 1.37 4.84 $ —

Vested and expected to vest June 30, 2016 12,098,598 $ 1.37 4.84 $ —

Exercisable June 30, 2016 9,898,598 $ 1.39 3.56 $ —

Schedule of unvested stock option activity
Unvested stock option activity for employees:

Number of
Options Weighted
Average
Exercise
Price Average
Remaining
Contractual
Term
(Years) Aggregate
Intrinsic
Value

Outstanding January 1, 2016 333,333 $ 0.29 7.82 $ —

Granted 2,225,000 .13 — —

Vested (358,333 ) .24 —

Forfeited — — — —

Outstanding June 30, 2016 2,200,000 $ .14 9.74 $ —

Non-Employees [Member]

Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]

Schedule of stock option activity
Stock option activity for non-employees:



Number of
Options Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Term (Years) Aggregate
Intrinsic
Value

Outstanding January 1, 2016 3,303,000 $ 1.29 4.31 $ —

Granted 550,000 .13 — —

Exercised — — — —

Forfeited (380,000 ) 3.73 — —

Outstanding June 30, 2016 3,473,000 $ .84 5.21 $ —

Vested and expected to vest June 30, 2016 3,473,000 $ .84 5.21 $ —

Exercisable June 30, 2016 2,923,000 $ .97 4.31 $ —

Schedule of unvested stock option activity
Unvested stock option activity for non-employees during the year:

Number of
Options Weighted
Average
Exercise
Price Average
Remaining
Contractual
Term
(Years) Aggregate
Intrinsic
Value

Outstanding January 1, 2016 — $ — — $ —

Granted 550,000 .13 — —

Vested — — — —

Forfeited — — — —

Outstanding June 30, 2016 550,000 $ .13 10.00 $ —

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the changes in outstanding nonvested shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=heb_Officer1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2

Inventories (Tables)
6 Months Ended

Jun. 30, 2016

Inventory Disclosure [Abstract]

Schedule of inventories
Unvested stock option activity for non-employees during the year:

Number of
Options Weighted
Average
Exercise
Price Average
Remaining
Contractual
Term
(Years) Aggregate
Intrinsic
Value

Outstanding January 1, 2016 — $ — — $ —

Granted 550,000 .13 — —

Vested — — — —

Forfeited — — — —

Outstanding June 30, 2016 550,000 $ .13 10.00 $ —

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2

Marketable Securities (Tables)
6 Months Ended

Jun. 30, 2016

Marketable Securities [Abstract]

Schedule of available for sale
Securities classified as available for sale consisted of:

June 30, 2016

(in thousands)

Securities Amortized
Cost Gross
Unrealized
Gains Gross
Unrealized
Losses Fair Value Short-Term
Investments Long Term
Investments

Mutual Funds $ 4,887 $ 87 $ — $ 4,974 $ 4,974 $ —

Totals $ 4,887 $ 87 $ — $ 4,974 $ 4,974 $ —

December 31, 2015

(in thousands)

Securities Amortized
Cost Gross
Unrealized
Gains Gross
Unrealized
Losses Fair Value Short-Term
Investments Long Term
Investments

Mutual Funds $ 6,892 $ — $ (97 ) $ 6,795 $ 6,795 $ —

Totals $ 6,892 $ — $ (97 ) $ 6,795 $ 6,795 $ —

Schedule of investments with continuous unrealized losses
As of June 30, 2016 there were no investments in a loss position.

December 31, 2015

(in thousands)

Less Than 12 Months 12 Months or Greater Totals

Securities Total
number
in loss
position Fair
Values Unrealized
Losses Fair
Values Unrealized
Losses Total
Fair
Value Total
Unrealized
Losses

Mutual Funds 2 $ 2,834 $ (159 ) $ 2,041 $ (21 ) $ 4,875 $ (180 )

Totals 2 $ 2,834 $ (159 ) $ 2,041 $ (21 ) $ 4,875 $ (180 )

X

- Definition
Tabular disclosure of fair value of investments in debt and equity securities in an unrealized loss position categorized neither as held-to-maturity nor trading securities.
+ References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_MarketableSecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2

Accrued Expenses (Tables)
6 Months Ended

Jun. 30, 2016

Payables and Accruals [Abstract]

Schedule of accrued expenses
Accrued expenses consist of the following:

(in thousands)

June 30,
2016 December 31,
2015

Compensation, including severance $ 558 $ 229

Professional fees 2,085 619

Clinical trial expenses 107 143

Other expenses 288 228

$ 3,038 $ 1,219

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2

Property and Equipment (Tables)
6 Months Ended

Jun. 30, 2016

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

(in thousands)

June 30,
2016 December 31,
2015

Land, buildings and improvements $ 10,530 $ 11,603

Furniture, fixtures, and equipment 5,630 5,490

Leasehold improvements — 85

Total property and equipment 16,160 17,178

Less: accumulated depreciation and amortization (6,103 ) (5,941 )

Property and equipment, net $ 10,057 $ 11,237

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2

Net Loss Per Share (Details Narrative) - shares
6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Earnings Per Share [Abstract]

Antidilutive securities excluded from computation of net loss per share 18,814,995 17,228,280

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2

Equity-Based Compensation (Details) - USD ($)
6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]

Granted 2,225,000 800,000

Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]

Outstanding, beginning of year 10,725,248

Granted 2,225,000

Forfeited (851,650)

Outstanding, end of year 12,098,598

Vested and expected to vest 12,098,598

Exercisable at end of year 9,898,598

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]

Outstanding, beginning of year $ 1.58

Granted 0.13

Forfeited 0.85

Outstanding, end of year 1.37

Vested and expected to vest 1.37

Exercisable at end of year $ 1.39

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Roll Forward]

Outstanding, beginning of year 4 years 7 days

Outstanding, end of year 4 years 10 months 2 days

Vested and expected to vest 4 years 10 months 2 days

Exercisable at end of year 3 years 6 months 22 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]

Outstanding, beginning of year

Granted

Forfeited

Outstanding, end of year

Vested and expected to vest

Exercisable at end of year

X

- References
No definition available.
+ Details

Name: heb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract

Namespace Prefix: heb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: heb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract

Namespace Prefix: heb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for vested option awards forfeited, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3

Namespace Prefix: heb_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2

Equity-Based Compensation (Details 1) - USD ($)
6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]

Granted 2,225,000 800,000

Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]

Outstanding, beginning of year 333,333

Granted 2,225,000

Vested (358,333)

Forfeited

Outstanding, end of year 2,200,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Exercise Price [Roll Forward]

Outstanding, beginning of year $ 0.29

Granted 0.13

Vested 0.24

Forfeited

Outstanding, end of year $ 0.14

Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Average Remaining Contractual Term [Roll Forward]

Outstanding, beginning of year 7 years 9 months 25 days

Outstanding, end of year 9 years 8 months 26 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic value [Roll Forward]

Outstanding, beginning of year

Granted

Vested

Forfeited

Outstanding, end of year

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to forfeited options outstanding.
+ References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to non vest options outstanding.
+ References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValueAbstract

Namespace Prefix: heb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to non vest granted options outstanding.
+ References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average remaining contractual term for non vested option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm

Namespace Prefix: heb_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for non vested option awards forfeited, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm1

Namespace Prefix: heb_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTermAbstract

Namespace Prefix: heb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of non-vested options forfeited.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of non-vested options forfeited.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2

Equity-Based Compensation (Details 2) - USD ($)
6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]

Granted 2,225,000 800,000

Non-Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]

Outstanding, beginning of year 3,303,000

Granted 550,000

Exercised

Forfeited (380,000)

Outstanding, end of year 3,473,000

Vested and expected to vest 3,473,000

Exercisable at end of year 2,923,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]

Outstanding, beginning of year $ 1.29

Granted 0.13

Exercised

Forfeited 3.73

Outstanding, end of year 0.84

Vested and expected to vest 0.84

Exercisable at end of year $ 0.97

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Roll Forward]

Outstanding, beginning of year 4 years 3 months 22 days

Outstanding, end of year 5 years 2 months 16 days

Vested and expected to vest 5 years 2 months 16 days

Exercisable at end of year 4 years 3 months 22 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]

Outstanding, beginning of year

Granted

Exercised

Forfeited

Outstanding, end of year

Vested and expected to vest

Exercisable at end of year

X

- References
No definition available.
+ Details

Name: heb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract

Namespace Prefix: heb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: heb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract

Namespace Prefix: heb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for vested option awards forfeited, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3

Namespace Prefix: heb_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=heb_Officer1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2

Equity-Based Compensation (Details 3) - USD ($)
6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]

Granted 2,225,000 800,000

Non-Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]

Outstanding, beginning of year

Granted 550,000

Vested

Forfeited

Outstanding, end of year 550,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Exercise Price [Roll Forward]

Outstanding, beginning of year

Granted 0.13

Vested

Forfeited

Outstanding, end of year $ 0.13

Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Average Remaining Contractual Term [Roll Forward]

Outstanding, end of year 10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic value [Roll Forward]

Outstanding, beginning of year

Granted

Vested

Forfeited

Outstanding, end of year

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to forfeited options outstanding.
+ References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to non vest options outstanding.
+ References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValueAbstract

Namespace Prefix: heb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to non vest granted options outstanding.
+ References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average remaining contractual term for non vested option awards forfeited, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm1

Namespace Prefix: heb_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTermAbstract

Namespace Prefix: heb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of non-vested options forfeited.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of non-vested options forfeited.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=heb_Officer1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2

Equity-Based Compensation (Details Narrative) - USD ($)
$ in Thousands
6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]

Stock-based compensation expense $ 238,000 $ 111,000

Unrecognized stock-based compensation $ 380,000 $ 269,000

Number of incentive shares granted 2,225,000 800,000

2016 Voluntary Incentive Stock Award Plan [Member]

Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]

Stock-based compensation expense $ 192,000

Number of incentive shares granted 1,477,201

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested options awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=heb_VoluntaryIncentiveStockAwardPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2

Inventories (Details) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended

Jun. 30, 2016

Dec. 31, 2015

Inventory Disclosure [Abstract]

Inventory work-in-process, beginning $ 1,326

Production ^[1] 1,443

Spoilage (117)

Inventory work-in-process, ending $ 1,326 $ 1,326

[1] Commercial sales of Alferon will not resume until new batches of commercial filled and finished product are produced and released by the FDA. The Company is continuing the validation of Alferon production and production of new Alferon API inventory commenced in February 2015. While the facility is approved by the FDA under the Biological License Application ("BLA") for Alferon, this status will need to be reaffirmed by an FDA pre-approval inspection. The Company will also need the FDA's approval to release commercial product once it has submitted satisfactory stability and quality release data.

X

- Definition
Inventory production amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
No definition available.
+ Details

Name: heb_InventoryProduction

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Inventory spoilage amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
No definition available.
+ Details

Name: heb_InventorySpoilage

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 48 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2

Marketable Securities (Details) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended

Jun. 30, 2016

Dec. 31, 2015

Schedule of Trading Securities and Other Trading Assets [Line Items]

Amortized Cost $ 4,887 $ 6,892

Gross Unrealized Gains 87

Gross Unrealized Losses (97)

Fair Value 4,974 6,795

Short-Term Investments 4,974 6,795

Long Term Investments

Mutual Funds [Member]

Schedule of Trading Securities and Other Trading Assets [Line Items]

Amortized Cost 4,887 6,892

Gross Unrealized Gains 87

Gross Unrealized Losses (97)

Fair Value 4,974 6,795

Short-Term Investments 4,974 6,795

Long Term Investments

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26610-111562
+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AvailableForSaleSecuritiesAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26626-111562
+ Details

Name: us-gaap_AvailableForSaleSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of unrealized gain before deducting unrealized loss on investments in debt and equity securities classified as available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of unrealized loss before deducting unrealized gain on investments in available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Available-for-Sale Securities
-URI http://asc.fasb.org/extlink&oid=6505594

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26626-111562
+ Details

Name: us-gaap_AvailableForSaleSecuritiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=heb_MutualFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2

Marketable Securities (Details 1)
$ in Thousands

Dec. 31, 2015

USD ($)

Number

Schedule of Trading Securities and Other Trading Assets [Line Items]

Total number in loss position | Number 2

Fair Value [Abstract]

Less Than 12 Months $ 2,834

12 Months or Greater 2,041

Unrealized Losses [Abstract]

Less Than 12 Months (159)

12 Months or Greater (21)

Totals [Abstract]

Total Fair Values 4,875

Total Unrealized Losses $ (180)

Mutual Funds [Member]

Schedule of Trading Securities and Other Trading Assets [Line Items]

Total number in loss position | Number 2

Fair Value [Abstract]

Less Than 12 Months $ 2,834

12 Months or Greater 2,041

Unrealized Losses [Abstract]

Less Than 12 Months (159)

12 Months or Greater (21)

Totals [Abstract]

Total Fair Values 4,875

Total Unrealized Losses $ (180)

X

- Definition
Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for twelve months or longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale in a continuous loss position.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for less than twelve months.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionQualitativeDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of investment positions in available-for-sale investments in a continuous unrealized loss position for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563
+ Details

Name: us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=heb_MutualFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2

Accrued Expenses (Details) - USD ($)
$ in Thousands

Jun. 30, 2016

Dec. 31, 2015

Payables and Accruals [Abstract]

Compensation, including severance $ 558 $ 229

Professional fees 2,085 619

Clinical trial expenses 107 143

Other expenses 288 228

Accrued expenses $ 3,038 $ 1,219

X

- Definition
Amount of accrued expense of clinical trial activity.
+ References
No definition available.
+ Details

Name: heb_AccruedClinicalTrialExpensesCurrent

Namespace Prefix: heb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2

Property and Equipment (Details) - USD ($)
$ in Thousands

Jun. 30, 2016

Dec. 31, 2015

Property, Plant and Equipment [Line Items]

Total property and equipment $ 16,160 $ 17,178

Less: accumulated depreciation and amortization (6,103) (5,941)

Property and equipment, net 10,057 11,237

Land, Buildings And Improvements [Member]

Property, Plant and Equipment [Line Items]

Total property and equipment 10,530 11,603

Furniture, Fixtures And Equipment [Member]

Property, Plant and Equipment [Line Items]

Total property and equipment 5,630 5,490

Leasehold Improvements [Member]

Property, Plant and Equipment [Line Items]

Total property and equipment $ 85

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandBuildingsAndImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2

Property and Equipment (Details Narrative)
6 Months Ended

Jun. 30, 2016

Minimum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful life 3 years

Maximum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful life 39 years

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2

Stockholders' Equity (Details Narrative) - USD ($)
$ in Thousands
1 Months Ended 6 Months Ended

Sep. 30, 2015

Jun. 30, 2016

Jun. 30, 2015

Dec. 15, 2015

Jun. 24, 2009

Proceeds from sale of common stock, net of issuance costs $ 163 $ 9,293

Number of shares granted 2,225,000 800,000

Equity Distribution Agreement (EDA) [Member] | Chardan Capital Markets, LLC [Member]

Percentage of fixed commissions aggregate gross proceeds 3.00%

Maximum number of shares issued upon transaction 1,270,233

Proceeds from sale of common stock, net of issuance costs $ 163

Payments for commissions $ 5

2009 Equity Incentive Plans [Member]

Number of authorized shares under plan 22,000,000 15,000,000

Expiration period 10 years

Vesting period 3 years

Termination period for few participant 2 years

X

- Definition
Refers to percentage of fixed commission on gross proceeds.
+ References
No definition available.
+ Details

Name: heb_PercentageOfFixedSalesAgentcommission

Namespace Prefix: heb_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Period from grant date that an equity-based award terminate, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: heb_SharebasedCompensationArrangementBySharebasedPaymentAwardTerminationPeriod

Namespace Prefix: heb_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of cash paid for commissions during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_PaymentsForCommissions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=heb_EquityDistributionAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=heb_ChardanCapitalMarketsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=heb_EquityIncentivePlans2009Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2

Cash and Cash Equivalents (Details Narrative) - USD ($)
$ in Thousands

Jun. 30, 2016

Dec. 31, 2015

Cash and Cash Equivalents [Abstract]

Escrow account for litigation settlement $ 1,750

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_EscrowDeposit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 55 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2

Funds Received from Sale of Income Tax Net Operating Losses (Details Narrative) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2015

Jan. 31, 2016

Dec. 31, 2014

Income Tax Contingency [Line Items]

Net operating loss carryforwards $ 166,000

Description of operating loss carryforwards
Expiring in the years 2018 through 2035.

Pennsylvania Division of Tax [Member]

Income Tax Contingency [Line Items]

Net operating loss carryforwards $ 36,000

Description of operating loss carryforwards
Expiring in the years 2018 through 2033.

New Jersey Division of Taxation [Member]

Income Tax Contingency [Line Items]

Net operating loss carryforwards $ 29,000 $ 1,320 $ 16,000

Research and development credits $ 241

Description of operating loss carryforwards
Expiring in the years 2034 and 2035.

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
No definition available.
+ Details

Name: heb_OperatingLossCarryforwardsExpirationDescription

Namespace Prefix: heb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Carryforwards
-URI http://asc.fasb.org/extlink&oid=6506874

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeTaxContingencyLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=heb_StateAndLocalJurisdiction1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2

Assets held for sale (Details Narrative) - USD ($)
$ in Thousands

Jun. 30, 2016

Dec. 31, 2015

Receivables [Abstract]

Assets held for sale $ 764

X

- Definition
Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 15
-Paragraph 4
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6390208&loc=d3e400-110220
+ Details

Name: us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 58 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * / var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 59 report.css IDEA: XBRL DOCUMENT / Updated 2009-11-04 / / v2.2.0.24 / / DefRef Styles / ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } / Report Styles / ..pl a, .pl a:visited { color: black; text-decoration: none; } / table / ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } / Top labels / ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; / word-wrap: break-word; / } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } / Header rows... / ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } / Calendars... / ..report .rc { background-color: #f0f0f0; } / Even rows... / ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } / Odd rows... / ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } / styles for footnote marker / ..report .fn { white-space: nowrap; } / styles for numeric types / ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } / styles for text types / ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 52 178 1 true 18 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://hemispherx.net/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://hemispherx.net/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://hemispherx.net/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://hemispherx.net/role/StatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Unaudited) Sheet http://hemispherx.net/role/StatementOfChangesInStockholdersEquity Consolidated Statement of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://hemispherx.net/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation Sheet http://hemispherx.net/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Net Loss Per Share Sheet http://hemispherx.net/role/NetLossPerShare Net Loss Per Share Notes 8 false false R9.htm 00000009 - Disclosure - Equity-Based Compensation Sheet http://hemispherx.net/role/Equity-basedCompensation Equity-Based Compensation Notes 9 false false R10.htm 00000010 - Disclosure - Inventories Sheet http://hemispherx.net/role/Inventories Inventories Notes 10 false false R11.htm 00000011 - Disclosure - Marketable Securities Sheet http://hemispherx.net/role/MarketableSecurities Marketable Securities Notes 11 false false R12.htm 00000012 - Disclosure - Accrued Expenses Sheet http://hemispherx.net/role/AccruedExpenses Accrued Expenses Notes 12 false false R13.htm 00000013 - Disclosure - Property and Equipment Sheet http://hemispherx.net/role/PropertyAndEquipment Property and Equipment Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders' Equity Sheet http://hemispherx.net/role/StockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 00000015 - Disclosure - Cash and Cash Equivalents Sheet http://hemispherx.net/role/CashAndCashEquivalents Cash and Cash Equivalents Notes 15 false false R16.htm 00000016 - Disclosure - Recent Accounting Pronouncements Sheet http://hemispherx.net/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 16 false false R17.htm 00000017 - Disclosure - Funds Received from Sale of Income Tax Net Operating Losses Sheet http://hemispherx.net/role/FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses Funds Received from Sale of Income Tax Net Operating Losses Notes 17 false false R18.htm 00000018 - Disclosure - Assets held for sale Sheet http://hemispherx.net/role/AssetsHeldForSale Assets held for sale Notes 18 false false R19.htm 00000019 - Disclosure - Subsequent Events Sheet http://hemispherx.net/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 00000020 - Disclosure - Equity-Based Compensation (Tables) Sheet http://hemispherx.net/role/Equity-basedCompensationTables Equity-Based Compensation (Tables) Tables http://hemispherx.net/role/Equity-basedCompensation 20 false false R21.htm 00000021 - Disclosure - Inventories (Tables) Sheet http://hemispherx.net/role/InventoriesTables Inventories (Tables) Tables http://hemispherx.net/role/Inventories 21 false false R22.htm 00000022 - Disclosure - Marketable Securities (Tables) Sheet http://hemispherx.net/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://hemispherx.net/role/MarketableSecurities 22 false false R23.htm 00000023 - Disclosure - Accrued Expenses (Tables) Sheet http://hemispherx.net/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://hemispherx.net/role/AccruedExpenses 23 false false R24.htm 00000024 - Disclosure - Property and Equipment (Tables) Sheet http://hemispherx.net/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://hemispherx.net/role/PropertyAndEquipment 24 false false R25.htm 00000025 - Disclosure - Net Loss Per Share (Details Narrative) Sheet http://hemispherx.net/role/NetLossPerShareDetailsNarrative Net Loss Per Share (Details Narrative) Details http://hemispherx.net/role/NetLossPerShare 25 false false R26.htm 00000026 - Disclosure - Equity-Based Compensation (Details) Sheet http://hemispherx.net/role/Equity-basedCompensationDetails Equity-Based Compensation (Details) Details http://hemispherx.net/role/Equity-basedCompensationTables 26 false false R27.htm 00000027 - Disclosure - Equity-Based Compensation (Details 1) Sheet http://hemispherx.net/role/Equity-basedCompensationDetails1 Equity-Based Compensation (Details 1) Details http://hemispherx.net/role/Equity-basedCompensationTables 27 false false R28.htm 00000028 - Disclosure - Equity-Based Compensation (Details 2) Sheet http://hemispherx.net/role/Equity-basedCompensationDetails2 Equity-Based Compensation (Details 2) Details http://hemispherx.net/role/Equity-basedCompensationTables 28 false false R29.htm 00000029 - Disclosure - Equity-Based Compensation (Details 3) Sheet http://hemispherx.net/role/Equity-basedCompensationDetails3 Equity-Based Compensation (Details 3) Details http://hemispherx.net/role/Equity-basedCompensationTables 29 false false R30.htm 00000030 - Disclosure - Equity-Based Compensation (Details Narrative) Sheet http://hemispherx.net/role/Equity-basedCompensationDetailsNarrative Equity-Based Compensation (Details Narrative) Details http://hemispherx.net/role/Equity-basedCompensationTables 30 false false R31.htm 00000031 - Disclosure - Inventories (Details) Sheet http://hemispherx.net/role/InventoriesDetails Inventories (Details) Details http://hemispherx.net/role/InventoriesTables 31 false false R32.htm 00000032 - Disclosure - Marketable Securities (Details) Sheet http://hemispherx.net/role/MarketableSecuritiesDetails Marketable Securities (Details) Details http://hemispherx.net/role/MarketableSecuritiesTables 32 false false R33.htm 00000033 - Disclosure - Marketable Securities (Details 1) Sheet http://hemispherx.net/role/MarketableSecuritiesDetails1 Marketable Securities (Details 1) Details http://hemispherx.net/role/MarketableSecuritiesTables 33 false false R34.htm 00000034 - Disclosure - Accrued Expenses (Details) Sheet http://hemispherx.net/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://hemispherx.net/role/AccruedExpensesTables 34 false false R35.htm 00000035 - Disclosure - Property and Equipment (Details) Sheet http://hemispherx.net/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://hemispherx.net/role/PropertyAndEquipmentTables 35 false false R36.htm 00000036 - Disclosure - Property and Equipment (Details Narrative) Sheet http://hemispherx.net/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://hemispherx.net/role/PropertyAndEquipmentTables 36 false false R37.htm 00000037 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://hemispherx.net/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://hemispherx.net/role/StockholdersEquity 37 false false R38.htm 00000038 - Disclosure - Cash and Cash Equivalents (Details Narrative) Sheet http://hemispherx.net/role/CashAndCashEquivalentsDetailsNarrative Cash and Cash Equivalents (Details Narrative) Details http://hemispherx.net/role/CashAndCashEquivalents 38 false false R39.htm 00000039 - Disclosure - Funds Received from Sale of Income Tax Net Operating Losses (Details Narrative) Sheet http://hemispherx.net/role/FundsReceivedFromSaleOfIncomeTaxNetOperatingLossesDetailsNarrative Funds Received from Sale of Income Tax Net Operating Losses (Details Narrative) Details http://hemispherx.net/role/FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses 39 false false R40.htm 00000040 - Disclosure - Assets held for sale (Details Narrative) Sheet http://hemispherx.net/role/AssetsHeldForSaleDetailsNarrative Assets held for sale (Details Narrative) Details http://hemispherx.net/role/AssetsHeldForSale 40 false false All Reports Book All Reports heb-20160630.xml heb-20160630.xsd heb-20160630_cal.xml heb-20160630_def.xml heb-20160630_lab.xml heb-20160630_pre.xml true true ZIP 63 0001615774-16-006802-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001615774-16-006802-xbrl.zip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�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
3Q1PFULGC)NCA@LEYDO\Z=UXN2,$@DOY X!A6%7'_4 M]!#2J.(Z^PIG7^'LYQ]A9AXWHAB07/8G))- I\4/#NY<1I#J%[C6B@4-- M=YH$O2&9A._MBQ=XZW2MDG6E&?;!H$$_JLDTFOBB<0+\XKZ 1+[?#'NS#1!Y M$U\T1-ZZOX:LU7J7W@KR=NN/1 -!7:6+VOTV71WOK& M#PE)Y-VG>:Z"B&4DJ)V2><+L/H@? M!&P?2M;&?_7[!7MP_4]\?>;[\N85C[>J-:)A)?)UKHGNTB=Q, GG\[?NGGB3 M_1;(LFT26TVP^Q3;6%!.'MUHZ08G[I.7N'Z>#CZ^N#B1K2:J/FA+24UBM34" MQBZ-K=(MIY5]=&-1O&PMWNL5 MRNBA]?=TVNW=?L^_6-\[?)U)K]-3Y.D\
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

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Aug. 01, 2016
Document And Entity Information
Entity Registrant Name	HEMISPHERX BIOPHARMA INC
Entity Central Index Key	0000946644
Document Type	10-Q
Trading Symbol	HEB
Document Period End Date	Jun. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		248,932,220
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2016

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 1,538	$ 2,115
Escrow account for litigation settlement	1,750
Marketable securities	4,974	6,795
Inventory-work in process	1,326	1,326
Assets held for sale	764
Prepaid expenses and other current assets	378	335
Total current assets	10,730	10,571
Property and equipment, net	10,057	11,237
Patent and trademark rights, net	899	862
Other assets	232	134
Total assets	21,918	22,804
Current liabilities:
Accounts payable	1,391	1,213
Accrued expenses	3,038	1,219
Current portion of capital lease		1
Total current liabilities	4,429	2,433
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, par value $0.01 per share, authorized 5,000,000; issued and outstanding; none
Common stock, par value $0.001 per share, authorized 350,000,000 shares; issued and outstanding 248,829,720 and 247,559,487, respectively	249	247
Additional paid-in capital	313,619	313,220
Accumulated other comprehensive income (loss)	87	(97)
Accumulated deficit	(296,466)	(292,999)
Total stockholders' equity	17,489	20,371
Total liabilities and stockholders' equity	$ 21,918	$ 22,804

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	350,000,000	350,000,000
Common stock, issued	248,829,720	247,559,487
Common stock, outstanding	248,829,720	247,559,487

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenues:
Clinical treatment programs	$ 15	$ 47	$ 54	$ 83
Total revenues	15	47	54	83
Costs and expenses:
Production costs	290	507	558	879
Research and development	900	2,439	1,902	5,113
General and administrative	1,639	2,002	4,087	3,915
Total costs and expenses	2,829	4,948	6,547	9,907
Operating loss	(2,814)	(4,901)	(6,493)	(9,824)
Interest expense				(2)
Interest and other income/expense	55	56	116	162
Insurance proceeds from legal settlement, net	1,436		1,436
Gain (Loss) on sales of short term marketable securities	20		(87)
Gain from sale of income tax net operating losses			1,561	1,374
Net loss	(1,303)	(4,845)	(3,467)	(8,290)
Other comprehensive income (loss):
Reclassification adjustments for loss on sales of short term marketable securities included in net loss			87
Unrealized gain (loss) on marketable securities	38	(137)	97	(26)
Net comprehensive loss	$ (1,265)	$ (4,982)	$ (3,283)	$ (8,316)
Basic and diluted loss per share (in dollars per share)	$ (0.01)	$ (0.02)	$ (0.01)	$ (0.04)
Weighted average shares outstanding, basic and diluted (in shares)	248,008,113	236,149,999	247,786,026	224,954,200

Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - 6 months ended Jun. 30, 2016 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Total
Balance, at beginning at Dec. 31, 2015	$ 247	$ 313,220	$ (97)	$ (292,999)	$ 20,371
Balance, at beginning (in shares) at Dec. 31, 2015	247,559,487
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation		238			238
Shares sold at the market	$ 2	161			163
Shares sold at the market (in shares)	1,270,233
Net comprehensive loss			184	(3,467)	(3,283)
Balance, at end at Jun. 30, 2016	$ 249	$ 313,619	$ 87	$ (296,466)	$ 17,489
Balance, at end (in shares) at Jun. 30, 2016	248,829,720

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net loss	$ (3,467)	$ (8,290)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	576	458
Amortization and abandonment of patent and trademark rights	70	79
Equity-based compensation	238	111
Realized loss on sale of marketable securities	87
Change in assets and liabilities:
Escrow account for litigation settlement	(1,750)
Inventories		(1,009)
Prepaid expenses and other current assets	(43)	61
Accounts payable	178	189
Accrued expenses	1,819	(836)
Net cash used in operating activities	(2,292)	(9,237)
Cash flows from investing activities:
Purchase of property, equipment and construction in progress	(160)	(240)
Additions to patent, trademark and licensing rights	(207)	(169)
Deposits on capital leases refunded	2
Sales and maturities of short-term and long-term marketable securities	1,918	54
Net cash provided by (used in) investing activities	1,553	(355)
Cash flows from financing activities:
Payments on capital leases	(1)	(15)
Proceeds from sale of stock, net of issuance costs	163	9,293
Net cash provided by financing activities	162	9,278
Net decrease in cash and cash equivalents	(577)	(314)
Cash and cash equivalents at beginning of period	2,115	2,156
Cash and cash equivalents at end of period	1,538	1,842
Supplemental disclosures of non-cash investing and financing cash flow information:
Issuance of common stock for accounts payable		672
Unrealized (loss) gain on marketable securities	184	(26)
Supplemental disclosure of cash flow information:
Cash paid for interest expense		(2)
Insurance proceeds from legal settlement	$ 3,536

Net Loss Per Share (Details Narrative) - shares	6 Months Ended
Net Loss Per Share (Details Narrative) - shares	Jun. 30, 2016	Jun. 30, 2015
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of net loss per share	18,814,995	17,228,280

Equity-Based Compensation (Details) - USD ($)	6 Months Ended
Equity-Based Compensation (Details) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Granted	2,225,000	800,000
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning of year	10,725,248
Granted	2,225,000
Forfeited	(851,650)
Outstanding, end of year	12,098,598
Vested and expected to vest	12,098,598
Exercisable at end of year	9,898,598
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of year	$ 1.58
Granted	0.13
Forfeited	0.85
Outstanding, end of year	1.37
Vested and expected to vest	1.37
Exercisable at end of year	$ 1.39
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Roll Forward]
Outstanding, beginning of year	4 years 7 days
Outstanding, end of year	4 years 10 months 2 days
Vested and expected to vest	4 years 10 months 2 days
Exercisable at end of year	3 years 6 months 22 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]
Outstanding, beginning of year
Granted
Forfeited
Outstanding, end of year
Vested and expected to vest
Exercisable at end of year

Equity-Based Compensation (Details 1) - USD ($)	6 Months Ended
Equity-Based Compensation (Details 1) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Granted	2,225,000	800,000
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Outstanding, beginning of year	333,333
Granted	2,225,000
Vested	(358,333)
Forfeited
Outstanding, end of year	2,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of year	$ 0.29
Granted	0.13
Vested	0.24
Forfeited
Outstanding, end of year	$ 0.14
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Average Remaining Contractual Term [Roll Forward]
Outstanding, beginning of year	7 years 9 months 25 days
Outstanding, end of year	9 years 8 months 26 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic value [Roll Forward]
Outstanding, beginning of year
Granted
Vested
Forfeited
Outstanding, end of year

Equity-Based Compensation (Details 2) - USD ($)	6 Months Ended
Equity-Based Compensation (Details 2) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Granted	2,225,000	800,000
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning of year	3,303,000
Granted	550,000
Exercised
Forfeited	(380,000)
Outstanding, end of year	3,473,000
Vested and expected to vest	3,473,000
Exercisable at end of year	2,923,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of year	$ 1.29
Granted	0.13
Exercised
Forfeited	3.73
Outstanding, end of year	0.84
Vested and expected to vest	0.84
Exercisable at end of year	$ 0.97
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Roll Forward]
Outstanding, beginning of year	4 years 3 months 22 days
Outstanding, end of year	5 years 2 months 16 days
Vested and expected to vest	5 years 2 months 16 days
Exercisable at end of year	4 years 3 months 22 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]
Outstanding, beginning of year
Granted
Exercised
Forfeited
Outstanding, end of year
Vested and expected to vest
Exercisable at end of year

Equity-Based Compensation (Details 3) - USD ($)	6 Months Ended
Equity-Based Compensation (Details 3) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Granted	2,225,000	800,000
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Outstanding, beginning of year
Granted	550,000
Vested
Forfeited
Outstanding, end of year	550,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of year
Granted	0.13
Vested
Forfeited
Outstanding, end of year	$ 0.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Average Remaining Contractual Term [Roll Forward]
Outstanding, end of year	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic value [Roll Forward]
Outstanding, beginning of year
Granted
Vested
Forfeited
Outstanding, end of year

Equity-Based Compensation (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock-based compensation expense	$ 238,000	$ 111,000
Unrecognized stock-based compensation	$ 380,000	$ 269,000
Number of incentive shares granted	2,225,000	800,000
2016 Voluntary Incentive Stock Award Plan [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock-based compensation expense	$ 192,000
Number of incentive shares granted	1,477,201

Marketable Securities (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
Marketable Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Schedule of Trading Securities and Other Trading Assets [Line Items]
Amortized Cost	$ 4,887	$ 6,892
Gross Unrealized Gains	87
Gross Unrealized Losses		(97)
Fair Value	4,974	6,795
Short-Term Investments	4,974	6,795
Long Term Investments
Mutual Funds [Member]
Schedule of Trading Securities and Other Trading Assets [Line Items]
Amortized Cost	4,887	6,892
Gross Unrealized Gains	87
Gross Unrealized Losses		(97)
Fair Value	4,974	6,795
Short-Term Investments	4,974	6,795
Long Term Investments

Marketable Securities (Details 1) $ in Thousands	Dec. 31, 2015 USD ($) Number
Schedule of Trading Securities and Other Trading Assets [Line Items]
Total number in loss position \| Number	2
Fair Value [Abstract]
Less Than 12 Months	$ 2,834
12 Months or Greater	2,041
Unrealized Losses [Abstract]
Less Than 12 Months	(159)
12 Months or Greater	(21)
Totals [Abstract]
Total Fair Values	4,875
Total Unrealized Losses	$ (180)
Mutual Funds [Member]
Schedule of Trading Securities and Other Trading Assets [Line Items]
Total number in loss position \| Number	2
Fair Value [Abstract]
Less Than 12 Months	$ 2,834
12 Months or Greater	2,041
Unrealized Losses [Abstract]
Less Than 12 Months	(159)
12 Months or Greater	(21)
Totals [Abstract]
Total Fair Values	4,875
Total Unrealized Losses	$ (180)

Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Compensation, including severance	$ 558	$ 229
Professional fees	2,085	619
Clinical trial expenses	107	143
Other expenses	288	228
Accrued expenses	$ 3,038	$ 1,219

Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 16,160	$ 17,178
Less: accumulated depreciation and amortization	(6,103)	(5,941)
Property and equipment, net	10,057	11,237
Land, Buildings And Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	10,530	11,603
Furniture, Fixtures And Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	5,630	5,490
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 85

Property and Equipment (Details Narrative)	6 Months Ended
Property and Equipment (Details Narrative)	Jun. 30, 2016
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	39 years

Stockholders' Equity (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Sep. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 15, 2015	Jun. 24, 2009
Proceeds from sale of common stock, net of issuance costs		$ 163	$ 9,293
Number of shares granted		2,225,000	800,000
Equity Distribution Agreement (EDA) [Member] \| Chardan Capital Markets, LLC [Member]
Percentage of fixed commissions aggregate gross proceeds				3.00%
Maximum number of shares issued upon transaction		1,270,233
Proceeds from sale of common stock, net of issuance costs		$ 163
Payments for commissions		$ 5
2009 Equity Incentive Plans [Member]
Number of authorized shares under plan	22,000,000				15,000,000
Expiration period	10 years
Vesting period	3 years
Termination period for few participant	2 years

Cash and Cash Equivalents (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Cash and Cash Equivalents [Abstract]
Escrow account for litigation settlement	$ 1,750

Funds Received from Sale of Income Tax Net Operating Losses (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Jan. 31, 2016	Dec. 31, 2014
Income Tax Contingency [Line Items]
Net operating loss carryforwards	$ 166,000
Description of operating loss carryforwards	Expiring in the years 2018 through 2035.
Pennsylvania Division of Tax [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards	$ 36,000
Description of operating loss carryforwards	Expiring in the years 2018 through 2033.
New Jersey Division of Taxation [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards	$ 29,000	$ 1,320	$ 16,000
Research and development credits	$ 241
Description of operating loss carryforwards	Expiring in the years 2034 and 2035.